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ABSTRACT 
Chlamydia trachomatis infections of the male and female reproductive tracts are the 
world’s leading sexually transmitted bacterial disease, and can lead to damaging 
pathology, scarring and infertility. The resolution of chlamydial infection requires the 
development of adaptive immune responses to infection, and includes cell-mediated 
and humoral immunity. Whilst cluster of differentiation (CD)4+ T cells are known to 
be essential in clearance of infection [1], they are also associated with immune cell 
infiltration, autoimmunity and infertility in the testes [2-3]. Conversely, antibodies are 
less associated with inflammation, are readily transported into the reproductive 
tracts, and can offer lumenal neutralization of chlamydiae prior to infection. 
Antibodies, or immunoglobulins (Ig), play a supportive role in the resolution of 
chlamydial infections, and this thesis sought to define the function of IgA and IgG, 
against a variety of chlamydial antigens expressed during the intracellular and 
extracellular stages of the chlamydial developmental cycle. Transport of IgA and IgG 
into the mucosal lumen is facilitated by receptor-mediated transcytosis yet the 
expression profile (under normal conditions and during urogenital chlamydial 
infection) of the polymeric immunoglobulin receptor (pIgR) and the neonatal Fc 
receptor (FcRn) remains unknown.   
The expression profile of pIgR and FcRn in the murine male reproductive tract was 
found to be polarized to the lower and upper reproductive tract tissues respectively. 
This demonstrates that the two receptors have a tissue tropism, which must be 
considered when targeting pathogens that colonize different sites. In contrast, the 
expression of pIgR and FcRn in the female mouse was found to be distributed in 
both the upper and lower reproductive tracts. When urogenitally infected with 
Chlamydia muridarum, both male and female reproductive tracts up-regulated 
expression of pIgR and down-regulated expression of FcRn. Unsurprisingly, the up-
regulation of pIgR increased the concentration of IgA in the lumen. However, down-
regulation of FcRn, prevented IgG uptake and led to an increase or pooling of IgG in 
lumenal secretions. 
As previous studies have identified the importance of pIgR-mediated delivery of IgA, 
as well as the potential of IgA to bind and neutralize intracellular pathogens, IgA 
against a variety of chlamydial antigens was investigated. The protection afforded by 
IgA against the extracellular antigen major outer membrane protein (MOMP), was 
found to be dependent on pIgR expression in vitro and in vivo. It was also found that 
in the absence of pIgR, no protection was afforded to mice previously immunized 
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with MOMP. The protection afforded from polyclonal IgA against the intracellular 
chlamydial antigens; inclusion membrane protein A (IncA), inclusion membrane 
proteins (IncMem) and secreted chlamydial protease-like activity factor (CPAF) were 
produced and investigated in vitro.  
Antigen-specific intracellular IgA was found to bind to the respective antigen within 
the infected cell, but did not significantly reduce inclusion formation (p > 0.05). This 
suggests that whilst IgA specific for the selected antigens was transported by pIgR 
to the chlamydial inclusion, it was unable to prevent growth.  Similarly, immunization 
of male mice with intracellular chlamydial antigens (IncA or IncMem), followed by 
depletion CD4+ T cells, and subsequent urogenital C. muridarum challenge, 
provided minimal pIgR-mediated protection.  Wild type male mice immunized with 
IncA showed a 57 % reduction (p < 0.05), and mice deficient in pIgR showed a 35 % 
reduction (p < 0.05) in reproductive tract chlamydial burden compared to control 
antigen, and in the absence of CD4+ T cells. This suggests that pIgR and secretory 
IgA (SIgA) were playing a protective role (21 % pIgR-mediated) in unison with 
another antigen-specific immune mechanism (36 %). Interestingly, IgA generated 
during a primary respiratory C. muridarum infection did not provide a significant 
amount of protection to secondary urogenital C. muridarum challenge. Together, 
these data suggest that IgA specific for an extracellular antigen (MOMP) can play a 
strong protective role in chlamydial infections, and that IgA targeting intracellular 
antigens is also effective but dependent on pIgR expression in tissues. However, 
whilst not investigated here, IgA targeting and blocking other intracellular chlamydial 
antigens, that are more essential for replication or type III secretion, may be more 
efficacious in subunit vaccines. 
Recently, studies have demonstrated that IgG can neutralize influenza virus by 
trafficking IgG-bound virus to lysosomes [4]. We sought to determine if this process 
could also traffic chlamydial antigens for degradation by lysosomes, despite 
Chlamydia spp. actively inhibiting fusion with the host endocytic pathway. As 
observed in pIgR-mediated delivery of anti-IncA IgA, FcRn similarly transported IgG 
specific for IncA which bound the inclusion membrane. Interestingly, FcRn-mediated 
delivery of anti-IncA IgG significantly decreased inclusion formation by 36 % (p < 
0.01), and induced aberrant inclusion morphology. This suggests that unlike IgA, 
IgG can facilitate additional host cellular responses which affect the intracellular 
niche of chlamydial growth. Fluorescence microscopy revealed that IgG also bound 
the inclusion, but unlike influenza studies, did not induce the recruitment of 
lysosomes. Notably, anti-IncA IgG recruited sequestosomes to the inclusion 
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membrane, markers of the ubiquitin/proteasome pathway and major 
histocompatibility complex (MHC) class I loading. To determine if the protection 
against C. muridarum infection afforded by IncA IgG in vitro translated in vivo, wild 
type mice and mice deficient in functional FcRn and MHC-I, were immunized, 
depleted of CD4+, and urogenitally infected with C. muridarum. Unlike in pIgR-
deficient mice, the protection afforded from IncA immunization was completely 
abrogated in mice lacking functional FcRn and MHC-I/CD8+. Thus, both anti-IncA 
IgA and IgG can bind the inclusion in a pIgR and FcRn-mediated manner, 
respectively. However, only IgG mediates a higher reduction in chlamydial infection 
in vitro and in vivo suggesting more than steric blocking of IncA had occurred.  
Unlike anti-MOMP IgA, which reduced chlamydial infection of epithelial cells and 
male mouse tissues, IgG was found to enhance infectivity in vitro, and in vivo. 
Opsonization of EBs with MOMP-IgG enhanced inclusion formation of epithelial cells 
in a MOMP-IgG dose-dependent and FcRn-dependent manner. When MOMP-IgG 
opsonized EBs were inoculated into the vagina of female mice, a small but non-
significant (p > 0.05) enhancement of cervicovaginal C. muridarum shedding was 
observed three days post infection in mice with functional FcRn. Interestingly, 
infection with opsonized EBs reduced the intensity of the peak of infection (day six) 
but protracted the duration of infection by 60 % in wild type mice only. Infection with 
EBs opsonized in IgG also significantly increased (p < 0.05) hydrosalpinx formation 
in the oviducts and induced lymphocyte infiltration uterine horns. As MOMP is an 
immunodominant antigen, and is widely used in vaccines, the ability of IgG specific 
to extracellular chlamydial antigens to enhance infection and induce pathology 
needs to be considered. 
Together, these data suggest that immunoglobulins play a dichotomous role in 
chlamydial infections, and are dependent on antigen specificity, FcRn and pIgR 
expression. FcRn was found to be highly expressed in upper male reproductive 
tract, whilst pIgR was dominantly expressed in the lower reproductive tract. 
Conversely, female mice expressed FcRn and pIgR in both the lower and upper 
reproductive tracts. In response to a normal chlamydial infection, pIgR is up-
regulated increasing secretory IgA release, but FcRn is down-regulated preventing 
IgG uptake. Similarly to other studies [5-6], we demonstrate that IgA and IgG 
generated during primary chlamydial infections plays a minor role in recall immunity, 
and that antigen-specific subunit vaccines can offer more protection. We also show 
that both IgA and IgG can be used to target intracellular chlamydial antigens, but 
that IgG is more effective. Finally, IgA against the extracellular antigen MOMP can 
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afford protection, whist IgG plays a deleterious role by increasing infectivity and 
inducing damaging immunopathology. Further investigations with additional antigens 
or combination subunit vaccines will enhance our understanding the protection 
afforded by antibodies against intracellular and extracellular pathogenic antigens, 
and help improve the development of an efficacious chlamydial vaccine. 
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1.1 DESCRIPTION OF THE SCIENTIFIC PROBLEM INVESTIGATED 
Reproductive tract Chlamydia trachomatis infections affect an estimated 90 million 
people annually [7] with notifications of infections quadrupling in Australia within the 
last decade [8]. Chlamydial infections are also often asymptomatic contributing to 
the development of chronic infections and infertility. Whilst antibiotics remain the 
gold standard for clearing chlamydial infections, antibiotic use can facilitate the 
evolution of resistance, and has also been demonstrated to enhance the incidence 
of chlamydial infections thought to be due to the abrogation of immune maturation 
[9]. Whilst the incidence continues to increase, and antibiotic treatment provides no 
lasting protection, the development of chlamydial vaccines to reduce transmission or 
pathology have attracted decades of research. The majority of research is focused 
on reducing female reproductive tract infections, while the development of male 
vaccines attracts considerably less attention, despite infection also causing 
damaging pathology in males. Males are also arguably the reservoir of chlamydial 
infection. 
The role of cell-mediated immunity in human female genital tract infections is well 
established [1]. However, the male reproductive tract is known to actively suppress 
immune responses and is considered an ‘immune privileged’ site. This suppression 
prevents the development of autoimmunity to sperm antigens during adolescence, 
long after immune tolerance has been established [10]. Experimentally, the 
protective role of CD4+ T helper 1 cells in protection from chlamydial infections is 
widely accepted [1], however the influx of this pro-inflammatory cell type into the 
testes is associated with inflammation, and the development of autoimmunity and 
infertility [2-3].  Whilst the maturation of immune responses in the male reproductive 
tract is suppressed under normal circumstances, humoral immunity can be 
developed at different mucosal sites via the common mucosal route. Additionally, 
immunoglobulin is readily transported into the lumen and can provide long-lasting 
antigen-specific immunity.  
Two important antibodies in mucosal tissues are IgA and IgG. These Ig’s are 
produced locally and from distant tissues, and are transported into the mucosal 
lumen via receptor-mediated transcytosis. Transport of IgA is mediated by the 
polymeric immunoglobulin receptor (pIgR) which binds IgA within the epithelia 
(lamina propria), facilitates endocytic delivery and cleavage of pIgR-bound IgA 
(termed SIgA) into the lumen. Intracellular IgA has also been shown to bind and 
extrude viral antigen in a pIgR-dependent manner [11] suggesting that it may also 
be able to bind intracellular chlamydial antigens. Unlike unidirectional pIgR-mediated 
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delivery of IgA, IgG is delivered to and from the lumen by the neonatal FcRn. Whilst 
bidirectional, FcRn transport of IgG is pH-mediated with binding occurring at acidic 
pH (< 6.5) and release at neutral pH (7.4). Similarly to pIgR, recent studies have 
demonstrated that FcRn also delivers IgG to intracellular antigens in epithelial cells 
[4].  As both the male and female reproductive tracts have mucosa of different 
lumenal pH (pH 4.5 - 7.4), and secreted IgA and IgG, we sought to determine the 
expression, function and role of FcRn and pIgR during chlamydial infections. 
 
1.2 SPECIFIC AIMS OF THE STUDY 
1. To investigate the distribution the pIgR and the FcRn in normal and C. 
muridarum-infected mice (Chapter 4).  
2. To investigate the role of the pIgR on delivery of antigen-specific IgA to 
intracellular and extracellular chlamydial antigens in vitro and in vivo 
(Chapter 5). 
3. To investigate the role of the FcRn on delivery of antigen-specific IgG to 
intracellular (Chapter 6) and extracellular (Chapter 7) chlamydial antigens in 
vitro and in vivo. 
 
1.3 PROGRESS OF RESEARCH LINKING THE SCIENTIFIC PAPERS   
The data presented in this thesis are directly linked to the topic of humoral immunity 
during male (and female) reproductive tract chlamydial infections. Combined, these 
findings expand our understanding of the mechanisms of immune regulation during 
chlamydial infection, and the role of pIgR, IgA, FcRn and IgG in intracellular and 
extracellular binding of chlamydial antigens in vitro and in vivo.  
Taken together, the results presented in Chapters 4, 5, 6 and 7 improve our 
understanding of pIgR and FcRn in a commonly used animal model, as well as 
determining the efficacy of protection afforded by IgA and IgG specific to a range of 
chlamydial antigens. These results may assist in the development of more 
specifically targeted vaccines for chlamydial infections, but also other intracellular 
pathogens and carcinomas.  
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2  INTRODUCTION 
2.1  EPIDEMIOLOGY OF CHLAMYDIAL INFECTIONS 
2.1.1  Origins and Taxonomy of Chlamydia trachomatis  
Chlamydia trachomatis is a bacterium that commonly infects the mucosal epithelia 
of the ocular, ano-rectal and urogenital tracts. Infections can also present clinically 
as colonization of the throat [12], mouth [13], liver [14], appendix [15], synovial 
membranes [16] and skin [17]. Chlamydia-like infections of the eye were first 
described in antiquity [18], but specifically by Halberstadter and von Prowazek in 
1907 when they noticed microscopic intracellular inclusions in exudates taken from 
infected eyes [19]. The etymology of ‘Chlamydia’ originates from Greek (chlamyos = 
cloak-like mantle) and describes the organism’s ability to drape around the host 
nuclei [20]. Due to the obligate intracellular growth cycle of chlamydiae, it was 
considered a virus until the 1960s when it was confirmed to be a bacterium due to 
the presence of prokaryotic ribosomes, DNA and RNA.  Serotyping of patients with 
C. trachomatis infections has categorized at least 19 serovars based on 
seroreactivity to MOMP and grouped the serotypes according to tissue tropism. C. 
trachomatis infections that lead to trachoma are grouped into serovars A, B, B1 and 
C, whilst serovars D-K are associated with genital infection. The most virulent 
serovars (L1, L2, L2b and L3) can lead to chlamydial invasion of the inguinal and 
ano-rectal draining lymphatics and lymph nodes, and are termed lymphogranuloma 
venereum (LGV) [21].  
2.1.2  Trachoma 
Direct inoculation of C. trachomatis (serovars A-C) into the eye commonly leads to 
mild inclusion conjunctivitis within 4-12 days and is typically accompanied by 
mucopurulent discharge. If left untreated, the infection can progress to chronic 
follicular conjunctivitis and scarring (termed trachoma). Globally, ocular C. 
trachomatis infection affects 41 million people annually, is the seventh leading cause 
of blindness (3.6%), and the leading cause of infectious blindness [22]. However, 
the incidence of trachoma is almost exclusively limited to developing countries 
where hygiene and sanitation are poor. Exceptionally, Australia is one of the few 
developed nations where the incidence of trachoma remains high in Indigenous 
populations. Recently, improvements in prevention and availability of widespread 
antibiotic treatment by the World Health Organization led the establishment of the 
Global Elimination of Trachoma by 2020 program (GET 2020), and has seen the 
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incidence of endemic trachoma fall from 360 million active infections in 1985, to 84 
million active infections in 2011 [23] .  
2.1.3  C. trachomatis Infections of the Genital Tract 
C. trachomatis is the world’s leading cause of bacterial sexually transmitted 
infections with an estimated 90 million new cases per annum [24]. Chlamydial 
infections of the genital tract remain the most commonly reported sexually 
transmitted bacterial infections of the developing and developed world, and is the 
leading cause of preventable infertility in the western world [24]. Despite the 
improvement of diagnostics and screening regimes, the incidence of chlamydial 
infections continues to rise with notifications quadrupling in the last 20 years in the 
USA [25], and the last 10 years in Australia [8]. In the USA, ethnicity may play a role 
in susceptibility to genital chlamydial infection, with blacks (8.7 times), 
Indian/Alaskan natives (4.7 times) and Hispanics (2.9 times) having higher rates of 
infections than in whites [26]. In Australia, the rate of chlamydial infection in rural 
Indigenous populations is three times higher than that of non-Indigenous people 
living the urban areas [27]. There has also been a consistently strong statistical bias 
of incidence towards females between the ages 15-25 and males 20-25, likely due 
to increased sexual activity [26]. Between genders, incidence is almost three times 
higher in females than males [26], presumably due to improved screening 
prevalence in female populations. Genital tract chlamydial infections are also often 
asymptomatic in females (70-90%), and males (30-50%) indicating that the 
incidence is likely to be higher than notifications suggest [28]. Despite improvements 
in screening and early treatment, chlamydial infections continue to put significant 
burdens on both healthcare systems and the economy, with a conservative estimate 
putting the annual cost at US$2 billion in the USA alone [29]. Improvements in 
diagnosis, including highly sensitive nucleic acid amplification tests (NAATs), and 
reliability of specimen handling have allowed non-invasive collection of urine 
specimens by health practitioners or by home-delivered personal tests.   
2.2  THE CHLAMYDIAL DEVELOPMENT CYCLE 
C. trachomatis is a Gram-negative obligate intracellular bacterium with a tropism for 
the mucosal epithelia. Chlamydiae have a morphologically distinct biphasic 
developmental cycle comprised of an rigid extracellular, infectious and metabolically 
inert elementary body (EB), approximately 0.3 µm in diameter; and an intracellular, 
non-infectious, metabolically active and pleomorphic replicating reticulate body (RB) 
approximately 1.0 µm in diameter. Despite the absence of detectable peptidoglycan 
in the cell wall, the EB shows high resistance to environmental and physical 
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disruption; due primarily to matrices of highly cross-linked disulfide-bonded outer 
membrane proteins [30-31]. The principle mass of these outer membranes consists 
of a transmembrane MOMP (39-45 kDa) [32], and two cysteine-rich proteins (12 and 
60 kDa), which when cross-linked are only susceptible to denaturing by strong 
anionic reducing surfactants (sodium dodecyl sulfate), but not non-ionic (Triton X-
100), dipolar ionic (Zwittergent TM314), or mild (sodium deoxycholate) detergents 
[33].  
Once an infectious EB attaches to the host cell membrane, it enters by clathrin-
mediated endocytosis and begins to form a parasitophorous vacuole, termed the 
inclusion (Figure 2.1). Within the inclusion, EBs differentiate into RBs and replicate 
by binary fission, before de-differentiating back into EBs and exiting the cell by 
extrusion or host cell lysis [34]. The duration of the life cycle varies between 
Chlamydia spp. with the murine biovar C. muridarum completing its life cycle within 
30 hours of infection, and C. trachomatis (serovars D-K and L2) life cycle completion 
within 72 hours.   
2.2.1  The Attachment and Entry of Chlamydial EBs 
Initially, chlamydial EBs attach to host cell outer membranes by electrostatic, 
relatively weak and reversible binding of heparin sulphate proteoglycans [35]. 
Following electrostatic attachment, the EB binds to a currently unknown secondary 
host protein and induces irreversible microvillar hypertrophy. The EB-mediated 
recruitment of host actin is dependent on the EB protein conformation evidenced by 
the attachment, but not internalization, of heat-killed or chemically fixed EBs and 
suggests either the modification of EB surface proteins, or delivery of new proteins 
is required to initiate endocytosis [36].  Microvillar hypertrophy is accompanied by 
type III secretion (T3S) of proteins such as translocated actin recruiting 
phosphoprotein (TARP), T3S needle (CdsD/F) and tip (CT584) proteins, chaperones 
(Scc1 and Scc2), secretion pore components (Cds C/ /F/J/L/N/Q/R/S/T/U/V), and 
secreted proteins (chlamydial outer protein (Cop) B/D/N); which together hijack and 
induce host cell actin recruitment, polymerization and remodeling, and subsequent 
internalization at the site of EB attachment [37-39]. Remodeling of the actin 
cytoskeleton facilitates invagination in host membrane architecture and induces 
clathrin-mediated endocytosis, evidenced by detectable EBs within clathrin-coated 
pits [40] and co localization of C. trachomatis with clathrin heavy chains [41].  Whilst 
clathrin-mediated endocytosis plays a crucial role in the internalization of     
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Figure 2.1   
The Chlamydial Life Cycle  
The chlamydial life cycle involves a complex pathway of extracellular and 
intracellular reactions with the host cell. EBs initially attach to host plasma 
membranes (1) mediating host plasma membrane reorganization and actin 
recruitment, which facilitates endocytosis of the EB (2). Internalized EBs are then 
transported within endosomes to the Golgi apparatus along microtubules (3) and 
secrete effector proteins which fragment the Golgi apparatus, allowing nutrient 
acquisition from the exocytic pathway. The EB begins to differentiate into the 
metabolically active RB phase (4) and replicates via binary fission (5) within a 
developing inclusion membrane. RBs continue to replicate over the next 24-48 
hours (6) before beginning to de-differentiate back into EBs (7-8). The life cycle 
completes with fusion of the inclusion with the host plasma membrane, facilitating 
lysis or extrusion of infectious EBs into the extracellular space (9). Antibody-bound 
EBs can also enter cells upon binding Fc gamma receptor III (10), and avoid fusion 
with lysosomes. In the presence of molecular stresses, chlamydiae can enter a 
persistent, viable but non-infectious phase (11).   
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C. trachomatis EBs into HeLa human uterine epithelial cells [42], it does not appear 
to be important in C. pneumoniae entry [43]. In contrast, Madin Darby Canine 
Kidney (MDCK) epithelial cells are permissive to C. trachomatis infection when sub-
confluent, but not once polarized [44]. Polarized MDCK cells continue to express 
clathrin [45] and caveolin-1 [46] at the apical surface but redistribute caveolin-2 
preferentially to the basolateral compartment [46] in turn making the cell non- 
permissive to apical infection. Together these studies suggest a role for calveolin-2 
as well as clathrin in endocytosis of chlamydial EBs. Targeting the attachment, T3S   
and/or   entry   mechanisms of Chlamydia spp. with neutralizing antibodies may 
prevent infection and/or interfere with the early replicative cycle. 
Unlike other intracellular pathogens, the entry of chlamydiae into cells can be active 
or passive. In the absence of antibody, Streptococcus pyogenes and S. pneumoniae 
are able to inhibit phagocytosis with M proteins or capsular polysaccharides, but this 
protection is abrogated in the presence of immunoglobulin (Ig), termed opsonization 
[47-48]. The opsonized S. pyogenes and S. pneumoniae-immune complexes can be 
phagocytosed via Fc receptors and targeted for degradation in lysosomes [49-50]. A 
similar mechanism of protection is observed in tripartite motif-containing 21 
(TRIM21)-mediated internalization of IgG opsonized virons [51]. Toxoplasma gondii 
are also non-fusogenic once internalized [52], but similarly to S. pyogenes and S. 
pneumoniae, once opsonized T. gondii are internalized via Fc-mediated endocytosis 
and are efficiently delivered to lysosomes and destroyed [53]. Uniquely, opsonized 
Brucella abortus and chlamydial EBs can also be internalized by Fc receptor-
mediated endocytosis but are able to avoid fusion with host lysosomes and continue 
to replicate [54-55], seemingly using the Fc-receptor mediated uptake as another 
mechanism of entry. Remarkably, mouse anti-MOMP IgG2b-opsonized C. 
trachomatis EBs have been shown to use this mechanism of Fc-gamma receptor 
(FcγR) III-mediated uptake to enhance infection in vitro and in vivo compared to 
non-opsonized controls [56]. These abilities of chlamydiae to enter host cells 
unchallenged, or opsonized with antigen-specific IgG, both enhances the infectivity 
of chlamydiae, but also weakens the efficacy of the immune response developed in 
response to infection.  
2.2.2  The Chlamydial Inclusion 
Unlike other intracellular pathogens, chlamydiae undergo their entire intracellular 
development within the inclusion. Following endocytosis, the internalized EB is 
encapsulated within a tightly bound membrane vacuole, which contains no markers 
of endocytic or lysosomal pathways, and hence is considered non-fusogenic. 
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However, the inclusion is able to initiate fusion with sphingomyelin-containing 
vesicles. This fusion allows chlamydiae to hijack vesicular trafficking and sequester 
sphingomyelin, cholesterol and other lipids destined for host plasma membranes 
[57]. The re-routing of host lipid pathways suggests that while being non-fusogenic 
and disassociated from endocytic compartments, chlamydiae are able to fuse with 
exocytic vesicles destined for the host cell plasma membrane.  
The inclusion membrane prevents fusion with the host endocytic pathway whilst 
permitting passive flux of cytoplasmic ions (H+, Na+, K+, Ca2+), but not low molecular 
weight particles (no larger than 0.5 kDa) suggesting receptor-mediated transport is 
utilized for nutrient acquisition [58-59]. The inclusion membrane mediates exocytic 
acquisition of host lipid-containing vesicles, in the absence of the essential soluble 
N-ethylmaleimide sensitive fusion attachment protein receptor (SNARE) and 
Sec1/Munc18-like intracellular membrane fusion pathway [60]. Interestingly, 
chlamydiae are able to subvert SNARE pathways by blocking and inhibiting SNARE 
machinery from endosomal fusion with the inclusion membrane [61]. Binding of 
SNARE pathway proteins (particularly vesicle associated membrane proteins (Vamp 
4, 7 and 8) is orchestrated by a few chlamydial inclusion proteins, which are 
cytoplasmic-facing and have predicted SNARE motifs. These chlamydial SNARE-
binding proteins include IncA, CT813, and CT223 [62]. Specific blocking of these 
SNARE-inhibiting chlamydial proteins under native conditions has proven difficult, 
however micro-injection of either guinea pig anti-IncA bivalent IgG or monovalent 
Fab fragments into C. psittaci-infected human epithelial cells has demonstrated that 
IncA is both uniformly distributed and cytoplasmic facing [63]. Furthermore, blocking 
IncA with bivalent IgG induced the aggregation of IncA proteins and the formation of 
aberrant-shaped inclusions but was unable to arrest development [64]. Whilst anti-
IncA IgG antibodies were unable to inhibit chlamydial growth as determined by 
microscopy, direct microinjection of anti-IncA antibodies from another host species 
was likely not sufficient to activate intracellular endosomal pathways targeting the 
chlamydiae for phagolysosomal degradation. Despite revealing that direct blockage 
of IncA is not sufficient to inhibit chlamydial growth, receptor-mediated transcytosis 
of antibody within endosomes to the inclusion may still trigger host-specific 
degradation pathways. 
2.2.3  Chlamydial Replication and Persistence 
The intracellular replicative development of C. trachomatis growth can be broadly 
grouped into 3 major temporal stages which express important proteins; early (0-6 
hours), intermediate (6-12 hours), and late (12+ hours) transcription [65]. Following 
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endocytosis the EB initiates cleavage of the EB outer membranes [30, 66] and 
begins transcription and translation within 15 minutes [67-68],  and within 4 hours 
has completed at least one round of binary fission [65]. This early replication 
process coincides with inclusion formation (IncB, C, D, E, F, G expression) [65], 
inhibition of phagolysosomal fusion [54] and trafficking to the host Golgi apparatus 
(GA) along microtubules [69]. After arriving at the GA, chlamydiae secretes 
proteases, including CPAF [70], which cleaves the integral GA protein golgin-84 
leading to fragmentation of the GA into ministacks that are utilized by the growing 
inclusion to sequester cholesterol, sphingomyelin and other lipids en route to host 
plasma membranes [70-71].  Surprisingly, transcription of important metabolic 
proteins involved in glycolysis and the pentose phosphate pathway do not appear 
until the intermediate phase [65]. Additionally, transcription of structural proteins 
(MOMP, peptidoglycan and lipopolysaccharide (LPS)) as well as some T3S proteins 
also are delayed until this intermediate phase of replication [65]. Late transcription is 
primarily focused on the de-differentiation of RBs back into EBs including homologs 
of histone (hctA), outer-membrane proteins (omcB) and packaging of untranslated 
mRNA into the condensed nucleoprotein core of EBs [65]. This untranslated mRNA 
is utilized together with normal DNA-dependent RNA synthesis during re-infection 
[54, 65].  After completing a single development cycle, a single EB can yield 
between 120 (C. trachomatis serovar H), 240 (C. trachomatis serovar D) and 950 
(C. muridarum) progeny which go onto to infect other cells or are spread to another 
host [72]. Together, these studies suggest that immediately following internalization, 
chlamydiae rapidly begins synthesis of proteins associated with blocking the 
endocytic pathway and establishing an intracellular niche. Following isolation from 
host defenses and the initiation of replication, chlamydiae begin utilizing traditional 
metabolic pathways which assist in the production of outer membrane proteins and 
T3S system pathways. Once a critical mass of replication has been achieved, RBs 
begin to de-differentiate back into EBs which includes precursor transcripts for the 
following infectious cycle.  
Chlamydiae can also enter a persistent state of growth if exposed to cellular and 
molecular stresses. This dormant phase of chlamydial growth is characterized by 
large pleomorphic RBs, termed aberrant bodies (AB), which are non-infectious but 
remain viable. A hallmark of ABs as opposed to dying RBs is that removal of the 
particular stresses can often allow the chlamydiae to re-enter the growth life cycle. 
Experimentally, the transition of RBs into ABs can be induced by treatment with 
antibiotics, deprivation of amino acids or iron, co-infections, heat-shock, or cytokines 
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[73]. Treatment with antibiotics (penicillin or erythromycin) blocks conversion of RBs 
into EBs arresting the developmental cycle and may explain why chlamydial DNA 
and antigen is detectable in the fallopian tubes of non-infectious infertile women 
previously treated with antibiotics [74]. Deprivation of nutrients also induces 
persistence, particularly removal of tryptophan [75-76] and iron [77-78]. Interestingly, 
an excess of amino acids can also induce persistence; specifically Phe, Met, Ile, 
Leu, Lys, Asn, Arg, His, Tyr and/or Thr [79]. This appears to function through 
inhibition of autophagy, which is inactivated in an excess of amino acids and is 
essential for chlamydial growth [79-80]. Pro-inflammatory cytokines such as 
interferon (IFN) γ can also induce persistence. Binding of IFNγ to its receptor 
induces expression of indoleamine 2,3-dioxygenase (IDO), which catalyzes the 
intracellular pool of L-tryptophan inducing persistence in a mechanism similar to 
nutrient deprivation [75-76]. Together, this variety of mechanisms to escape death 
and persist allows chlamydiae to remain viable until the alleviation of the stresses 
and adds to the complications and pathogenesis associated with chronic infections. 
2.3 PATHOGENESIS AND SEQUELAE IN CHLAMYDIAL INFECTIONS 
C. trachomatis infections of the human urogenital tract can place significant 
economic burden on healthcare systems globally, primarily due to prolonged 
pathological outcomes. There is also indirect burden associated with Chlamydia-
infected individuals having a significantly increased risk of acquiring and transmitting 
other sexually transmitted pathogens such as human immunodeficiency virus (HIV), 
human papilloma virus (HPV) and herpes simplex virus (HSV) [81]. While acute 
infections can be self-resolving within a few months, chronic infections of 
reproductive tract tissues can lead to destructive pro-inflammatory responses, 
occlusion of tracts, scarring, pelvic inflammatory disease (PID), ectopic pregnancy 
and infertility.  
2.3.1 Pathogenesis of Female Genital Tract Chlamydial Infections  
In females, infection of the urogenital tract by C. trachomatis commonly presents as 
vaginal or cervical colonization, but the more severe pathological outcomes are 
associated with ascending infection, particularly infection and inflammation of the 
uterus, fallopian tubes (salpingitis) and ovaries. Following infection of the female 
reproductive tract (FRT) (commonly the columnar epithelia of the endocervix), 
infected epithelia secrete pro-inflammatory mediators; chemokine ligand (CXCL) 1, 
CXCL16, interleukin (IL)-1, IL-6, IL-8, granulocyte/monocyte colony stimulating 
factor (GM-CSF) and tumor necrosis factor (TNF) [82]. The secretion of these 
cytokines attracts natural killer (NK) cells and neutrophils which are co-stimulated by 
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CXCL5 and CXCL10 to secrete IFNγ, IFNα, IFNβ, and IL-12 [82]. The production of 
these pro-inflammatory cytokines polarizes the developing infection towards a T 
helper (Th) 1 type immune response which is necessary for overcoming infection, 
but is also associated with deleterious tissue pathology [1]. Lower reproductive tract 
infection typically results in colonization of the endocervix, and can present clinically 
as an inflamed cervix with a mucopurolent discharge. Importantly, the incidence of 
lower reproductive tract infections that ascend to cause PID are estimated to be as 
high as 30%, with 10-20% of those PID patients progressing to tubal infertility [83]. 
Infections ascending into the uterus and fallopian tubes are associated with the 
damaging pathology but are difficult to diagnose without laparoscopy. Attempts to 
minimize the invasiveness of diagnosis and simplify the differentiation of acute from 
chronic chlamydial infections have proven difficult. Whilst commercially available 
serum tests are able to distinguish between acute and chronic chlamydial induced 
inflammation with some confidence, their specificity varies from 62-100% likely due 
to cross reactivity with C. pneumoniae antigens, but more alarmingly their sensitivity 
varies from 12-69 % (i.e. 31-88% of patients are misdiagnosed) [84]. Currently, 
there are only a few non-commercial groups focusing on improving and simplifying 
chronic chlamydial infection diagnosis in an attempt to identify patients at risk of PID 
without the need for invasive laparoscopy [85-86]. In the absence of a vaccine, the 
development of more accurate and rapid clinical tests to identify PID will improve 
prognosis and reduce morbidity associated with chronic female reproductive tract 
chlamydial infections.   
2.3.2 Pathogenesis of Male Urogenital Tract Chlamydial Infections  
In males, C. trachomatis can colonize and cause inflammation in the penile urethra, 
bladder [87], prostate gland [88] and accessory organs [89], but can also ascend to 
the upper reproductive tract infecting the vas deferens, epididymes, and testes [90]. 
Similarly to females, infection of the male reproductive tract (MRT) is also thought to 
negatively influence fertility [90]. Chlamydial infection can occlude MRT tubules, 
decrease acrosome reaction capacity [91], increase spermatozoa DNA 
fragmentation [92],  adhere to spermatozoa disrupting normal motility or acting as 
vectors of infection for females [93], and induce phagocytosis of infected 
spermatozoa by epithelia [94]. As most diagnostics are now performed by NAAT of 
first void urine or urethral swabs, the sensitivity and ease of collection has led to 
increased notifications. Interestingly, routine chlamydial screening of first void urine, 
urethral swabs and semen from patients attending an andrology clinic demonstrated 
that of the 26 % of patients that were C. trachomatis positive, 5.3 % of these were 
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positive in semen, but not urine or urethral swabs indicating that conventional 
sampling will not identify infections that disseminate from the bladder or urethra [95].  
2.3.2.1  Chlamydial Infections of the Lower MRT 
The lower MRT includes the penile urethra, prostate gland, bladder and accessory 
glands and is the point of entry for reproductive tract pathogens. The MRT has a 
variety of innate and adaptive immune responses to assist in minimizing infectious 
burden and ascension. The simplicity and relatively non-invasive nature of specimen 
collection from the lower MRT allows rapid diagnosis of chlamydial infections and 
makes it a popular indicator of colonization, but is unable to differentiate between 
upper and lower MRT infections [95-96]. 
2.3.2.1.1. Chlamydial Urethritis 
Unlike the shorter female urethra that only expels urine; the male urethra also 
expels ejaculate and provides the initial site of contact for pathogens into the MRT. 
The role of C. trachomatis infection in male urethritis is estimated to be between 
30% [97] and 56.6% [98] depending on the type of diagnostic test performed. 
Anatomically, the male urethra is divided into four distinct regions each lined with 
different types of epithelia; the pre-prostatic, prostatic, membranous and penile 
urethra [99].  
Chlamydial infection of the urethra and the influence on inflammation has been 
investigated with urethral swabs sampling the prostatic urethra and penile urethra. 
Infection of the prostatic urethra has been described and was associated with 
inflammation and presence of bullous lesions in patients with asymptomatic gross 
hematuria [100]. Infection of the penile urethra leads to increased urethral lumen 
concentrations of secretory immunoglobulin A (SIgA), IgG, and IL-8; but not serum 
Ig concentrations suggesting localized plasma cell Ig secretion and epithelial IL-8 
(but not IL-1, 2, 6, 10, 12, 18 or IFNγ) production [101]. Chlamydial infection of the 
pre-prostatic urethra and membranous urethra have not been reported, likely due to 
the small length and difficulty in sampling but data on the other urethral sections and 
infectability of afferent tissues (such as the bladder and prostate) suggest they are 
also permissive to infection. Whether or not this infectability leads to inflammation 
remains undetermined. 
2.3.2.1.2 Chlamydial Prostatitis 
Unlike urethritis which is generally short lived, symptomatic prostatitis lasts at least 3 
months, which facilitates prolonged exposure to the deleterious side effects 
associated with chronic inflammation [102]. The ability of C. trachomatis to infect the 
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prostate is undeniable, but its role in prostatitis remains controversial, primarily due 
to the difficulty in obtaining prostatic specimens uncontaminated with other tissue 
sites [103]. Between 2-30 % of patients suffering from prostatitis have a C. 
trachomatis incidence as determined by prostatic biopsy showing the high variability 
in specimen collection and sampling [104]. However, a recent study found that 70 
out of 762 (9%) patients  with chronic prostatitis also had C. trachomatis infections 
of the prostate [102]. Taken together, C. trachomatis infections appear to account 
for between 8 - 40 % (mean 25 %) of cases of prostatitis in humans [88, 102, 105-
106].  There is some evidence that chronic C. trachomatis infection of the prostate 
can lead to prostate cancer either through prolonged inflammatory damage or 
increased susceptibility to human papilloma virus infection [107]; however, other 
serology-based large cohort studies screening for prostate cancer antigens appear 
to be in disagreement [108-110]. 
2.3.2.2  Chlamydial Infections of the Upper MRT 
Bacterial infection of the male upper reproductive tract tissues can increase immune 
cell infiltration and inflammation and is associated with infertility. While the influence 
of chlamydial infection on male infertility is unconfirmed, it is known that prolonged 
infections can cause occlusion, scarring, and could also be associated with immune 
infiltration and production of anti-sperm antibodies [90, 111]. Unlike the female 
reproductive tract, the upper MRT is relatively isolated from the systemic immune 
system (termed ‘immune privileged’). The most widely accepted model of immune 
tolerance is clonal deletion theory and suggests that under normal circumstances, 
the developing human immune system recognizes host antigens and clonally 
deletes or anergizes auto-reactive precursor lymphocytes, but also induces 
production of antigen-specific regulatory T cells [112]. Immune tolerance is 
established early in life, but males only develop spermatazoa in adolescence. Thus, 
to prevent the development of androgen-deficiency, sterility and autoimmunity in the 
testes, the testicular environment is under strict immune regulation. To prevent 
autoimmunity, antigen is sequestered behind the blood-testis and blood epididymis 
barriers, and both immune activation and presentation is impaired and suppressed 
[10]. However, acute and chronic bacterial infection of the upper MRT could 
compromise the immune suppression mediated by somatic cells such as Sertoli 
cells in the testes. Prolonged infection could also compromise the integrity of the 
blood-testes and blood-epididymal barriers, allowing the invasion of antigen-
presenting cells and non-tolerant immune cells from the circulation. This could lead 
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to the subsequent development of adaptive immune responses to self antigens 
(autoimmunity).  
2.3.2.2.1 Chlamydial Epididymitis 
As the epididymes house the spermatozoa in the final stages of maturation, infection 
of these ducts poses significant hazards. Together with Neisseria gonorrhoeae, C. 
trachomatis infections of the epididymes are the most common etiological agents of 
epididymitis, and unlike prostatitis, the influence of chlamydiae on inflammation is 
widely accepted [113]. Quantitatively, C. trachomatis infections account for 31 % of 
cases of epididymitis and are the most common cause of epididymitis in men under 
35 years of age [114-115]. Besides the risk of infection compromising the blood-
epididymal barrier and immune privilege, the epididymes directly drain the testes 
and increase the risk of immune infiltration into the gonads, potentially exacerbating 
and accelerating infertility. 
2.3.2.2.2 Chlamydial Orchitis 
Ascending chlamydial infection can lead to infection of the testes and potentially 
increases the risks of infertility from compromised blood-testes barrier, damaged 
Sertoli cells, impaired spermatogenesis, immune infiltration and auto-immunity [90]. 
Ascending chlamydial infection of the testes has been widely documented in 
mammals, with rodents [116-117], monkeys [118], koalas [119], bulls [120], boars 
[121], and humans [122-123] all having viable chlamydiae in the testes. Similarly to 
chlamydial epididymitis, patients with acute epididymo-orchitis infected with C. 
trachomatis was high, and was dependent on age with the C. trachomatis detectable 
in 45 % of men under 35, but only 9% of men over 35 [122]. Together, these studies 
demonstrate that chlamydiae can infect the testes, but can also subsequently induce 
inflammation (particularly in younger males), which could lead to chronic damage 
and infertility. 
2.4  EFFECTOR MECHANISMS OF THE HOST IMMUNE RESPONSE 
Effector mechanisms elicited by pathogenic challenge are observable throughout 
nature, from bacterial resistance to bacteriophages, non-specific innate protection in 
insects, and more specified adaptive responses in more complex organisms such as 
vertebrates. These host effectors must also synchronously balance symbiosis and 
immunity. It is critical that the immune effectors are not (or at least minimally) 
activated against the host protein (autoimmunity), non-hazardous antigens (allergy), 
and the standard background level of normal flora, but must paradoxically be primed 
to rapidly respond to pathogenic assault. Zoonotic chlamydial infections have been 
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reported throughout the animal kingdom; including fish [124], amphibians [125], 
birds [77], marsupials [119] and placentals [126], and all engage the respective host 
immune system differently. For the purposes of brevity and clinical significance, only 
the effector immune responses to genital tract chlamydial infections of human and 
experimental mice will be discussed in detail. 
2.4.1  Innate Responses to Chlamydial Infections 
The innate immune response is an important arm in protection against pathogens 
[127-128]. It can immediately activate upon infection (within 4 hours), and is followed 
by early induced responses (up to 4 days), which includes inflammation, chemotaxis 
and humoral influx. The innate immune response itself can only generate non-
specific protective immunity, but is crucial in activating inflammatory cascades, 
secretion of chemokines and cytokines to attract effector cells of both innate and 
adaptive immune responses. The pattern recognition of conserved microbial 
molecules is dependent on germline-encoded receptors, which are able to 
distinguish the host from normal flora and pathogenic assault. The distribution of the 
innate response is tissue specific, and to minimize reactivity to non-threatening 
antigens or normal flora, often requires a threshold of activation to be reached 
before a complete immune response is initiated [129].  
The innate immune response can be broadly categorized into four parts; 
phagocytes, the complement system, anti-microbials, and pattern-recognition. The 
three major phagocytes involved in the innate immune response are macrophages, 
dendritic cells, and polymorphonuclear leukocytes (PMNs)/neutrophils, which 
together can phagocytose pathogens and target them for degradation in 
phagolysosomes with the aid of toxic molecules including nitric oxide, superoxide 
anion and hydrogen peroxide. Nitric oxide is produced in high amounts under the 
control of nitric oxide synthase and has been implicated in the reducing the 
dissemination of pathogens from the initial site of infection, including chlamydial 
infections of the female reproductive tract [130]. Whilst the complement system has 
a limited affect on chlamydiae in the absence of antibody, C. trachomatis does 
induce chemotaxis of PMNs meditated by the alternative pathway of activation 
(specifically C5a) [131]. Similarly, anti-microbials such as natural antimicrobial 
peptides including protegrins and defensins are ubiquitously present in both the 
male and female reproductive tracts [127, 132]. These anti-microbials are produced 
by a variety of cell lines (including phagocytes) and assist cell-mediated responses 
in limiting pathogenic replication, including C. trachomatis [133-135], but are outside 
the scope of this review.   
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Pattern recognition receptors (PRR) are a super family of host intracellular and 
membrane bound proteins that recognize cellular damage as well as conserved 
molecules, termed pathogen associated molecular patterns (PAMPs), present in 
viruses, fungi and bacteria as well as cellular damage. One of the most important 
subgroups of the PRRs are the toll-like receptors (TLR) of which there are 13 known 
transcripts in humans and mice, all responding to different PAMP ligands. In human 
females, TLRs 1-10 are expressed throughout the FRT with TLR2 and TLR4 highly 
expressed in the upper reproductive tissues [128]. In the MRT, TLRs 1-11 are 
expressed, with TLR 1, 2, 4 and 6 being highly expressed in the testes, epididymes 
and vas deferens [136]. Whilst the exact mechanisms of TLR activation in 
chlamydial infections remains poorly understood, it is currently known that TLR2 
recognizes intact chlamydiae, whilst TLR4 recognizes LPS and the 60 kDa 
chlamydial heat shock protein (cHSP60) [82, 137-141]. While these TLRs are 
important in chlamydial infections, using knockout female mice, Darville and 
colleagues [138] demonstrated that TLR2 but not TLR4 is responsible for severe 
fallopian tube immunopathology. Furthermore, virulent wild type and plasmid-cured 
C. muridarum and C. trachomatis infections have demonstrated that the virulence 
plasmid in Chlamydiae plays a crucial role in TLR2 activation which is associated 
with tubule damage [142-143]. In addition to TLRs, cytosolic NOD-like receptors can 
also be triggered by chlamydial infection of epithelia, activating the inflammasome 
and facilitating pro-inflammatory cytokine secretion [144-145]. It is clear that the 
innate immune response plays an important role in both chlamydial infection and 
pathology. Further understanding of the positive and negative mechanisms of the 
innate immune response will improve prognosis and assist in vaccine design by 
restricting bacterial growth and dissemination, limiting inflammatory damage, and 
also target specific mediators of the adaptive immune response. 
2.4.2  Adaptive Immunity in Chlamydial Infections 
Innate immunity is the first line of defense against infections and is often sufficient, 
but many pathogens have evolved mechanisms to evade and/or escape elimination 
by innate responses. To counter this, the innate immune system induces and 
shapes (through co-stimulation) a highly specialized adaptive immune response to 
specifically target, overcome and remember a primary infection. This adaptive 
immune response is crucial in resolving established infections as well as rapidly 
clearing future infections and involves an arsenal of different cell types and secreted 
proteins. Initially, professional antigen presenting cells such as dendritic cells (DCs) 
and macrophages phagocytose antigen, digest it into peptides, complex them within 
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the surface exposed peptide-binding grooves of the MHC and present them to naïve 
T lymphocytes. Maturing T cells are then able to further activate and differentiate the 
immune system (T cell-dependent B cell maturation, Th1, Th2, Th17, T regulatory 
cells) to specifically target the pathogen. The role of the adaptive immune response 
in chlamydial infections is critical, as homozygous athymic nude mice (essentially 
free of T cells) are unable to resolve a vaginal chlamydial infection after 265 days, 
whilst heterozygous nude mice resolved infection within 20 days [146]. Similarly, 
respiratory chlamydial infection of homozygous nude mice leads to mortality while 
heterozygous nude mice recover [147]. These two simple studies laid the 
foundations for understanding the immune-mediated responses required to resolve 
chlamydial infections and demonstrate the necessity of an adequate adaptive 
immune response. 
2.4.2.1  Cell-Mediated Immunity in Chlamydial Infections 
Cell-mediated immunity (CMI) encompasses the effector immune cells involved in 
the adaptive immune response. Generally CMI includes, but is not limited to, 
macrophages, NK cells, T lymphocytes and the cytokines they secrete. In response 
to infection, DCs and macrophages enter the site of infection where they encounter 
pathogens. Upon phagocytosis of extracellular pathogen, DCs and macrophages 
degrade and present peptides on MHC-II for presentation to CD4+ T lymphocytes 
(the exogenous pathway). If the naïve T cell has an affinity for the presented 
peptide, it is activated and will differentiate into a mature T cell. Although not fully 
understood, it is at this point that co-stimulation from the innate immune system and 
cytokines secreted from other CMI cells can polarize the adaptive immune system 
towards various Th cell subsets. In primary genital tract chlamydial infection, 
activated CD4+ T cells are naturally polarized towards a Th1 (+/- Th17) response 
and it is these responses that enable the infection to be efficiently overcome. Critical 
processes (evidenced by gene knockout mice) in this CD4+ Th1-mediated 
resolution of chlamydial infection are MHC-II [148], and the pro-inflammatory 
cytokine IFNγ or its receptor [82, 149-150]. Unlike CD4+ T cells, CD8+ T cells are 
cytotoxic and are able to recognize infected cells via presentation of peptide on 
MHC-I. Whilst not as crucial as CD4+ T cells, MHC-I and CD8+ T cells play a 
synergistic role in resolution of primary chlamydial infection [151-152]. Interestingly, 
although crucial in resolution of primary chlamydial infections, depletion of CD4+ or 
CD8+ T cells following acquisition of immunity does not affect the duration or the 
pathology of subsequent challenges suggesting effectors downstream of CD4+ 
activation deliver immunity [153]. Similarly, immunity to secondary chlamydial 
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infection is attenuated in CD4+ depleted, antibody-deficient mice suggesting 
antibody, but not CD4+ T cells are important in recall immunity [5].    
2.4.2.2  Humoral Immunity  
The humoral arm of the adaptive immune response primarily refers the production of 
antigen-specific Ig and the effector functions that they initiate. Immunoglobulins, or 
antibodies, are antigen-specific glycoproteins produced by B cells following (but not 
limited to) antigen-presentation from activated CD4+ T cells. Activated B cells then 
expand and mature into plasma cells which secrete Ig specific for the antigen they 
were initially presented with. These activated B cells are produced in response to 
infection and can remain as memory B cells for many years [154]. In mammals, 
serum antibodies constitute approximately 18% of the protein mass, second only to 
serum albumin (60%) and the principal classes of antibodies vary in frequency and 
terminology based on heavy chain variations, but can be generally structured into 
classes of polymeric Ig (IgA or IgM), and monomeric immunoglobulins (IgG, IgE, 
and IgD). Serum concentrations of individual classes of antibody vary between 
individuals and disease state, but generally human serum antibody is comprised of 
IgG1 (9 mg/mL), IgG2 (3 mg/mL), IgA1+2 (2.1 mg/mL), IgM (1.5 mg/mL), IgG3 (1 
mg/mL), IgG4 (0.5 mg/mL), IgD (0.04 mg/mL), and IgE (3 x 10-5 mg/mL) [129]. 
Antibodies are also present at high concentrations in mucosal secretions and confer 
protection at the interface of the external environment and the host. Unlike serum, 
the dominant antibodies in the microbiome-dense mucosal sites alternate between 
IgA and IgG dominance (Table 2.1). As the majority of human pathogens establish 
infections via the mucosal tracts, designing vaccines (including adjuvant/s) that bias 
immune responses towards the site-specific dominant endogenous immunoglobulin 
classes could improve efficacy of immunity. 
2.4.2.2.1 Delivery of Antibody to the Mucosal Tract 
The presence of endogenous Igs in mucosal secretions plays a crucial role in the 
regulation of the microbiome and defense against mucosal tract pathogens. The 
bioavailability of Igs in mucosal secretions was widely believed to be simply due to 
transport from the circulatory system via passive diffusion [155].  Arguing against 
this is the high expression of cellular tight junction proteins (mainly claudins and 
occuldins) in the mucosal epithelia, which prevent diffusion of molecules in excess 
of 0.6 kDa [156], significantly smaller than the molecular masses of 
immunoglobulins (150 - 900 kDa). The excretion rate of Ig into mucosal secretions is 
also not in agreement with the passive diffusion hypothesis.  Polymeric 
immunoglobulin A (pIgA) secretion into the human small intestine has been 
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documented at 217 µg/40cm2/min, compared with 35 µg for IgG and 132 µg for 
albumin, despite serum concentrations of albumin and IgG exceeding that of pIgA 
by 3 fold and 10 fold respectively [157]. The low rate of passive diffusion of large 
proteins, together with the tissue-specific differences in concentrations of Ig, strongly 
suggests that mucosal antibodies in secretions are mediated by specific receptors. 
2.4.2.2.2  Mucosal IgA 
IgA within mammalian and avian hosts exists within two different environments and 
has two different protective roles. The second most abundant class of antibody in 
serum (following IgG), serum IgA exists primarily as monomers (in humans) and 
functions in a relatively sterile environment [158]. In contrast, SIgA exists exclusively 
in mucosal secretions and not only assists in protection from pathogens, but also 
tolerates the commensal microbiome and food allergens [158]. To determine the 
origin of mucosal IgA, intravenous injection of 125I-labeled IgA demonstrated that 
only 2% was transported to the gastrointestinal tract (GIT) (quantitatively the largest 
producer of immunoglobulin) suggesting that the majority of IgA (at least in the GIT) 
is locally produced [157]. That rate of antibody secretion does not agree with the 
distribution of antibody in the serum with 218 times more pIgA relative to albumin 
(the dominant protein in serum) in GIT secretions [159].  This strongly suggests that 
the majority of pIgA at mucosal sites is locally produced by mucosal IgA-secreting 
plasma B cells and transported by a specific receptor. 
IgA-secreting plasma cells produce monomers and polymers (principally dimers) of 
IgA. Polymerization of IgA requires the incorporation of separately expressed 15 
kDa polypeptides termed the joining chains (J chains). Experimental data suggests 
that the J chain allows the polymerization of IgA and IgM by linking two monomers 
of IgA tail-to-tail with either one [160] or two [161] J chains. Dimeric IgA (dIgA) 
typically forms when cellular J chain is abundant, but trimeric and tetrameric IgA can 
also form, albeit less frequently [162]. Once synthesized in plasma cells, dIgA is 
secreted into the lamina propria and binds the pIgR at the basolateral surface of 
epithelial cells, where it is subsequently transcytosed into the mucosal lumen.  
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Fluid  IgA 
[µg/mL] 
IgG  
[µg/mL]  
IgA : IgG  
 
Tear 80 - 400 Trace – 16 30 
Nasal Secretions 70 - 846 8 - 304 3 
Parotid Saliva 15 - 39 
120 - 319 
0.1 
2 - 5 
270 
63 
Whole Saliva 99 - 206 26 - 42 4.5 
Bronchoalveolar Fluid 3 13 0.2 
Colostrum 12,340 - 
53,800 
100 331 
Milk 470 - 
1,632 
40 - 168 10 
Duodenal Fluid 313 104 3 
Jejunal Fluid 32 - 276 4 - 340 0.9 
Colonic Fluid 240 - 827 1 534 
Intestinal Fluid 166 4 42 
Rectal Fluid 143 
3,624* 
2,317** 
0.9 
379 
297 
159 
10 
8 
Urine 0.1-1.0 0.06 - 0.56 1.8 
Pre-ejaculate 1.7 0.6 2.8 
Ejaculate 11 - 23 16 - 33 0.7 
Uterine Cervix 3 - 330 1 - 200 1.7 
Vaginal Fluid 21 - 118 10 - 467 0.3 
Serum 1,000 -
5,000 
10,000 -
15,000 
0.2 
 
Table 2.1   
Total IgA and IgG Concentrations in Human Mucosal Secretions  
* Dry, ** Wet. 
Adapted from [158, 163]. 
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2.4.2.2.2.1 The Polymeric Immunoglobulin Receptor (pIgR) 
The pIgR is an integral membrane protein synthesized in the rough endoplasmic 
reticulum and expressed on the basolateral surface of glandular and mucosal 
epithelial cells. The pIgR is a 100-120 kDa glycoprotein composed of five 
extracellular Ig-like domains, a single pass transmembrane region, and a 
cytoplasmic tail (Figure 2.2). IgA heavy chains (the Cα3 domain) bind the pIgR non-
covalently at extracellular domain 1, followed by sequential binding of domains 2-4, 
and finally disulfide bonding to domain 5 [164]. Once bound, the dIgA:pIgR complex 
is endocytosed and transcytosed from the basolateral surface along microtubules, 
presenting the dIgA:pIgR complex on the lumenal-facing apical surface plasma 
membrane [165]. This surface-exposed complex is proteolytically cleaved 
downstream of domain 5 after arginine-585 [166], leaving the transmembrane and 
cytoplasmic tail domains attached to the cell. Once cleaved, the covalently bound 
dIgA and pIgR fragment (SIgA) is released into the lumenal space where it can bind 
antigen. The transcytosis of IgA by this method is unidirectional in epithelial cells 
(with the exception of microfold cells in the GIT [167]), occurring only in the 
basolateral to apical direction, and is non-reversible.  
2.4.2.2.2.2 Beneficial Phenotypes of SIgA in Mucosal Defense 
Secretory IgA has many benefits over the non-secretory component bound antibody. 
Firstly, secretory component protects IgA from proteolysis by gut and bacterial 
proteases [168]. Secondly, unlike IgA, SIgA cannot bind Fcα receptor I (CD89) in 
the absence of the complement receptor 3 integrin αMβ2, presumably due to steric 
hindrance by SC or pIgR; and hence minimizes FcαRI effector functions which are 
generally understood to be associated with localized inflammation [169]. Thirdly, N-
linked oligosaccharide side chains of SIgA provide an innate specificity for bacterial 
adhesion lectins and plant holotoxins, improving immune exclusion from epithelial 
barriers [170-172]. Lastly, secretory component adds additional glycan residues to 
dIgA which bind mucins, allowing SIgA to remain embedded within mucosal 
secretions and improves physical exclusion of pathogens and toxins from epithelia. 
These benefits allow SIgA to remain functional and localized to mucosal surfaces 
providing a direct barrier from pathogenic invasion.  
2.4.2.2.2.3 Intracellular Neutralization of Pathogens by IgA and pIgR  
Interestingly, the pIgR is also able to transcytose antigen-bound dIgA, releasing it 
into the lumen, thereby reducing sub-mucosal and systemic exposure [173]. This 
phenomenon of antigen extrusion also occurs while the dIgA:pIgR complexes are in 
the process of transcytosis. In vitro and ex vivo viral models have shown that  
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Figure 2.2   
The pIgR Binds Dimeric IgA Forming SIgA  
(A) The integral membrane glycoprotein pIgR (green) consists of 5 Ig-like domains, 
with key glycosylation sites (orange), and an extracellular cleavage site for release 
of SIgA upon lumenal delivery. (B) pIgR binds domains Cα3 and the J chain (yellow) 
of dimeric IgA (grey) irrespective of binding to antigen (red). Adapted from [174-
175]. 
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dIgA:pIgR complexes reduce viral burden by both binding and neutralizing 
intracellular HIV antigen (35 - 36 % reduction), as well as then excreting it to the 
apical surface in non-infective sIgA:HIV immune complexes (IC) (38 – 40 % 
reduction) [11, 176-177]. The intracellular location of IgA interaction with HIV is 
thought to occur within apical recycling endosomes, and neutralization achieved by 
excretion of immune complexes, and does not appear to be targeted to the 
phagolysosome [177]. This suggests a mechanism by which the intracellular phase 
of viral pathogen replication can also be targeted by IgA. The benefit of utilizing both 
intracellular and extracellular pathogenic epitopes not only increases the quantity of 
potential antibody epitopes and the efficacy of immune clearance in response to 
infection, but also reduces localized inflammation associated with Fc activation by 
non-secretory component-bound Igs. Whether or not this neutralization and 
extrusion mechanism of IgA and the pIgR is sufficient to inhibit or reduce the 
infectious burden of larger intracellular pathogens such as bacteria (and specifically 
C. trachomatis) remains undetermined.  
2.4.2.2.2.4 Evolution of the pIgR 
The contrast in systemic and mucosal immunoglobulin concentrations and effector 
function is widely observed throughout vertebrates. Highly conserved orthologs of 
the coding regions of the pIgR (particularly the IgA binding domain 1) have been 
described in placentals (humans, chimpanzees, rabbits, rodents), marsupials 
(wallabies, possums), aves (chickens), amphibians (frogs) and teleosts (zebra fish, 
rainbow trout) [178-179]. These variants of the pIgR all participate in the delivery of 
IgA (IgT in teleosts) to the mucosal surfaces and demonstrate a strong evolutionary 
requirement for antibody delivery to the mucosal tracts. Interestingly, homologs of 
IgA are only detected in mammals and aves, but not modern reptiles or fish, 
suggesting the requirement to transport Ig conjugated to SC predated the 
appearance of IgA [178]. Whilst IgA and IgT are phylogenetically distinct arising 
through convergent evolution [179], they are both transported by the pIgR 
suggesting that an Ig predating either class was outcompeted by IgA/IgT, or simply 
that similarly to bacterial flagellum evolving from a T3S apparatus [180], the delivery 
of free SC to mucosal tracts was co-opted to include an Ig transport mechanism ex 
post facto. This highly conserved mucosal Ig transport mechanism dating back at 
least to a primitive vertebrate ancestor in the late Devonian period (359-374 million 
years ago) demonstrates the crucial role afforded by the pIgR in the delivery of 
antibody to mucosal surfaces. 
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2.4.2.2.2.5 Distribution of the pIgR 
As the amount of SIgA in mucosal secretions is directly dependent on pIgR 
expression, it is unsurprising that the pIgR is widely distributed throughout mucosal 
tracts. The pIgR is ubiquitously expressed by epithelial cells in the lungs, pancreas, 
GIT, FRT, MRT, kidney, gall bladder, urinary bladder, as well as sweat, mammary, 
lacrimal and salivary glands, [117, 155, 175, 181-182]. With respect to the 
reproductive tracts, the pIgR has been detected in both human and rodent 
reproductive tracts with higher expression observable in the upper reproductive tract 
tissues of females [175, 181], but lower reproductive tract tissues of males [183].  
2.4.2.2.2.6 Regulation of pIgR Expression 
Whilst widely distributed, the basal expression of the pIgR is not static. Regulation of 
the pIgR expression is mediated by innate and adaptive responses to infection. 
Innate up-regulation of the pIgR is mediated by TLR3 (double-stranded RNA) and 
TLR4 (LPS) activation [184]. Up-regulation of pIgR can also be induced by pro-
inflammatory cytokines; specifically IFNγ, TNF, IL-1 and IL-4 [175, 185-187]. 
Atypically, IFNγ (Th1 response) and IL-4 (Th2 response) can also have a synergistic 
effect on pIgR up-regulation [185]. As well as innate and cytokine-mediated control 
of pIgR expression, hormones can have a regulatory role. In female rats, estrogen 
(estradiol in particular) up-regulates pIgR expression, in turn increasing SIgA 
release into the lumen to coincide with ovulation [155, 188-189]. However, in 
primates, ovulation coincides with a decrease in mucosal antibodies [190-191]. 
Conversely, progesterone down-regulates pIgR expression and SIgA release in rats 
[192]. In the MRT, both estrogen and androgen (dihydrotestosterone) enhance 
secretion of SC (cleaved pIgR) into prostatic and seminal vesicle fluid [183]. In 
general, hormonal and immune control of the pIgR expression appears to bias 
towards up-regulation, in the presence of infection by viruses (TLR3), Gram-
negative bacteria (TLR4), inflammation, and hormones. 
2.4.2.2.2.7 Chlamydial Infections and the pIgR 
The specific role of the pIgR in chlamydial infections remains questionable. Using 
wild type and pIgR-deficient mice, the role of pIgR transport of antigen-specific IgA 
has been correlated with a reduction of chlamydial burden in the reproductive tracts 
of male mice [117, 193]. Similarly, there is an increase in total IgA in the urethral 
lumen of C. trachomatis-infected human males  [101]. However in female wild type 
and IgA deficient mice there is no significant difference in the resolution of either 
primary or secondary infections [6]. Unlike female rodents, protection afforded by 
IgA appears to be important in controlling chlamydial infections of guinea pig and 
27 
 
human female reproductive tracts [194-195]. While the specific role of IgA in genital 
tract chlamydial infections remains undetermined in natural genital infections of 
mice, the protective role of IgA and the pIgR may be important in subunit vaccine 
development.  
2.4.2.2.3 Transcytosis of IgG  
Unlike the addition of secretory component to IgA following binding and cleavage of 
the pIgR, IgG does not undergo modification during delivery to the mucosal lumen 
and it has been argued that its presence is due to mechanisms such as specific 
receptor mediated transport, by nonspecific paracellular transport (e.g. passive 
diffusion), or fluid phase endocytosis [155]. As discussed earlier, non-specific 
transport seems unlikely largely due to the expression of tight junction proteins and 
the fluctuating tissue dependent concentrations of IgA and IgG. Thus, an IgG-
specific transporter that does modify the IgG following vesicular transport is likely 
responsible for mucosal IgG delivery. 
2.4.2.2.3.1 Fc Receptors 
The immunoglobulin super family of FcγRs are important cell surface 
transmembrane effector glycoproteins that bind the Fc region of IgG and mediate 
differential immune outcomes. The FcγR family consists of several classes with 
different affinities for IgG and immune activation including FcγRI (CD64), FcγRII 
(CD32) and FcγRIII (CD16). FcγRI is the Fc receptor with the highest affinity for IgG 
and which can be activated by a single IgG molecule, whilst FcγRII and FcγRIII 
require binding of multiple IgG molecules to activate (typically in an IC). FcγRI and 
FcγRII are involved in phagocytosis whilst FcγRIII is associated with antibody-
dependent cell-mediated cytotoxicity (ADCC). Commonly, these FcγRs are 
expressed on immune cells such as macrophages, neutrophils, eosinophils, mast 
cells, DCs and NK cells, and upon binding IgG:IC activate effector outcomes such 
as phagocytosis of opsonized pathogen, granule release, targeting for killing by NK 
cells or cytokine release [129]. These FcγR, together with FcR specific for the other 
immunoglobulin heavy chains; FcαR/CD89 (IgA), FcµR (IgM), FcδR (IgD), FcεRI-II 
(IgE); are involved exclusively in effector responses and not transcytosis (with 
exception of IgE and FcεRII/CD23 [196]), and are not highly expressed on epithelial 
cells suggesting transcytosis of IgG is mediated by another mechanism. 
2.4.2.2.3.2 Fc Receptors in Chlamydial Infections 
To role of FcγRs in chlamydial infection in mouse models remains controversial. 
FcγRs have been demonstrated to be both detrimental with monoclonal anti-MOMP 
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IgG2b and FcγRIIb/FcγRIII-mediated enhancement [56], but also protective with 
respect to naturally acquired IgG isotypes and FcγR I, II and III-mediated effector 
functions [197]. The former study demonstrated monoclonal IgG2b against surface 
exposed MOMP enhanced infection in vitro and significantly increased vaginal 
chlamydial burden in female BALB/c mice [56]. Conversely, the latter study 
demonstrated that C57BL/6 wild type and FcγR -/- (FcγRI-III -/-) female mice had 
equivocal primary infection chlamydial shedding and pathology, but upon re-
infection the wild type mice had 3 log10 fewer inclusion forming units (IFUs) per mL 
than FcγR -/- mice, and that FcγR -/- mice had 21.5 times more live C. muridarum in 
upper reproductive tract tissues after 7 days of secondary infection. The function of 
this FcγR-mediation protection was determined ex vivo to be principally derived from 
IgG activation of FcγR on macrophages, which activated ADCC and enhanced 
protective Th1 responses [197]. Together, these data suggest that polyclonal IgG 
(but not monoclonal anti-MOMP IgG2b) and FcγRI, II, III or a combination of the 
three receptors plays an important role increasing the effectiveness of innate 
immune killing of Chlamydia and in activation of effector Th1 responses, which 
minimize bacterial burden following secondary infection. 
2.4.2.2.3.3 The Neonatal Fc Receptor (FcRn) 
The FcRn was first hypothesized as a receptor that rescued IgG from catabolism 
and transported maternal IgG to the neonate in the 1960s [198], and soon thereafter 
discovered in neonatal rat intestine [199]. FcRn is a MHC class I-like 
transmembrane protein that is non-covalently associated with B2m. While being 
MHC-I-like and sharing a similar structure including the requirement of dimerization 
with the separately expressed B2m subunit, the FcRn lacks the α1-α2 peptide-
binding grove of MHC-I. The FcRn is expressed as a 45-50 kDa monomer 
consisting of three extracellular alpha domains, one single-pass transmembrane 
region, and a short cytoplasmic tail (Figure 2.3) [200]. It binds all subclasses of IgG 
with a stoichiometry of two FcRn-B2m heterodimers to a single IgG protein [201].  
The function of the FcRn-B2m heterodimer and its ligand IgG is well established, 
however, FcRn also binds and endocytoses albumin with a stoichiometry of 2:1 
[202]. The ability of the FcRn to bind both IgG and albumin, which together 
constitute approximately 90% of serum protein, not only allows bidirectional 
transcytosis but increases the serum half-life of the glycoproteins from one day to 
between six  and  eight  days  for  IgG  specifically as  a  result  of  intracellular   
storage [203]. The importance of the FcRn in improving IgG and albumin half-life is 
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observed in FcRn-deficient mice which have 20-30% less serum IgG [204], and 40% 
less serum albumin compared to that of wild type mice [205].   
2.4.2.2.3.4 Distribution of the FcRn 
Unlike the other FcγRs, the FcRn is expressed in a wide variety of cell lines 
including hepatocytes, syncytiotrophoblasts, endothelial cells, myeloid-derived 
professional antigen-presenting cells (APCs) (macrophages/monocytes/DCs) and 
importantly epithelial cells [203]. Similarly to the pIgR, expression of the FcRn in vivo 
differs between organs and is complicated by the differential outcomes. The FcRn 
has been detected in the human placenta where it transports maternal IgG to the 
fetus [206], lines the endothelium where it rescues IgG from catabolism [207], the 
fetal and adult GIT [208-209], the blood-brain barrier [210], kidneys [211], lungs 
[212], FRT [213], and MRT [214]. Due to acidic pH affinity of FcRn for IgG, the 
expression of FcRn in mucosal tracts with acidic lumens offers a mechanism of 
antibody reabsorption. Both the MRT and FRT have acidic lumens, specifically the 
epididymes (pH 6.5 [215]) prostate (pH 6.1-6.5 [216]), vagina (pH 4.5 [217]), and 
cervix (pH 6.5 [217]), and thus make the FcRn an important Ig receptor in these 
tissues. This expansive variety of the FcRn expression on differentiated cells and 
throughout multiple systemic and mucosal tissues offers a promising target for 
passive delivery of therapeutic antibodies that will not activate other FcγRs [212], as 
well as vaccines that can efficiently deliver IgG to multiple tissues.  
2.4.2.2.3.5 FcRn Binding and Affinity for IgG 
Although first described in neonates, the FcRn has been documented across a 
diverse age range and is not limited to the intestine of weaning rats but also occurs 
across multiple tissue sites in all mammals. Human FcRn homologs are observed in 
rats [218], mice [209], and rabbits [219] and can bind IgG from other species [220]. 
Mouse FcRn strongly binds IgG from mice, rats, humans, rabbits, guinea pigs, cows 
and sheep; but human FcRn only binds IgG from humans, rabbits and guinea pigs, 
revealing structurally important regions in the binding domains of human FcRn [220]. 
Pharmacokinetically unlike FcγRs, which bind the upper Cγ2 and hinge region of 
IgG, FcRn binds IgG by forming a salt bridge between the α2 extracellular region of 
FcRn and the Cγ2-Cγ3 domains of heavy chains of IgG. The pH-mediated binding to 
IgG occurs by formation of a salt bridge between histidine residues in the IgG Cγ2-
Cγ3 region (critically His310 and His435), and (Glu117, Glu132 and/or Glu135, 
Asp137) in the α2 domain of FcRn [203]. Interestingly, N’ linked glycosylation of 
FcRn is important in trafficking to the apical membrane [218],  but unlike other 
FcγRs, the glycosylation of IgG does not influence binding affinity to FcRn [221]. In  
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Figure 2.3   
Functional MHC I and FcRn Requires Dimerization with B2m  
(A) The structure of the MHC I (light blue) / B2m (orange) heterodimer presenting an 
endogenously acquired peptide (dark blue) in the peptide groove between the α1 
and α2 domains to CD8+ T cells. (B) The structure of the FcRn (green) / B2m 
(orange) heterodimer binding at the α2 domain to the Cγ2:Cγ3 interface of an IgG 
(grey) +/- antigen (red). Glycosylation of Asn 297 is critical for IgG binding to FcγR I, 
II, and III, but not FcRn. The FcRn can bind and transcytose IgG or IgG:immune 
complexes with similar affinity. Adapted from [203, 222]. 
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addition, binding occurs with minimal conformational change and exclusively under 
acidic conditions, including within lysosomes pH 4.5 - 6.5 [222], and release of IgG 
at pH > 7.5 [200]. Site-directed mutagenesis studies have revealed that the 
stringency of human FcRn binding to IgG is reduced with mutations to residues 137, 
and 121-132 in the α2 domain of FcRn [223]. Whilst the binding affinity of FcRn to 
IgG varies between species, the homology remains conserved between mammals 
indicating the strong evolutionary dependence of this mechanism. 
2.4.2.2.3.6 Evolution of the FcRn 
The evolutionary origin of FcRn in mammals was deduced by examining the 
differences between mammals and birds. Both mammals and aves express 
orthologs of MHC-I, however, only mammals express FcRn (chromosome 19 in 
humans) suggesting its recent evolutionary divergence from a paralogous 
duplication of MHC-I (chromosome 6 in humans). Despite the lack FcRn, aves 
remain able to passively transport maternal IgY across the yolk sac to developing 
chicks, a process mediated by FcRY. Similarly to FcRn, FcRY binds IgY (an avian 
homolog of mammalian IgG) with a strong pH dependence of 6.0-6.5 but not >7. 
Unlike FcRn however, FcRY undergoes conformational change at pH 8 releasing 
bound IgY and prevents further binding. Despite the similar pH affinity and 
phenotypic outcomes, FcRY is not related to FcRn by sequence or domain 
organization, but is homologous with the mammalian secretory phospholipase α2 
receptor (55%) [224]. Whilst unrelated to FcRn, FcRY does show a requirement for 
pH-dependent internalization and transcytosis of antibody that convergent evolution 
has achieved via disparate genes.  
2.4.2.2.3.7 FcRn in Bidirectional Transcytosis and Immunity 
Similar to the pIgR, the FcRn has been shown to traffic antigen-bound antibody 
across cells. This was observed by Blumberg and colleagues [225], in murine FcRn 
(mFcRn) deficient mice that were reconstituted with human FcRn (hFcRn) and 
human B2m (hB2m). While mice naturally lose the expression of mFcRn in the 
intestinal epithelia after weaning, humans continue to express intestinal hFcRn into 
adult life [209]. Under the control of the endogenous hFcRn promoter, transgenic 
mFcRn -/- mice continued to express hFcRn/hB2m in the small and large intestines, 
as well as the lungs. The authors then demonstrated that IgG was transported 
across the intestinal and lung epithelia into the lumen where it bound its respective 
antigen (ovalbumin). IgG-bound ovalbumin IC were able to remain in the lumenal 
cavity, and interestingly were also transported back into the lamina propria where 
they were taken up by CD11c+ DCs and subsequently presented on MHC class II to 
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CD4+ T cells which then proliferated [225]. Additionally, FcRn expressed by PMNs 
binds IgG-opsonized bacteria, and together with FcγR enhances phagocytosis and 
phagolysosomal degradation of the pathogen [226]. In a recent study, FcRn-
mediated cross-presentation was demonstrated in monocyte-derived CD8-/CD11c+ 
DCs [227]. These DCs were able to internalize IgG:IC via FcγRs, which was then 
bound by intracellular FcRn, trafficked to the proteasome, digested, and loaded onto 
MHC-I for presentation to CD8+ T cells [227]. Together, these studies demonstrate 
the FcRn’s ability to transport IgG bidirectionally in vitro and in vivo, bind specific 
antigen in the lumen forming IC, internalize these IC back into mucosal epithelia, 
and present them to DCs which can activate both CD4+ and CD8+ T cells.  
In addition to enhancing phagocytosis, trafficking and cross presentation of IC; 
FcRn-mediated transport of a monoclonal IgG in FcRn-transfected MDCK epithelial 
cells has recently been demonstrated to bind an intracellular influenza A virus 
envelope hemagglutinin protein blocking fusion of the viral protein with host 
endosomal membranes and neutralizing infection [4]. There is also speculation that 
anti-MOMP IgG-opsonized chlamydial EB internalization by FcRn may be 
responsible for enhanced ascending chlamydial infection in the mouse female 
reproductive tract [228]. It is apparent that the FcRn and IgG orchestrate pivotal 
roles in infectious disease, but there remains limited data with respect to viruses, 
intracellular bacteria, and specifically chlamydiae. These highly specified 
mechanisms mediated by the FcRn and IgG to target extracellular and intracellular 
antigens enable the immune system to engage and adapt in disease, and reveals 
numerous advantageous therapeutic possibilities for infectious diseases, immune 
tolerance, and cancer.   
2.5  SUMMARY 
The adaptive immune response plays a critical role in the resolution of chlamydial 
infections of the male and female reproductive tracts. As immunoglobulins have 
been shown to play an important role in immunity, understanding the transport of 
antigen-specific antibodies to the site of infection could improve efficacy of potential 
vaccines. Similarly, the delivery of antigen-specific immunoglobulin to the 
reproductive tracts by the pIgR and the FcRn in response to chlamydial infection 
warrants investigation. In addition to chlamydial infections, the wide distribution of 
the pIgR and the FcRn in mucosal epithelia offers potential mechanisms to deliver 
antibody targeting both extracellular and intracellular pathogenic and cancer 
antigens.  
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Chapter 3 
 
Materials and Methods 
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3.1  GENERAL STOCKS AND SOLUTIONS 
3.1.1  Phosphate Buffered Saline (PBS) 
PBS was made as a 10x stock by combination of 81 g of NaCl, 4 g Na2HPO4, and 
1.65 g NaH2PO4 in 1 L of milli-Q H2O. The pH was adjusted to 6.6 with 5 M NaOH. 
Working stocks of 1x were made by dilution of one part 10x PBS in nine parts milli-Q 
H2O followed by sterilization by autoclaving at 121oC for 15 minutes. 1x PBS (pH 
7.4) was stored at room temperature.  
3.1.2  PBS – Tween (PBST) 
PBST was prepared by addition of Tween 20 to PBS to a final concentration of 0.1% 
(v/v). PBST was stored at room temperature. 
3.1.3  Sucrose Phosphate Glutamate (SPG) 
SPG was prepared with 75 g sucrose, 0.52 g Na2HPO4 and 1.22 g Na2PO4 in 1 L of 
milli-Q H2O. The solution was pH adjusted to 7.0 with 5 M HCl and sterilized by 
autoclaving at 121oC for 15 minutes. Prior to use 5 mM L-Glutamine was added. 
SPG was stored at -20oC until required. 
3.1.4  Bacterial Lysis Buffer 
Low osmotic shock bacterial lysis buffer was prepared with 50 mM Tris, 1 mM 
ethylenediaminetetraacetic acid (EDTA) and 100 mM of NaCl, pH adjusted to 8.0. 
Bacterial lysis buffer was autoclaved at 121oC for 15 minutes at stored at 4oC until 
required. 
3.1.5  Luria Bertani (LB) – Miller Agar 
LB-Miller agar was prepared with 10 g tryptone (Oxoid, Thebarton, SA, Australia), 
10 g NaCl, 5 g yeast extract (Oxoid) and 15 g of agar (Oxoid) in 1 L of milli-Q H2O. 
The solution was pH adjusted to 7.4 with 5 M NaOH and autoclaved at 121oC for 15 
minutes. Agar was cooled to 50oC and 100 µg/mL ampicillin (Roche Diagnostic, 
Castle Hill, NSW, Australia) +/- 50 µg/mL chloramphenicol (Sigma Aldrich, Castle 
Hill, NSW, Australia) added. LB agar was aseptically poured into 150 mm Petri 
dishes (Crown Scientific, Minto, NSW, Australia) and allowed to solidify at room 
temperature. Agar plates were stored at 4oC. 
3.1.6  LB Broth 
LB-Miller broth was prepared with 10 g tryptone, 10 g NaCl, 5 g yeast extract 
(Oxoid) dissolved in 1 L of milli-Q H2O. The solution was pH adjusted to 7.4 with 5 
M NaOH and autoclaved at 121oC for 15 minutes. Sterile LB broth was stored at 
room temperature. Before inoculation, 0.2 µm filter sterilized ampicillin (final 
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concentration 100 µg/mL) (Roche Diagnostics) +/- chloramphenicol (final 
concentration 50 µg/mL) (Sigma Aldrich) was added.  
3.1.7  Terrific Broth (TB) 
TB was prepared in two separate parts. Part A was prepared with 12 g tryptone 
(Oxoid), 24 g yeast extract (Oxoid), 4 mL glycerol dissolved in 900 mL of milli-Q 
H2O and pH adjusted to 7.4 with 5 M NaOH. The media was autoclaved at 121oC 
for 15 minutes. Part B was prepared by dissolving 2.31 g of KH2PO4 and 12.54 g of 
K2HPO4 in 100 mL of milli-Q H2O and pH adjusted to 7.4. 100 mL of Part B was 0.2 
µm filter sterilized into 900 mL of sterile Part A prior to use.  
3.1.8  His-Tagged Protein Purification 
3.1.8.1  Equilibration Buffer 
Prior to binding, TALON™ metal affinity his-tag protein purification resin (Scientifix, 
Cheltenham, VIC, Australia) was equilibrated in 25 mM Na2HPO4, 25 mM 
NaH2PO4, 300 mM NaCl in milli-Q H2O at pH 7.0. Prior to use, equilibration buffer 
was autoclaved at 121oC for 15 minutes, and stored at 4oC. 
3.1.8.2  Stringency Wash Buffer 
The stringency wash was prepared from the equilibration buffer, with an additional 5 
mM imidazole (Sigma Aldrich) and 0.1 % (v/v) Triton X-100.  
3.1.8.3  Elution Buffer 
His-tagged protein elution buffer was prepared from the stringency wash, with a final 
concentration of 150 mM imidazole. 
3.1.9  Protein G - Antibody Purification 
3.1.9.1  Elution Buffer 
Protein G elution buffer was prepared by dissolving 100 mM of glycine in milli-Q 
H2O, pH adjusting to 2.0 with 5 M HCl, and 0.2 µm filter sterilized. Elution buffer was 
prepared fresh prior to use. 
3.1.9.2  Neutralization Buffer 
Protein G neutralization buffer was prepared with 1 M Tris in milli-Q H2O, and pH 
adjusted to 8.0 with 5 M NaOH. Neutralization buffer was autoclaved at 121oC for 15 
minutes and stored at room temperature. 
36 
 
3.1.10  Red Blood Cell (RBC) Lysis Buffer 
RBC lysis buffer was prepared by dissolving 8.3 g of NH4Cl, 1.0 g NaHCO3, and 37 
mg of EDTA in 1 L of milli-Q H2O. RBC lysis buffer was pH adjusted to 7.4 and 
stored at 4oC. Prior to use, RBC lysis buffer was 0.2 µm filter sterilized. Each batch 
of RBC lysis buffer was tested on splenocytes left over from other experiments to 
ensure it was functional and would not lyse non-RBC. 
3.2  PRODUCTION AND PURIFICATION OF ANTIGENS 
3.2.1  Recombinant Major Outer Membrane Protein (MOMP)  
Escherichia coli K12 (DH5α pMM3) transformed with a pMAL-c2 vector encoding a 
recombinant fusion protein N terminal-tagged maltose binding protein continuous 
with the full length of C. muridarum MOMP was a generous gift from Harlan Caldwell 
(Rocky Mountain Labs, Hamilton, MT, USA) and was expressed and purified as 
previously described [229]. Briefly, E. coli pMAL-c2 was inoculated into 1 L of LB 
broth with 100 µg/mL of ampicillin in a 2 L conical flask, and incubated at 37oC 200 
rpm until the optical density (OD) at 600 nm was approximately 0.6. Cultures were 
then induced with 0.1 mM of isopropyl β–D-1-thiogalactopyranoside (IPTG) for 4 
hours at 37oC and 200 rpm. Induced bacteria were centrifuged at 4,000 g for 12 
minutes, the supernatant discarded and the pellet resuspended in PBS. The 
resuspended pellet was probe sonicated with an ultrasonic liquid processor 
(Misonix, Farmingdale, NY, USA) 4 times at amplitude setting 7 for 15 seconds, with 
15 second rests on ice. The bacterial lysate was centrifuged at 20,000 g for 20 
minutes at 4oC to pellet insoluble proteins. The supernatant was then discarded, the 
pellet washed in PBS and repelleted by centrifugation at 20,000 g for 20 minutes at 
4oC. Washed, insoluble pellets were resuspended in 8 M urea in H2O containing 1x 
bacterial protease inhibitor cocktail (Sigma Aldrich) and incubated for 2 hours at 
37oC on a rotating wheel. The remaining insoluble material was pelleted by 
centrifugation at 7,200 g for 20 minutes at room temperature. The urea-solubilized 
protein supernatant was pooled, aliquoted into 10 kDa cut-off dialysis tubing (Sigma 
Aldrich) and dialyzed in decreasing concentrations of 6 M, 4 M, 2 M, and 1 M urea in 
H2O for 2 hours each. Protein was then dialyzed into PBS for 4 hours, a total of 4 
times. The protein was then concentrated by centrifugation at 2,500 g for 15 minutes 
using a 30 kDa molecular weight cut-off (MWCO) centrifuge filter (Millipore, North 
Ryde, NSW, Australia). Protein concentration was determined by bicinchoninic acid 
(BCA) assay according to manufacturer’s instructions (Thermo Fisher Scientific, 
Scoresby, VIC, Australia). Semi-purified recombinant C. muridarum MOMP-MBP (80 
kDa) was diluted to 5 mg/mL in PBS and stored in aliquots at -80oC until required. 
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LPS endotoxin concentration was determined as per the manufacturer’s instructions 
with Limulus amebocyte lysate endotoxin quantification kit (Genscript, Piscataway, 
NJ, USA).  
3.2.2  Recombinant Inclusion Membrane Protein A (IncA) and 
Chlamydial-like Protease Activity Factor (CPAF) 
Recombinant C. muridarum IncA and CPAF were prepared by amplifying the coding 
regions of IncA or CPAF from C. muridarum boiled lysate with oligonucleotide 
primers including BamHI/EcoRI restriction endonuclease (RE) sites for IncA and 
BamHI/KpnI RE sites for CPAF respectively. IncA primers (5’ CG GGATCC 
ATGACATCACCTACTCTAG 3’; 5’ CCG GAATTC TTAGGCGGAAGAATCAG 3’) 
and CPAF primers (5’ CG GGATCC ATGAAAATGA ATAGGATTTTGCTACTGC 3’; 
5’ CCGGTACC TTAAAAACTTCCATCCTCTGAGA GAATAATTACAC 3’) were used 
to amplify full length IncA (845 bp) and CPAF (1806 bp) with a high fidelity Pfu 
polymerase (Promega, Alexandria, NSW, Australia) by conventional PCR with 30 
cycles of 95oC denaturating for 1 minute, 60oC annealing for 1 minute, and 72oC 
extension for 5 minutes. Amplicons were purified using PCR purification columns 
(Invitrogen, Mulgrave, VIC, Australia) as per the manufacturer’s instructions. The 
purified amplicons and the E. coli protein expression vector pRSET-A (Invitrogen) 
were RE digested in appropriate RE enzymes and buffers (Promega) for 1 hour at 
37oC, purified and ligated using T4 DNA ligase (Promega) overnight at 4oC. Ligated 
pRSET-A - C. muridarum IncA (pRSETA CmuIncA) or pRSET-A - C. muridarum 
CPAF (pRSETA CmuCPAF) was transformed into DH5-alpha E. coli; and screened 
for positive transfectants by PCR using the above primers, and confirmed by 
purifying the plasmid, RE digesting with EcoRI/BamHI or BamHI/KpnI, then 
separating the products in 1% (w/v) agarose in tris-borate buffer by gel 
electrophoresis. Positive PCR and RE digest plasmids were confirmed by 
commercial sequencing using the above appropriate primers (Australian Genome 
Research Facility, Brisbane, QLD, Australia).  Positive pRSETA-CmuIncA was 
transformed into E. coli K12 (BL21 (DE3) pLysS) by heat shock. BL21 (DE3) pLysS-
pRSETA-CmuIncA/CPAF were streak-inoculated onto LB agar supplemented with 
ampicillin (100 µg/mL) and chloramphenicol (50 µg/mL) and grown overnight at 
37oC. The following day, a single clone was selected and inoculated into 1 L of TB 
broth and incubated at 37oC at 200 rpm until OD600 nm reached mid-log growth at 
0.6. Cultures were then cooled on ice for 5 minutes before adding 0.1 mM IPTG and 
then incubated overnight at 15oC and 60 rpm. Following incubation, bacteria were 
pelleted at 4,000 g for 12 minutes. Pellets were resuspended in bacterial lysis buffer 
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(20 mL per 1 L of culture pellet), incubated for 15 minutes at room temperature with 
100 µg/mL DNAse I (Roche Diagnostic), 250 µg/mL lysozyme (Sigma Aldrich),  2 
mM phenylmethylsulfonyl fluoride (PMSF), and 20 µL of bacterial protease inhibitor 
cocktail for histidine tagged proteins (Sigma Aldrich). Lysates were then sonicated 
with a probe attached to an ultrasonic liquid pro sonicator (Misonix) at a power 
setting 7 for 4 bursts of 15 seconds with intermediate resting on ice. Debris was 
pelleted by centrifugation at 4,000 g for 15 minutes, the supernatant collected and 
further clarified at by centrifugation at 12,000 g for 15 minutes at 4oC. The his-
tagged protein was then purified using a modified batch/column his-tag purification 
protocol supplied by resin manufacturer. Briefly, the supernatant was collected and 
diluted four times its volume in equilibration buffer, added to equilibrated TALON™ 
resin on a rotating wheel for 1 hour at 30 rpm and 4oC. Following binding, resin was 
pelleted by centrifugation at 500 g for 7 minutes and 4oC, the supernatant discarded, 
and resin resuspended in stringency wash buffer. The resin was again pelleted and 
resuspended in stringency wash buffer a further 6 times. To minimize resin-loss and 
carry-over into elution fractions, protein-bound resin was poured into a column, the 
wash buffer allowed to run through, plugged and covered in elution buffer, placing it 
on a rotating wheel overnight at 4oC. The column was then allowed to settled, and 
flow through collected containing the first elution. The remaining resin was 
resuspended in elution buffer and returned to the rotating wheel for a further 2 
hours, before eluting the same way. The eluted fractions were dialyzed into PBS 
four times, 4 hours each, at 4oC. Protein was concentrated in a 10 kDa MWCO 
concentrator (Millipore), quantified by BCA, and stored at -80oC until required. 
Proteins expression was confirmed by SDS-PAGE, and mouse anti-his tag antibody 
(Sigma Aldrich) western immunoblot. Both proteins were also screened by western 
blotting against mouse serum collected from a pool of immune sera from female 
mice genitally infected with C. muridarum 35 days earlier. Female mice that had 
been vaginally infected with C. muridarum EBs had developed IgG to both natively 
expressed IncA and CPAF proteins revealing the immunogenicity of the proteins.    
3.2.3  Native C. muridarum Inclusion Membrane Lysate (IncMem) 
C. muridarum inclusion membrane lysate was prepared as described by Scidmore-
Carlson MA et al. with minor modifications [230]. McCoy B cells were infected with 
C. muridarum (Weiss) at a multiplicity of infection (MOI) of 1 and incubated for 26 
hours at 37oC 5% CO2. Cells were washed with PBS, and cells gently trypsinized for 
5 minutes at 37oC. Cells were pooled and trypsin digestion stopped with 5% (v/v) 
heat-inactivated fetal calf serum (HI-FCS) in Dulbecco’s modified Eagle Medium 
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(DMEM). Cells were pelleted by centrifugation at 300 g for 5 minutes at 4oC. The 
supernatant was discarded, and the infected McCoy pellet gently resuspended in 
0.25 M sucrose. Cells were lysed with a probe sonicator twice at amplitude setting 9 
for 15 seconds. Cell debris was pelleted by centrifugation at 900 g for 5 minutes at 
4oC. The supernatant was collected and clarified at 15,000 g for 15 minutes at 4oC. 
The supernatant was again collected and centrifuged at 100,000 g for 30 minutes at 
4oC. The supernatant was discarded, and the pellet resuspended in PBS. The 
proteins were again centrifuged at 100,000 g for 30 minutes at 4oC. The supernatant 
was discarded and the pellet resuspended in PBS. Protein concentration was 
determined by BCA (Thermo Fisher Scientific) and diluted in PBS to 5 mg/mL. 
Fractioned inclusion membrane protein was stored at -80oC until required. Immune 
sera from mice immunized with IncMem demonstrated localization around the 
inclusions of C. muridarum-infected McCoy B cells. 
3.3  CHLAMYDIAL STRAIN 
Chlamydia muridarum (Weiss) (VR-123), formally the mouse pneumonitis biovar of 
C. trachomatis (MoPn) was purchased from the American Type Culture Collection 
(ATCC). C. muridarum was grown and purified as previously described with minor 
modifications [117]. Briefly, C. muridarum was directly inoculated onto confluent 
monolayers of McCoy B cells in supplemented DMEM for 26 hours at 37oC 5% CO2. 
Host cells were washed with PBS, trypsinized into suspension, and pooled in media. 
Cells were pelleted at 500 g for 5 minutes. The supernatant was discarded and host 
cells resuspended in PBS supplemented with 100 µg/mL heparin sulphate (Sigma 
Aldrich). Cells were lysed with a Misonix Microson ultrasonic cell disruptor 
(Interpath) at power setting 9.0 for 10 seconds. Host cell debris was pelleted at 800 
g for 5 minutes. The supernatant was collected and C. muridarum EBs and RBs 
pelleted by centrifugation at 18,000 g for 10 minutes. The chlamydial pellet was 
resuspended in PBS for ultra-purification or SPG for semi-purification. Ultra 
purification was performed by layering C. muridarum on top of a 29% Renografin 
(Urografin) (Bayer, Pymble, NSW, Australia) and centrifuging at 70,000 g for 30 
minutes. Pellets were collected and resuspended on a gradient of 29%, 34% and 
49% Renografin and centrifuged at 70,000 g for 30 minutes. EBs were collected 
from interface of the 34% and 49% Renografin gradient and washed twice in PBS by 
pelleting at 70,000 g for 30 minutes at 4oC. Ultra-purified EBs were resuspended in 
SPG and stored at -80oC. UV-inactivated EBs were prepared by incubating known 
concentrations of inclusion forming units (IFUs) within 10 cm of a UV bulb for 40 
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minutes. UV-inactivated EBs were quantified from titration of the pre-inactivation 
EBs. 
3.3.1  Quantification of Chlamydial Infection 
To quantify C. muridarum, McCoy B cells were infected with dilutions of vaginal 
swabs, urines, tissue homogenates or in vitro neutralizations for 24 hours at 37oC 
5% CO2. To stop cell growth in titration, vaginal swab and tissue homogenate 
experiments, 100 µg/mL of cycloheximide (Sigma Aldrich) was added in a media 
change after 3 hours of infection. After 24 hours of infection, cells were washed at 
least two times with PBS, and fixed with 100% methanol for 5 minutes. Methanol 
was removed. If transwells were used, the insert was excised at this point with a 
scalpel blade. Cells were rehydrated in PBS. Cells were blocked overnight in 10% 
(v/v) HI-FCS in PBST at 4oC. Blocking buffer was removed, and cells stained with a 
1/250 dilution of sheep anti-recombinant C. muridarum MOMP (prepared in house) 
diluted in blocking buffer for 90 minutes at room temperature. Cells were washed 3 
times with PBST, and incubated with 1 µg/mL donkey anti-sheep IgG conjugated to 
Alexa Fluor 488 (Invitrogen) and 50 ng/mL 4’,6-diamidino-2-phenylindole (DAPI) 
(Invitrogen) in blocking buffer, in the dark for 1 hour at room temperature. Cells were 
washed 4 times with PBST and once with PBS. Chlamydia were detected in the 
fluorescein isothiocyanate (FITC) channel and imaged with an inverted microscope, 
or confocal microscope (transwells). Imaged chlamydiae were enumerated using 
MetaMorph software (MDS Analytical Technologies). Neutralization values were 
determined from the formula: Neutralization (%) = [(Control treatment IFUs per well 
– Sample treatment IFUs per well)] / Control treatment IFUs per well) x 100. 
3.4  ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
ELISAs were performed using medium-binding Grenier Bio-One ELISA plates 
(Interpath, West Heidelberg, VIC, Australia). End point titer (EPT) was calculated 
from the dilution intercept with mean aborbance of the negative controls (PBS), plus 
two standard deviations. 
3.4.1  Antigen-Specific (Direct) ELISA 
To quantify antigen-specific antibody production; purified MOMP, IncA, CPAF, 
IncMem, ovalbumin (OVA) (Sigma Aldrich), cholera toxin (Sapphire Bioscience, 
Waterloo, NSW, Australia) or ultraviolet (UV)-inactivated C. muridarum EBs were 
diluted to 10 µg/mL or 100,000 EBs/mL in borate-buffered saline (Sigma Aldrich) at 
pH 8. Protein was aliquoted onto ELISAs plates with 50 µL per well and allowed to 
bind overnight at 4oC. Unbound antigen was removed by washing plates three times 
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with PBST, and plates blocked with 5% (v/v) HI-FCS in PBST for 2 hours at room 
temperature. Blocking medium was removed, and three-fold dilutions of mouse 
serum in blocking buffer made across the length of the ELISA plates. Plates were 
incubated at room temperature for 90 minutes. Plates were washed 5 times with 
PBST, and then incubated for 1 hour at room temperature with goat anti-mouse IgA 
conjugated to horseradish peroxidase (HRP) (In vitro Technologies, Noble Park 
North, VIC, Australia), or goat anti-mouse IgG conjugated to HRP (In vitro 
Technologies) diluted 1 in 1000 in blocking buffer. Plates were washed 7 times with 
PBS and developed with 3,3’,5,5’-tetramethylbenzidine (TMB) (Sigma Aldrich) 
diluted 1:50 in phosphate citrate buffer (PCB) (Sigma Aldrich), and the reaction 
stopped with sulfuric acid (Sigma Aldrich). Plates were read at 450 nm on an xMark 
microplate spectrophotometer (Bio-Rad Spectroscopy, Philadelphia, PA, USA). End 
point titers (EPT) were calculated using non-linear regression quadratic equations 
(Prism 5 Software) and the EPT determined from the intercept of the dilution signal 
and the average of negative controls + 2 standard deviations.  
3.4.2  Capture (Sandwich) ELISA 
To quantify antibody concentrations, 5 µg/mL goat anti-mouse Ig (In vitro 
Technologies) or goat anti-chicken IgG in borate buffered saline (BBS) pH 8.0 in a 
volume of 50 µL per well was allowed to bind to ELISA plates overnight at 4oC. 
Plates were washed 3 times with PBST, and blocked with 5% HI-FCS in PBST for 2 
hours at room temperature. Blocking solution was discarded from wells, and 
dilutions of sample and known positives (mouse IgA or IgG) made in blocking buffer 
across the rows. The plates were incubated for 90 minutes at room temperature. 
The solution was discarded, and plates washed 5 times with PBST. The plates were 
then incubated with 1:1000 dilutions of goat anti-mouse IgA-HRP or goat anti-mouse 
IgG-HRP in blocking buffer, for 1 hour at room temperature. Plates were washed 7 
times with PBS and developed with TMB in PCB, with the reaction stopped with 
sulfuric acid. Plates were read at 450 nm with an xMark microplate 
spectrophotometer (Bio-Rad) and sample antibody concentration determined from 
the linear curve of positive controls. 
3.5  CELL CULTURE 
3.5.1  Heat-Inactivated Fetal Calf Serum (HI-FCS) 
To inactivate endogenous complement, fetal calf serum (Lonza, Mt Waverley, VIC, 
Australia) was heat inactivated at 56oC for 30 minutes. 25 mL aliquots of sera were 
stored at -20oC until required. 
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3.5.2  Growth Media 
High glucose DMEM (Invitrogen) and Roxwell Park Medical Institute (RPMI) 1640 
(Invitrogen) were purchased and stored at 4oC until required. Media was 
supplemented with 10% HI-FCS (Lonza, Mt Waverley, VIC, Australia), 2 µg/mL 
gentamycin sulfate (Invitrogen), 100 µg/mL streptomycin sulfate (Sigma Aldrich) and 
1x GlutaMax (Invitrogen). Supplemented media was periodically made and stored at 
4oC. 
3.5.3  Cell Lines  
Cell lines used in this study were received from the American Type Culture 
Collection (ATCC) unless otherwise indicated. Human colonic epithelium C2Bbe1 
(CRL-2102) cells were grown in supplemented DMEM with an additional 10 mg/mL 
human transferrin (Invitrogen). HEC-1A (HTB-112) human endometrial epithelial 
cells were grown in supplemented DMEM. ECC-1 (CRL-2923) human endometrial 
epithelial cells were a generous gift from Charles Wira (Dartmouth Medical College, 
Lebanon, USA) and were grown in supplemented DMEM. McCoy B (CRL-1696) 
murine fibroblast cells were grown in supplemented DMEM. BEAS-2B (CRL-9609) 
human immortalized bronchial epithelial cells were a generous gift from Phillip 
Hansboro (University of Newcastle, Newcastle, Australia) and were grown in 
supplemented RPMI 1640. GK1.5 murine monoclonal hybridoma was a generous 
gift from Graham Le Gros (Malaghan Institute of Medical Research, Wellington, New 
Zealand) and was maintained in supplemented RPMI 1640 with an additional 50 mM 
2-mercaptoethanol (Sigma Aldrich). MDCK I epithelial cells (CCL-34) were a 
generous gift from Russell Simmons (Queensland Health Scientific Services, 
Brisbane Australia) and were maintained in supplemented DMEM. MDCK II cells 
(CRL-2936) were a generous gift from Finn-Erik Johansen (University of Oslo, Oslo, 
Norway) and were maintained in supplemented DMEM. Immortalized murine caput 
epididymal epithelial cells (mECap18) [231] were a generous gift from Petra Sipila 
(University of Turku, Turku, Finland) and were grown in supplemented DMEM with 
50 nM 5α-androstan-17β-ol-3-one (dihydrotestosterone) (Sigma Aldrich). Vero E6 
(CRL-1586) green African monkey kidney epithelial cells were a generous gift from 
John Aaskov (Queensland University of Technology, Brisbane, Australia) and were 
grown in supplemented RPMI 1640. All cells were grown in a humidified incubator at 
37oC and 5% CO2. Cells were periodically determined as Mycoplasma spp. free by 
PCR.  
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3.5.4  Transwell Cell Culture 
Cells used in these studies were grown on uncoated transwells, 0.4 µm pore-sized, 
24 well format (BD Diagnostics, North Ryde, NSW, Australia) in 24 well plate 
holders (BD Diagnostics). Cells were evenly distributed onto a transwell insert 
previously equilibrated in media for 30 minutes at 37oC. Cells grown in transwells 
had 200 µL of media in the apical chamber, and 600 µL in the basolateral chamber. 
Media changes were performed by carefully inverting the insert and discarding used 
media into bleach waste, before returning to empty plates. Media was first replaced 
into the insert, followed by the basolateral chamber to minimize shock. 
Transepithelial electrical resistance (TEER) measurements were taken with a 
Millipore EVOM electrode and cell culture electrode probes (Merck, Kilsyth, VIC, 
Australia). 
3.5.5  Purification of CD4+ Depleting Antibody 
The rat-anti mouse CD4 monoclonal hybridoma (clone GK1.5) was cultured in a 
CELLine CL1000 bioreactor chamber (Sartorius Stedim Australia, Dandenong 
South, VIC, Australia) at 37oC 5% CO2. Supernatant was routinely collected, and 
anti-CD4 IgG purified using a Protein G resin column (Genscript) as per the 
manufacturer’s instructions. IgG was dialyzed into PBS, concentrated with a 30 
MWCO centrifuge filter (Millipore), quantified by BCA, and stored at -80oC until 
required.   
3.6  ANIMAL EXPERIMENTATION 
3.6.1  Mice 
Male and female BALB/c, and C57BL/6 wild type, pIgR -/- and B2m -/- mice (> 6 
weeks) were used in these studies. Wild type mice were purchased from the 
Australian Research Centre (Western Australia, Australia), and pIgR -/- mice bred 
and shipped by Odilia Wijburg (University of Melbourne, Melbourne, Australia). B2m 
-/- breeding pairs were generously obtained from Mark Smyth (Peter MacCallum 
Cancer Centre, East Melbourne, Australia) and a colony was established at the 
Herston Medical Research Centre (HMRC). Mice were housed and fed ad libitum 
with procedures performed under physical containment level 2 (PC2) conditions at 
the HMRC. Ethics approval was acquired from the Queensland University of 
Technology (QUT) Ethics Committee.  
3.6.2  Anesthesia 
Mice were anesthetized by intraperitoneal (IP) injections of ketamine (100 mg/kg) 
(Parnell Laboratory) and xylazine (10 mg/kg) (Bayer). Ketamine was handled and 
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stored under a drug license as per the requirements of the Queensland Health 
(Drugs and Poisons) Regulation Act (1996).  
3.6.3  Intra-Nasal Immunization for Antibody Production 
To produce polyclonal antigen-specific antibodies that would be purified for use in in 
vitro neutralization assays, mice were anesthetized and received 50 µg of antigen 
and 1 µg of cholera toxin (Sapphire Bioscience), in a total volume of 5 µL, delivered 
as 2.5 µL to each nare. Mice were immunized on days 0, 7, 14 and boosted on day 
25. Mice were euthanized by lethal overdose of sodium pentobarbitone (200 
mg/kg)(Virbac), and blood obtained via cardiac puncture.  
3.6.4  Intra-Vaginal Chlamydial Infection 
7 days prior to infection, female mice were sub-cutaneously injected with 2.5 mg 
progesterone. Female mice were anesthetized, and infected intravaginally with 5 x 
104 inclusion forming units (IFUs) of C. muridarum (Weiss) in a total volume of 10 
µL. The dose of 106 was chosen to guarantee 100% of mice were infected [116]. 
3.6.5  Intra-Penile Chlamydial Infection 
Male mice were anesthetized, the penis extracted with gentle pressure, glans 
exposed by pulling back the foreskin, and infected with 106 IFUs of C. muridarum 
(Weiss) in a total volume of 5 µL. 
3.6.6  Respiratory (Intra-Nasal) Chlamydial Infection 
Mice were anesthetized and infected via the nares with 103 IFUs of Chlamydia 
muridarum (Weiss), in a 10 µL volume, 5 µL into each nare. Mice were weighed 
daily to monitor the progression of lung infection indirectly through cachexia [232-
233]. 
3.6.7  Cervicovaginal Swabs 
Vaginal swabs were taken using sterile swabs pre-soaked in SPG. Swabs were 
rotated clockwise and anti-clockwise 5 times. Swabs were placed in labeled tubes 
with three glass beads and 500 µL of SPG. Swabs were stored at -80oC until 
required. 
3.6.8   Vaginal Lavage 
Vaginal lavages were taken by depositing 40 µL of PBS containing protease 
inhibitors (Sigma Aldrich) into the vaginal vault, aspirating and depositing three 
times, and collecting into a tube. Vaginal lavages were centrifuged at 18,000 g for 
10 minutes and stored at -80oC. 
45 
 
3.6.9  Uterine Horn Lavage 
Uterine horn lavages were collected by pipetting 100 µL of PBS with 1x protease 
inhibitors into the proximal end of the uterine horn and collecting the flow through 
into microfuge tubes. Tubes were centrifuged at 18,000 g for 10 minutes and stored 
at -80oC. 
3.6.10  Prostatic Fluid Collection 
Male mice were anesthetized, the IP cavity exposed and the bladder drained with a 
26 gauge needle and 1 mL syringe. Electrodes connected to a Kymograph (Harvard 
Apparatus, Holliston, MA, USA), were placed on either side of the prostate gland 
(directly below the bladder) and were pulsed with voltage (0.1-25 V at frequency of 
1/s) until prostatic fluid was excreted from the glans urethra. Prostatic fluid was 
collected with a capillary tube from the penis. Mice were then euthanized by cervical 
dislocation. Prostatic fluid was stored in microfuge tubes at -80oC until required. 
3.6.11  Urine Collection 
Mice were placed in sterile plastic containers and urine collected with a pipette. 
Urine was centrifuged at 18,000 g for 10 minutes. Supernatant was used for 
sandwich ELISA and pellet resuspended in 100 µL of SPG for quantification of C. 
muridarum by cell culture. Both samples were stored at -80oC until required. 
3.6.12  Saphenous Vein Bleeding 
Mice were restrained in 50 mL plastic tube (BD Falcon), with the left leg exposed. 
Mice fur was wet with soap mixed with 70 % ethanol, and shaved off with a scalpel 
blade. The skin was covered in petroleum jelly, the saphenous vein located and 
punctured with a 26 gauge needle and blood collected with a capillary tube. Blood 
was expelled into microfuge tubes, allowed to clot overnight at 4oC, centrifuged at 
18,000 g for 10 minutes and the sera collected and stored at -80oC until required. 
3.6.13  Cardiac Bleeding 
Mice were injected IP with a lethal dose of sodium pentobarbitone (200 mg/kg), skin 
pulled back, and heart located. The heart was punctured with a 26 gauge needle 
and blood drawn with a 1mL syringe. Blood was expelled into microfuge tubes and 
serum collected as per 3.6.12. 
3.6.14  Tissue Collection (TC) 
3.6.14.1 TC mRNA Collection 
Whole tissues were collected after euthanasia, placed in pre-weighed tubes and 
snap-frozen in an ethanol/dry ice slurry. Tissues were homogenized with a sterile 
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mortar and pestle, and RNA extracted using phenol-chloroform (Invitrogen) following 
standard methodology. Extracted RNA was further purified through RNA purification 
columns and yield calculated using spectrophotometry. All 260/280 values were >2 
indicative of high RNA purity. Complementary DNA was then synthesized from total 
RNA using Superscript reverse transcriptase (Invitrogen) with random hexamers as 
per the manufacturer’s instructions. Complementary DNA (cDNA) was stored at -
20oC until required. 
3.6.14.2 TC Immunohistochemistry 
Mice were euthanized by cervical dislocation and tissues immediately placed into 
histology cassettes and submerged in ice cold 95% (v/v) ethanol for 6 hours. Tissue 
cassettes were then transferred into 100% (v/v) ethanol and stored at -20oC for 1 
week. Tissues were paraffin-embedded, and 5 µm sections taken and fixed to slides 
at 50oC overnight. Sections were dewaxed in xylene, followed by hydration through 
a decreasing ethanol gradient (100%-50% (v/v)), into dH2O.  Antigen retrieval of 
sections was performed in a bath of 50 mM tri-sodium citrate (Sigma Aldrich) pH 5, 
by microwaving submerged slides on high (600 W) for 15 minutes. Slides were 
placed in dH2O and allowed to cool to room temperature (RT). Endogenous 
peroxidase was blocked using 0.5% (v/v) H2O2 in methanol for 20 min. Slides were 
washed in PBST, and blocked overnight in blocking buffer at 4oC. Slides were then 
washed briefly in dH2O, and endogenous avidin blocked with 1 egg white emulsified 
in 5% (w/v) bovine serum albumin (Sigma Aldrich) in dH2O  for 20 minutes at RT 
[234]. Slides were washed with dH2O and endogenous biotin blocked in 5% w/v 
skim milk powder in PBST for 20 minutes at room temperature [234]. Slides were 
washed once in PBST, before primary antibody (1-10 µg/mL in blocking buffer) was 
added and allowed to bind at room temperature for 1 hour. Negative controls did not 
receive primary antibody, and remained in blocking solution. Slides were washed in 
4 x 5 minutes of PBST. Secondary antibody (1/1000 in blocking buffer) was then 
added and allowed to bind at room temperature for 1 hour. Slides were washed 4 x 
5 minutes in PBST, followed by a final wash of dH2O. Metal Enhanced 3,3’-
diaminobenzidine (DAB) substrate (Thermo Fisher Scientific) was prepared in 
supplied H2O2 buffer to a final concentration of 1x, and added to slides for 5 minutes 
at room temperature. DAB precipitation was stopped in dH2O. Tissue was counter-
stained in Nuclear Fast Red (Sigma Aldrich) or Mayer’s hematoxylin (Sigma Aldrich) 
for 5 minutes. Slides were washed twice in dH2O, before dehydration through an 
ethanol gradient (50-100% (v/v)), and xylene. Slides were mounted using Depex 
Mountant (Sigma Aldrich). 
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3.6.14.3 TC – Cell Culture 
Tissues were extracted and placed into pre-labeled pre-weighed microfuge tubes 
containing 500 µL of SPG. Tissues were homogenized with a 220V generator probe 
(OMNI International, Kennesaw, USA) for 10 seconds. Tissues were centrifuged at 
1,000 g for 10 minutes at 4oC and supernatant collected and placed into fresh 
microfuge tubes. Tubes were stored at -80oC until required. 
3.6.15  Collection of Lymphocytes and Spenocytes 
Mice were euthanized with a lethal dose of sodium pentobarbitone. The caudal 
lymph nodes, lumbar lymph nodes and spleens were collected and pushed through 
a 70 µm sieve. Cells were transported on ice in supplemented DMEM containing 
100 µg/mL of DNase I (Roche Diagnostics). Red blood cells were lysed in 
splenocyte homogenates by incubating in RBC lysis buffer for 5 minutes on ice. 
Cells were diluted and pelleted at 500 g for 5 minutes. Cells were resuspended in 
media and quantified by microscopy with trypan blue (Sigma Aldrich) and a 
hemocytometer. 
3.6.16  Hydrosalpinx Measurement 
To determine the degree of hydrosalphinx after 35 days of vaginal infection, the 
diameter of oviduct dilation was determined using a ruler. 
  
48 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
C. muridarum Infection Influences the 
Expression of the pIgR and the FcRn 
in the Murine Reproductive Tract 
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4.1  ABSTRACT 
Antibodies play an important role in host immunity, but often require active transport 
into mucosal sites to facilitate protection. The functional roles of the IgG transporter 
FcRn and the IgA transporter pIgR are well established, but knowledge about their 
distribution throughout the FRT and MRT during chlamydial infections is limited.  
Using qRT-PCR and IHC we demonstrate that there appears to be a contrasting 
distribution of FcRn and pIgR in both the FRT and MRT under normal conditions. 
FcRn was found to be highly expressed in the upper MRT tissues (epididymis, rete 
testes and testes), likely to prevent antibody infiltration into the testes, and 
autoimmunity. Conversely, pIgR was found to be present predominantly in the lower 
MRT tissues (anterior prostate, bladder and urethra). In female mice, FcRn and 
pIgR was expressed in the vagina, cervix and unterine horns. Following chlamydial 
infection, the relative expression of FcRn and pIgR in the MRT and FRT was down-
regulated and up-regulated respectively, implying a typical host response towards 
SIgA and not IgG secretion. These data demonstrate the distribution of 
immunoglobulin transporter receptors FcRn and pIgR in the murine female and male 
reproductive tracts, and reveals major differences in FcRn and pIgR expression 
following chlamydial infection of the reproductive tracts. 
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4.2  INTRODUCTION 
The FcRn and the pIgR are important Ig transporters found at a variety of 
mammalian mucosal interfaces. These receptors facilitate the transport of 
immunoglobulins into and from the lumen, where they are able to bind and 
neutralize pathogens. The transcytosis of immunoglobulin; importantly FcRn 
transport of IgG and pIgR transport of secretory IgA (SIgA) and secretory IgM 
(SIgM), does not affect the barrier function of mucosal epithelia. 
The FcRn has a range of functions in humans including bidirectional and pH-
dependent transcytosis of IgG by epithelia, and protection of IgG and albumin from 
catabolism, increasing the half-lives of these proteins [235-236]. FcRn is a MHC-I–
like glycoprotein, consisting of three extracellular domains (α1, α2, α3), a single 
transmembrane domain, and a short cytoplasmic tail [236]. Similarly to MHC-I, 
functional FcRn requires non-covalent binding with B2m to form a heterodimer [237-
238]. The functional FcRn-B2m heterodimer binds the Fc domain of IgG within an 
acidic pH range of 4.5 - 6.5, and releases IgG at a neutral pH of 7.5 [200, 239]. 
Currently the FcRn is known to be expressed on a variety of differentiated cells 
including APCs, syncytiotrophoblasts, hepatocytes, endothelial cells, and epithelial 
cells [203, 225, 227, 236, 239]. This expansive expression distribution is also 
observed throughout the body with FcRn detectable in the human placenta [206], 
GIT [208-209], respiratory tracts [212], kidney [211], blood-brain barrier [210], FRT 
and MRT [213-214]. As well as delivery of IgG, the FcRn also participates in 
immune surveillance and delivery of antigen-bound IgG to DCs [225]. Whilst 
expression of the FcRn has been shown to be important in delivery of virus-
neutralizing IgG in the female reproductive tract of mice [213], and mRNA expressed 
in the rat MRT [214], the expression of FcRn in the mouse male reproductive tract 
and its role in chlamydial infection remain unknown. 
The pIgR also plays an important role in immunoglobulin transcytosis, binding both 
IgA, and IgM. The binding, basolateral to apical transcytosis, and release of SIgA 
into the mucosal lumen leaves IgA with the extracellular domains of pIgR (1 and 5) 
still attached. This cleaved pIgR product (termed secretory component), prevents 
the return of the SIgA back into the epithelia, and also protects IgA from bacterial 
proteases secreted by pathogens like Neisseria gonorrhœae [240]. Secretory IgA is 
important at mucosal interfaces, acting to inhibit attachment of pathogens (immune 
exclusion) and maintenance of tolerance against commensal flora [241]. Chlamydia 
trachomatis is the most common sexually transmitted bacterial infection in both the 
male and female reproductive mucosa and the leading cause of preventable 
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infertility [242], which makes FcRn and pIgR-mediated delivery of immunoglobulin of 
particular interest. 
The MRT is known to be an immune-privileged site, separated from the systemic 
immune system by the blood-testes barrier, blood-epididymal barrier and the 
immunosuppressive environment created by cells such as Sertoli cells [10]. This 
physical isolation is one of the mechanisms that prevent the development of auto-
immunity against maturing spermatozoa which begin to develop during 
adolescence; long after tolerance to self has been established and continues 
throughout adult life. Consequently, immune cell populations within the testes are 
less numerous and tend to suppress adaptive immunity, thereby preventing hyper-
inflammatory responses to host antigens (auto-immunity) and subsequent immune 
cell infiltration [10].  The varying functions of cells lining the MRT requires 
distributions of different cellular types; with pseudo/stratified columnar epithelium 
lining the urethra, glandular epithelium lining the accessory organs, smooth muscle 
lining the bladder, pseudostratafied columnar epithelium lining the epididymis, 
cuboidal epithelium lining the rete testes, and seminiferous epithelium lining the 
seminiferous tubules in the testes [99]. As mice are a commonly used model of 
human genital tract infections, testing vaccine efficacy, and IgG and IgA are 
implicated in protection against infections, identifying the normal expression and 
response to infection of the immunoglobulin transporters FcRn and pIgR in the MRT 
is critical to future studies of the mechanisms of immunity in the urogenital system in 
humans. 
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4.3  MATERIALS AND METHODS 
Chlamydial Culture and Infection of Animals 
C. muridarum (Weiss) formally the mouse biovar of C. trachomatis, was prepared 
and purified as described in material and methods 3.3. Male and female BALB/c and 
C57BL/6 mice (> 6 weeks) were infected with C. muridarum (Weiss) as described in 
materials and methods 3.6.4. and 3.6.5. respectively.  All procedures involving mice 
where approved by the QUT animal care and ethics committee (0800000824). 
Tissue and Fluid Collection 
Tissues vaginal swabs and fluids were collected from euthanized mice for 
chlamydial cell culture, capture ELISA and mRNA quantification as described in 
materials and methods 3.3.1, 3.4.2, and 3.6.14.1 and respectively. Viable chlamydial 
inclusion forming units (IFUs) were determined by direct inoculation of tissue 
homogenate onto McCoy cells and quantified by microscopy as described in 
materials and methods 3.3.1. 
Purification and Quantification of mRNA by qRT-PCR 
Tissues were collected, mRNA purified and cDNA prepared as described in 
materials and methods 3.6.14.1. Oligonucleotide cDNA primers spanning exon 
regions were designed from the mRNA sequences for mouse FcRn (NCBI ID: 
NM_010189; forward: 5’-CCTGGAGTGGAAGGAGCCGC-3’; reverse 5’-
TCCATTGGGACCA GTGCTGC-3’, 217 bp), pIgR (NCMI ID: NM_011082.3; 
forward: 5’- CGACATCGGAAGAATGTAGACCGC-3’; reverse: 5’- 
CTCAGCGGTGCACTCC GTG-3’, 183 bp), and GAPDH (NCMI ID: NM_008084.2; 
forward: 5’- GAAGGTCGGTGTGAACGGATTTGGC-3’; reverse: 5’- 
GATGGGCTTCCCGTTGAT GACAAGC-3’; 211 bp [243]). Each reaction was 
performed with 50 ng of total cDNA in 20 µL with mastermixes of 2 µL 10x Buffer, 
1.5 mM MgCl2, 100 µM dNTPs, 2.5 mM of each primer, 3 µL SYBR green, 0.5 µL of 
Platinum Taq Polymerase, 1 µL of template, and dH2O to 20 µL. qRT-PCR 
conditions were as follows: 10 minutes initial denature, followed by 40 cycles of 
denaturation at 95oC for 20 s, annealing at 65oC for 20 s, and extension at 72oC for 
20 s. Each sample was performed in triplicate, with histograms representing the 
mean relative expression (n = 3) ± SEM. Cycling was performed on a Rotorgene Q 
PCR cycler (Qiagen). Melt curves were used to identify correct amplicons. Initial 
FcRn and pIgR cDNA copy numbers were each divided by the initial copy numbers 
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of the housekeeping gene GAPDH cDNA, and arbitrarily multiplied to 106 as levels 
are considerably lower than housekeeping genes as previously reported [214].  
Immunohistochemistry (IHC) Reagents 
Mice were euthanized and reproductive tracts taken for IHC, as per materials and 
methods 3.6.14.2. Primary antibodies: rabbit anti-mouse FcRn cytoplasmic domain 
(mFcRn-CD) generously donated by Richard Blumberg (Brigham Women’s Hospital, 
Boston, USA) was immunoprecipitated from the sera of rabbits repeatedly 
immunized with a purified recombinant mFcRn-CD and used for IHC at 5 µg/mL in 
blocking buffer. Goat anti-mouse pIgR extracellular domain was used to detect 
functional extracellular domains of pIgR (R&D Systems) and used at a concentration 
of 0.5 µg/mL in blocking buffer. Both primary antibodies were confirmed by Western 
immunoblot with bands visible for FcRn (45 kDa), and pIgR (120 kDa). Secondary 
antibodies: goat anti-rabbit IgG-HRP (Southern Biotechnology), Rabbit anti-goat 
IgG-HRP (R&D Systems) were used to detect respective primary antibodies.  
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4.4  RESULTS 
4.4.1  Kinetics of C. muridarum Infection in Mice 
To determine the chlamydial burden in the adolescent and sexually mature (> 6 
weeks) murine male reproductive tract tissues over time, mice were infected with 
106 IFUs of C. muridarum (Weiss) and housed for several weeks as previously 
described [116]. Mice were sacrificed every seven days, tissues collected, and 
chlamydial burden determined by direct culture onto McCoy cell monolayers and 
enumerated by fluorescent microscopy. The chlamydial burden in the murine male 
reproductive tract tissues revealed that all mice (n = 6) remained infected for 6 
weeks after urethral inoculation revealing a reduced ability of male mice, compared 
to female mice to clear infection (Figure 4.1 A).  
The peak of infection was tissue-specific. In lower reproductive tract tissues (penis 
and bladder) the chlamydial burden peaked at weeks 2 and 3 respectively. These 
tissues remained infected throughout the duration of the experiment. The testes had 
the largest chlamydial burden within the first week of infection, which gradually 
decreased over the following 5 weeks. Likewise, the epididymes also reached a 
peak of infection by the end of the first week, but the burden remained consistent for 
the following 5 weeks. Together, these data demonstrate that inoculation of the male 
urethra with C. muridarum is able to infect all tissues screened, that all tissues were 
infected by week 1, and that all tissues remained infected for 6 weeks. Interestingly, 
an ascending chlamydial infection in the upper reproductive tract tissues was 
detected within 1 week, demonstrating the ability of this pathogen to rapidly reach 
and colonize the gonads.  
Female mice were hormonally synchronized with depot medroxyprogesterone 
acetate one week prior to challenge as it is required to facilitate vaginal infection of 
mice with C. muridarum [244]. Cell culture of cervicovaginal swabs demonstrated a 
peak of infection on day 6, which had resolved by day 28 (Figure 4.1 B). As the peak 
of hydrosalpinx at this inoculum was day 35, mice were housed until this time point 
before collecting tissues.   
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Figure 4.1  
The Chlamydial Burden in the Murine Reproductive Tracts Over Time 
 A) Male mice (n = 6) were urethrally infected with 106 IFUs of C. muridarum (Weiss) 
and testes, epididymes, bladder and the penis taken for culture weekly. B) Female 
mice were infected with 5 x 103 IFUs of C. muridarum (Weiss) and vaginal swabs 
taken every 3 days. Error bars represent standard deviation. 
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4.4.2  FcRn is Down-regulated in Response to Chlamydial Infection 
To determine the level of in vivo FcRn mRNA transcribed in response to chlamydial 
infection of the MRT, quantitative reverse transcription PCR (qRT-PCR) was 
performed on tissues collect from mice mock infected with SPG, or infected with C. 
muridarum. At the peak of infection (21 days), mice had a down-regulation of FcRn 
mRNA in the upper MRT (Figure 4.2). In the absence of chlamydial infection, higher 
levels of expression were observed in the caput, corpus, and cauda epididymis, as 
well as in the testes and anterior prostate. Expression in the lower MRT such as the 
bladder, seminal vesicles and the penis was much lower, presumably due to a 
higher ratio of connective tissues relative to the lining epithelia. Interestingly, after 3 
weeks of C. muridarum infection, FcRn mRNA was generally down-regulated in all 
tissues except the corpus and cauda epididymes. 
To determine if down-regulation of FcRn mRNA transcription correlated with protein 
down-regulation, IHC on paraffin-embedded murine MRT tissues (with or without 
chlamydial infection) was performed and demonstrated detectable FcRn protein 
expression in all of the screened tissues (Figure 4.3). Similarly to mRNA 
transcription, FcRn protein expression was highest in the columnar epithelia lining 
the tubular tissues of the upper MRT including the rete testes, epididymes and vas 
deferens. Mouse FcRn was found to localize in endosomes around the nuclei of the 
cuboidal epithelia lining the rete testes and columnar epithelia lining the ductulus 
efferens, with no detectable FcRn in the seminiferous tubules. Endosomal staining 
was observed due to the antibody used specifically targeting the cytoplasmic tail of 
FcRn and because 90% of FcRn protein produced resides within the cell cytoplasm 
[245]. FcRn is also strongly detectable in pseudostratafied columnar epithelia of the 
caput, corpus and cauda epididymis. The epithelium lining the ejaculatory ducts in 
the anterior prostate also demonstrated strong expression of FcRn. There was weak 
FcRn expression in the prostatic fibromuscular stroma. Low levels of FcRn were 
weakly visible in the smooth muscle of the bladder, and stratified epithelia lining the 
urethra. Following 3 weeks of C. muridarum infection, FcRn was visibly less intense 
in all tissues screened indicating that FcRn down-regulation occurred at both the 
mRNA and protein level. 
To determine if down-regulation of FcRn was also observed during chlamydial 
infection of the murine FRT, female mice were hormonally synchronized with Depo-
Provera® 1 week prior to infection. Mice were then mock infected with SPG, or  
infected with 5 x 103 IFUs of C. muridarum for 35 days (approximately 5 - 10 days 
after infection has self-resolved [126]) and tissues processed for IHC (Figure 4.4). 
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IHC staining of the vagina and uterine horns of female mice with or without 
chlamydial infections demonstrated weak staining of FcRn (relative to the MRT) in 
both the vagina and uterine horns. Interestingly, FcRn was not detected in the 
columnar epithelia lining the lumen of the uterine horns, but appeared to be 
expressed in the deeper epithelia. Similarly to the murine MRT, chlamydial infection 
of the murine FRT resulted in an absence of any detectable FcRn protein. Together, 
these data suggests that C. muridarum infections of both male and female mouse 
reproductive tracts down-regulates both FcRn mRNA and protein. 
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Figure 4.2   
Transcription of FcRn mRNA is Down-Regulated in the MRT during an Active 
Chlamydial Infection  
Mice were mock infected (black) or infected with C. muridarum for 3 weeks (white). 
Tissues were collected for qRT-PCR. Relative FcRn mRNA transcription was 
determined against GAPDH mRNA. Results are shown as a mean ± SEM, (n = 3 
mice/group). 
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Figure 4.3  
Down-Regulation of FcRn Protein in the MRT during an active Chlamydial 
Infection  
Tissues taken from male mice mock infected or infected with C. muridarum for 3 
weeks were assessed for FcRn protein by DAB IHC (Brown) and counterstained 
with nuclear fast red. Images are representative of triplicate experiments. Scale bars 
= 30 µm. 
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Figure 4.4  
FcRn Remains Down-Regulated in the Uterine Horns but not in the Vagina 
Following Clearance of C. muridarum Infection  
Vagina and uterine horns from progesterone-treated genital mock or C. muridarum-
infected mice were collected 35 days after infection. Tissues were fixed, and stained 
by IHC for FcRn (brown) and counterstained with hematoxylin. Images are 
representative of triplicate experiments. Scale bars = 20 µm 
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4.4.3  The pIgR is Up-Regulated in Response to Chlamydial Infection 
To determine in vivo transcription of pIgR mRNA in response to chlamydial infection 
of the MRT, qRT-PCR was performed on a variety of tissues from the MRT. In 
contrast to FcRn, the transcription of pIgR mRNA in non-infected males was higher 
in the lower MRT (penis, bladder, prostate, seminal vesicles) than in the upper MRT 
(testes, epididymes, vas deferens) (Figure 4.5). Interestingly, compared to FcRn 
mRNA, pIgR mRNA transcription was approximately 10 fold fewer than GAPDH 
mRNA in most tissues. When male mice were infected with C. muridarum, pIgR 
mRNA transcription appears to be up-regulated in all tissues, but particularly in the 
bladder, prostate and penis.  
To determine if increases in pIgR mRNA correlated with an increase in pIgR protein, 
IHC was performed on paraffin-embedded MRT tissues of mice with or without 
chlamydial infection. Similarly to qRT-PCR, IHC staining of the MRT demonstrated 
that expression of pIgR is dominant in the lower MRT (Figure 4.6), with no 
detectable pIgR protein throughout the testes, rete testes, caput, corpus and cauda 
epididymis. The pIgR was detected in the epithelium lining the ejaculatory ducts of 
the anterior prostate, bladder and urethra. Following 3 weeks of C. muridarum 
infection, male mice appear to have a less intense staining of pIgR by IHC. 
To determine if pIgR expression was up-regulated during chlamydial infection of the 
FRT, IHC was performed on tissues of female mice infected with C. muridarum 35 
days earlier (Figure 4.7). The vagina and uterine horns of non-infected and C. 
muridarum-infected female mice demonstrated pIgR expression, which appeared to 
be up-regulated in response to infection. Strong extracellular pIgR was detectable 
on the lumenal surface of epithelia lining the vagina and uterine horns. Together, 
transcription of pIgR mRNA and expression of pIgR protein appears to increase in 
the MRT and FRT following infection, although some weaker staining was observed 
in the MRT bladder and penis. 
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Figure 4.5  
Transcription of pIgR mRNA is Up-Regulated in the MRT during an Active 
Chlamydial Infection  
Mice were mock infected (blanck) or infected with C. muridarum for 3 weeks (white). 
Tissues were collected for qRT-PCR. Relative pIgR mRNA transcription was 
determined as a percentage of GAPDH mRNA. Results are shown as a mean ± 
SEM, (n = 3 mice/group). 
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Figure 4.6  
The pIgR is Not Expressed in the Upper MRT but Remains Expressed in the 
Lower MRT during an Active Chlamydial Infection  
Following 3 weeks of C. muridarum infection, tissues were embedded and pIgR 
expression determined by DAB IHC (brown) and counterstained with nuclear fast 
red. Images are representative of triplicate experiments. Scale bars = 30 µm. 
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Figure 4.7  
The pIgR is Up-Regulated in the Mouse FRT after Clearance of Chlamydial 
Infection  
Vagina and uterine horns from progesterone-treated mock or C. muridarum-infected 
female mice were collected after 35 days of infection. Tissues were fixed, and 
stained by IHC for pIgR (brown) and counterstained with nuclear fast red. Images 
are representative of triplicate experiments. Scale bars = 30 µm. 
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4.4.4  Total Antibody Secretion in Response to Chlamydial Infection 
To determine if changes in FcRn and pIgR expression in response to chlamydial 
infection of the reproductive tracts affected the amount of IgA and IgG secreted, 
male and female mice were infected with C. muridarum for 23 days and 30 days 
respectively. The endpoint titer of non-specific total IgA and IgG in prostatic fluid 
(Figure 4.8.A), urine (Figure 4.8.B), vaginal lavages (Figure 4.8.C) and uterine horn 
lavages (Figure 4.8.D) was quantified by sandwich ELISA.  
In male mice, chlamydial infection of the reproductive tract demonstrated a non-
significant increase in prostatic IgA (p = 0.09) and IgG (p = 0.2), as well as urine 
total IgA and IgG compared to non-infected controls. The small volumes of prostatic 
fluid and varying levels of hydration may have contributed to the large standard error 
of mean observed in the male samples. In female mice, there was also a small but 
non-significant increase in vaginal lavage IgA, but a significant increase in IgG (p = 
0.02). Likewise in the upper reproductive tract, there was a small but non-significant 
increase in uterine horn lavage IgA, and a larger but non-significant (p = 0.07) 
increase in total IgG. Together, these data suggest both IgA and IgG secretion 
increased in response to chlamydial infection of the MRT and FRT tissues.  
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Figure 4.8  
Total IgA and IgG in Mucosal Secretions of C. muridarum-Infected Mice  
Total IgA and IgG EPT were calculated in male prostatic fluid (A) and urine (B), as 
well as female vaginal (C) and uterine horn lavages (D) from control (white bars) 
and C. muridarum-infected (red bars) male and female mice. Error bars represent 
mean ± S.E.M. (n = 5). Statistics calculated with Student’s t test.[96] 
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4.5  DISCUSSION 
In the MRT and FRT innate immune response include physical barriers, host 
defensins, cathelicidins, protease inhibitors, lipocalins, lactoferrins, lysozyme and 
toll-like receptors [127-128, 246]. However, adaptive immunity, particularly cell-
mediated immunity, appears to be actively suppressed in the MRT by multiple 
mechanisms including tolerance induction (regulatory T cell activation and a 
dominance of type 2 macrophages), sequestration of antigen behind the blood-testis 
and blood-epididymis barrier, reduced immune activation and production of multiple 
immunosuppressive cytokines by somatic cells including Sertoli cells [10]. This state 
of immune privilege results in extended survival of allografts and xenografts 
implanted in the testes of many species [10].  
Humoral immunity in upper MRT luminal fluids may also be reduced, as evidenced 
by the lack of local antigen-specific antibodies following intra-testicular 
immunizations [247]. Systemic immunization of both rats and rabbits results in high 
titers of serum IgG; however, specific IgG titers in fluids collected from the rete 
testis, cauda epididymis, seminal vesicles and prostate of immunized animals are 
less than 1% of serum levels [214, 248] suggesting that antibody is excluded, or 
removed, from these regions of the MRT. Intranasal immunization of mice however, 
elicits a strong local IgA response in the prostate [193] and this IgA provides 
significant protection against chlamydial infection in male mice [117]. IgA-secreting 
plasma cells have also been demonstrated in the human prostate and penile urethra 
[249] and human seminal plasma contains both IgG and IgA subclass antibodies, of 
which IgG is the dominant [250]. It is widely accepted that the FcRn and the pIgR 
play a role in delivery of immunoglobulin to mucosal sites, that the expression of 
these receptors is likely to enhance protective immunity [167, 225] and remove IgG 
from the ducts of the MRT [214]. Indeed, the expression of pIgR specifically, has 
previously been shown to significantly reduce C. muridarum burden in the prostate 
and testes of mice [117]. 
Here we demonstrate that FcRn expression in the MRT is localized predominantly to 
the upper reproductive tract tissues including the rete testes, ductulus efferens, 
caput/corpus/cauda epididymis, and vas deferens, but also the anterior prostate in 
non-infected mice which agrees with previous studies in rats [214]. After 3 weeks of 
C. muridarum infection there was a down-regulation of FcRn mRNA transcription 
and protein expression in the tissues analyzed (except cauda epididymes). This is 
likely due to the induction of interferon-gamma (IFNγ) expression during chlamydial 
infection [251], a cytokine known to down-regulate FcRn expression [252]. One 
68 
 
hypothesis to explain the predominant expression of FcRn in the upper regions of 
the MRT is that this IgG transport system is present to remove IgG from the lumen 
of the male reproductive ducts [214], that could potentially bind and damage 
developing spermatozoa. Certainly the acidic pH in the lumen of the proximal 
epididymes [253] would facilitate pH-dependent FcRn-mediated binding and uptake 
of IgG at these sites. 
In contrast to our data on FcRn expression in the upper MRT, pIgR expression is 
primarily localized to the lower MRT tissues. The pIgR expression in the bladder, 
prostate, seminal vesicles and urethra would result in increased SIgA concentrations 
in the lumen at these sites and should assist in SIgA-mediated protection from 
ascending infections. C. muridarum infection led to the up-regulation of pIgR mRNA 
in most tissues, but a large increase in transcription was primarily observed in the 
lower MRT tissues. In contrast to FcRn, IFNγ has been shown to increase pIgR 
[187] and SC [254] mRNA expression, as well as enhancing dimeric IgA binding 
[185], suggesting that chlamydial infection induced an IFNγ-mediated enhancement 
of pIgR expression in these tissues. This presumably leads to increased SIgA levels 
during chlamydial infection and is consistent with previous data from our group 
showing that male mice lacking the pIgR are more susceptible to C. muridarum 
infection [117]. 
Collectively, these data clearly show that the transport of antibody varies throughout 
regions of the MRT. The FcRn and IgG appear to be distributed throughout the 
entire MRT, but expressed at the highest levels (as determined by IHC) in the rete 
testes, caput epididymis and prostate. In contrast, pIgR and IgA appear to have a 
bias for tissues of the lower MRT including the prostate, bladder and penis.  
Female rodents require progesterone pre-treatment to become infected with 
Chlamydia [244] as well as other STDs [255], and depo-Provera® treatment 
maintains secretory phase conditions beyond 30 days in mice [255]. As the female 
mice in this study were depo-Provera® treated to establish an infection, these 
results represent chlamydial infections during the secretory phase only. Similarly to 
male mice, FcRn was found in upper reproductive tract tissues (uterine horns) of 
female mice, however; unlike males, pIgR staining was more intense in the upper 
reproductive tract. C. muridarum infection is typically self-resolving by day 30 in wild 
type female mice [126], and tissues were sampled after resolution, it would appear 
that there is a residual effect of pIgR up-regulation after infection.  
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Functionally, the down regulation of FcRn in the MRT and FRT was inversely 
associated with an increase of IgG in urine, and prostatic, vaginal and uterine horn 
secretions. Whilst the inverse relationship of FcRn and IgG was observed in this 
study, increases in mucosal total IgG in response to chlamydial infection have also 
previously been reported in males [101]. Whilst FcRn mRNA transcription was 
highest in the caput epididymes and in agreement with studies in male rats [214], 
15-fold more IgG is secreted by rete testes than the caput epididymes [214], and 
that 94% of this IgG is immediately reabsorbed by the proximal (caput and corpus) 
epididymes along an acidic pH gradient [214, 253]. Passive diffusion of IgG into rete 
testes secretions seems unlikely as serum concentrations of passively delivered 
water and urea equilibrate with rete testes fluid within 3 hours, ion transport (Na+, 
K+, Rb+, Cl-, I-), creatine and galactose are slower, and larger molecules such as 
EDTA, inulin and albumin are completely excluded [256]. This suggests that the 
FcRn may not exclusively control IgG delivery to the lumen. If down-regulation of 
FcRn could prevent uptake of IgG from the lumen, it is conceivable that IgG could 
pool in lumenal fluid. It would be interesting to determine if the rete testes continue 
to secrete IgG in the absence of the FcRn to determine if this is a plausible 
explanation. Nevertheless, the down-regulation of FcRn was observed at both the 
transcript and protein level for males and female (protein only) mice suggesting 
FcRn is indeed down-regulated during active and following clearance of infection in 
the reproductive tracts.  
The FcRn has previously been shown to bidirectionally mediate the delivery of rabbit 
IgG (with a strong affinity for mouse FcRn [220]) to and from the vaginal mucosa of 
mice and also mediate the transcytosis of IgG dependent on the stage of the estrus 
cycle [213]. Li and colleagues demonstrated that vaginal mouse IgG concentrations 
were significantly higher in WT mice compared to FcRn-deficient mice and that 
vaginal IgG peaked during diestrus. Interestingly, the mice deficient in FcRn still had 
detectable IgG in vaginal lavages suggesting another mechanism may also deliver 
IgG into the FRT. IgG transport into this tract may also be due to an increased 
mucosal leakiness in the absence of FcRn, which similarly has been observed with 
IgA in mice deficient in pIgR [257].  Hormonal control of total IgG in mucosal 
secretions has also been observed in human cervical secretions [190, 258-259] 
suggesting either progesterone positively, or estrogen negatively regulates FcRn 
expression. Similarly, estrogen (estradiol) delivery to male rats reduces the 
secretion rate and distally displaces the absorption of IgG from the caput 
epididymes [214]. This hormonal control of FcRn-mediated IgG delivery is in 
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disagreement with previous studies demonstrating neither androgens 
(dihydrotestosterone) nor estrogens (estradiol) have an effect on FcRn expression 
[260]. Furthermore, Cianga and colleagues have also demonstrated in the mouse 
mammary gland that FcRn does not facilitate systemic delivery of IgG into the 
mucosal lumen, but rather functions in IgG recycling, as evidenced by the 
transcytosis of IgG with no affinity for FcRn into the milk [261].  
Similarly, IHC to detect FcRn expression in human and female mice demonstrated 
that only human vaginal tissue, and not human uterine or mouse vaginal and uterine 
tissue, had diffuse FcRn expression beyond the lumenal facing epithelia suggesting 
FcRn at theses tissues does not participate in systemic IgG delivery to the lumen 
[213]. Chlamydial infection of the epithelia may have also damaged tissue integrity 
and increased the permeability of the epithelia allowing passive flux of antibody into 
the lumen. Whist controversial, data obtained in this thesis also suggests that FcRn 
is not the sole mediator of IgG transcytosis, but likely that it assists in IgG uptake 
from the acidic lumen rescuing IgG from catabolism and presenting IgG-immune 
complexes to APCs. Additionally, this function is suppressed during chlamydial 
infection, possibly in response to IFNγ production [82, 262].  
Unsurprisingly, an increase in transcription of pIgR mRNA in response to chlamydial 
infection correlated with an increase of total IgA in urine, prostatic and vaginal 
secretions. Whilst the vast majority of chlamydial studies do not calculate total IgG, 
and look at systemic but not local antibody production [263], our findings are in 
agreement with Pate and colleagues [101] who observed increases in lumenal total 
IgA of C. trachomatis-infected human male urethras. However, despite a large 
increase in pIgR observed in the uterine horns, there was no difference in the total 
IgA in the lumen of the FRT. Why pIgR up-regulation in this tissue does not lead to 
increased IgA remains undetermined. It is possible that whilst pIgR was up-
regulated (as well as SC release), local IgA production remained the same in this 
tissue and hence no increase in IgA transcytosis was detected in the uterine horn 
lumen. This observable in the human upper FRT which increases pIgR expression 
but not SIgA release during the secretory phase [96]. Similarly in castrated 
hormone-treated male rats, SC release into the prostate was increased 22 fold, but 
IgA secretion only minimally affected [183].  
Because murine models are commonly used in the development of vaccines, we 
have examined the expression of both of these immunoglobulin transporter 
molecules in the murine MRT, in control mice and mice infected with C. muridarum. 
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Within the murine MRT, the FcRn and the pIgR have a contrasting distribution under 
normal conditions. The FcRn is dominantly expressed in the upper reproductive 
tract, and the pIgR dominantly expressed in the lower reproductive tract. C. 
muridarum infection resulted in opposing affects on the expression of these 
receptors in the MRT, where the expression of FcRn in the upper MRT was greatly 
decreased by infection, and pIgR expression in the lower MRT was increased. We 
have also supplied evidence that FcRn may not be the sole transporter of IgG into 
mucosa consistent with other studies [261]. Both of these receptors are important in 
the transcytosis of antibody into the lumen, and we have demonstrated that the role 
of FcRn is likely to become less influential as urogenital chlamydial infection 
progresses, whilst the influence of pIgR may be of more clinical significance. 
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Chapter 5 
 
The pIgR Mediates Delivery of IgA to 
Chlamydial Antigens Expressed 
During the Extracellular and 
Intracellular Phase of the Chlamydial 
Life Cycle 
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5.1  ABSTRACT 
The role of IgA in tolerance to normal flora, homeostasis and immunity within 
mucosal excretions is widely accepted. As Chlamydia spp. commonly infect the 
ocular, respiratory and urogenital mucosal tracts, we sought to define the protective 
role of IgA and its transcytosis ligand pIgR in genital tract chlamydial infections. We 
established an in vitro model to test intra and extra-epithelial cell IgA against a 
variety of antigens expressed throughout the chlamydial developmental cycle. 
Secretory IgA against extracellular chlamydial MOMP was found to reduce 
infectious burden in vitro and in vivo, in a pIgR-dependent manner. Interestingly, this 
protection was not dependent on IgG, or CD4+ T cells. Intracellular IgA specific for 
IncA and CPAF only moderately reduced inclusion formation in vitro, but IncA-IgA 
was found to co-localize with the chlamydial inclusion in a pIgR-dependent manner. 
Furthermore, immunization of wild type and pIgR deficient mice with IncA provided 
significant reductions in chlamydial burden, and was not dependent on CD4+ T 
cells. Both wild type and pIgR deficient mice that had recovered from a previous 
chlamydial infection were not protected against a second infection in the absence of 
CD4+ T cells, suggesting that pIgR-mediated transport of IgA or other non-CD4+ T 
cell-mediated processes were not sufficient to provide recall immunity. Together, 
these data demonstrate pIgR-mediates transport of protective IgA that binds both 
intracellular and extracellular chlamydial antigens. Thus, identification of additional 
extracellular and intracellular chlamydial antigens targetable by pIgR-mediated 
delivery of IgA, as well as improving IgA-inducing adjuvants will enhance the 
efficacy of chlamydial vaccines. 
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5.2  INTRODUCTION 
Antibodies in external secretions were originally assumed to originate from the 
circulatory system, and would exit the endothelium/vasculature via transudation into 
the tissues and lumen where they could bind and neutralize antigens and 
pathogens. However; pioneering studies by Alexandre Besredka (1870-1940) led to 
the discovery that locally produced antibody in the gut is unrelated to the serum 
antibody [264]. Discovery and characterization of IgA in the 1950s [265], and its 
disparate concentrations in mucosal concentrations led to the discovery of the pIgR 
nearly 40 years ago [266-267]. It is now widely accepted that the pIgR unilaterally 
mediates the delivery of IgA to mucosal surfaces, where pIgR is then proteolytically 
cleaved releasing the extracellular domains of pIgR (secretory component) still 
bound to IgA (termed SIgA) into the lumen. This process is so efficient, that despite 
IgG being the dominant class in the serum, SIgA is quantitatively the most abundant 
antibody in many mucosal secretions, with approximately 3 g secreted daily [268]. 
PIgR and IgA are known to have pivotal roles in immune tolerance [241], mucosal 
homeostasis [257], commensal symbiosis [257], and immunity [250, 263]. 
Understanding the role of these two glycoproteins in chlamydial infection will provide 
further insight into mechanisms of immunity and may assist in the development of a 
protective chlamydial vaccine.  
The role of IgA in chlamydial infections is controversial. Whist IgA-deficient  
unimmunized female mice show no difference to WT female mice in their ability to 
clear primary, or secondary genital tract chlamydial infections [6], anti-MOMP SIgA 
appears to be crucial in male primary infections [117, 193]. Similarly, adoptive 
transfer of anti-MOMP monoclonal IgA recognizing a surface-exposed domain of the 
EB to naïve female mice also significantly reduced intensity and duration of 
chlamydial shedding [269] suggesting the antigen-specific antibodies elicited by 
subunit vaccines may provide neutralizing immunity. A similar protective role of 
antibody against secondary infection is observed in immune sera of athymic mice 
[147], mice lacking Fc receptors [197, 270], guinea pigs [271], monkeys [272], and 
humans [195]. Furthermore, while MHC-II, IFNγ and CD4+ Th1 responses are 
necessary in acquiring immunity [273], neither CD4+ nor CD8+ T cells appear to be 
essential for resolution of secondary infections [5, 153]. This suggests that whilst 
CD4+ cells are fundamentally important in acquiring immunity, they may not be 
necessary once adaptive immune processes have matured. 
A large amount of research is focused on developing a female chlamydial vaccine, 
work on a male vaccine has gained little ground. The MRT is commonly infected 
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with C. trachomatis, and similarly to females, can also induce deleterious pathology 
including inflammation of the urethra, prostate, epididymes and testes, tubule 
occlusion and the potential loss of fertility [90]. One of the principle complications in 
developing a male chlamydial vaccine is overcoming the immune suppression and 
immune privilege that occurs in the upper MRT [10]. Additionally, while CD4+ T cells 
secreting IFNγ are widely accepted to be important in the resolution of chlamydial 
infections [1], an influx of these cells into the upper MRT induces the development of 
orchitis, autoimmunity and sterility [2-3]. Despite the immune suppression that 
occurs in the MRT, IgA is readily transcytosed by pIgR across epithelial barriers 
throughout the MRT, and may provide sterilizing immunity without the deleterious 
side effects associated with pro-inflammatory cytokines IFNγ and TNFα. 
Research in virology has demonstrated that intracellular IgA can bind and neutralize 
internalized influenza virus [274] and HIV [11, 176-177], minimizing the 
dissemination of disease. Whilst IgA specific to extracellular chlamydial antigens like 
MOMP have been examined extensively [56, 193, 269, 275-277], the protective role 
of IgA against intracellular chlamydial antigens remains largely unknown [278]. 
Thus, in addition to identifying the protection elicited from pIgR-transcytosed IgA 
(SIgA) specific for MOMP, the potentially protective role of IgA against chlamydial 
antigens associated with the intracellular replicative phase was investigated. 
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5.3  MATERIALS AND METHODS 
Supplemented DMEM (DMEM+) 
DMEM high glucose (Invitrogen) was supplemented with 10% (v/v) HI-FCS, 2 µg/mL 
gentamycin sulphate, 100 µg/mL streptomycin sulphate, 2 mM L-glutamine. HEC1A, 
MDCK I, MDCK II, Vero E6 and McCoy B cells were cultured in DMEM+. DMEM+ 
was stored at 4oC. 
Supplemented DMEM for C2Bbe1 Cells (DMEM+ C2Bbe1) 
DMEM+ media was prepared with an additional 10 mg/mL of human transferrin 
(Sigma Aldrich) included. C2Bbe1 and pcDNA3.1-mpIgR transfectants were grown 
in DMEM+ C2Bbe1 media +/- 550 µg/mL G418 (Invitrogen). DMEM+ C2Bbe1 media 
was stored at 4oC. 
Production and Purification of Antibodies 
Immunization Schedule of Mice to Obtain Antigen-Specific IgA 
Male and female C57BL/6 pIgR -/- mice were generously bred and supplied by 
Odilia Wijburg (University of Melbourne, Melbourne, VIC, Australia). Unlike human 
serum which is composed principally of monomeric IgA, mice principally have 
dimeric IgA (dIgA) in the serum, which in the absence of pIgR-mediated transport, 
pools in the circulation [257]. Thus, to obtain high titers of dIgA, we immunized pIgR 
-/- mice. Mice were immunized intranasally with 20 µg of antigen and 0.5 µg of 
cholera toxin on days 0, 7, 14 and 25. Mice were euthanized by overdose of sodium 
pentobarbitone on day 35 and blood collected via cardiac puncture.  
Purification of Murine Total IgA from Sera 
Sera from immunized groups were pooled and poorly solubilizing proteins 
precipitated by slow addition of half the serum volume of saturated ammonium 
sulfate, bringing the final volume of ammonium sulfate to approximately 30%. The 
serum was incubated at 4oC on a rotating wheel for 6 hours. Weakly soluble 
proteins were precipitated by centrifugation at 4,000 g for 30 minutes at 4oC. The 
supernatant was collected and half the initial volume of saturated ammonium sulfate 
was added to bring the final concentration to 50%. The sera were incubated on a 
rotating wheel overnight at 4oC. Immunoglobulin was precipitated at 4,000 g for 30 
minutes at 4oC. The supernatant was discarded, and the immunoglobulin 
resuspended in PBS to 10 times the initial volume of sera. Sera was pooled and 
depleted of IgG by passing over an equilibrated Protein G resin (Genscript) column 
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and collecting the flow through as per manufacturer’s instructions. IgG-depleted 
ammonium sulfate fractioned antibody was further purified with Mouse IgA 
Purification Resin Kit (Affliland SA, Ans-Liege, Belgium) as per manufacturer’s 
instructions. Briefly, ammonium sulfate fractioned immunoglobulin in PBS was 
diluted to 15 mL in PBS, and IgA precipitated with 35 mL of precipitation buffer (50 g 
precipitation agent solubilized in 140 mL of milli-Q H2O) (Affliand SA) for 15 minutes 
at room temperature. Protein was allowed to rest at 4oC for 30 minutes, and then 
centrifuged at 4,000 g for 15 minutes. The supernatant was collected (containing 
IgG, IgD IgE and other highly soluble proteins), and the precipitate (containing IgA 
and IgM) was resuspended in 10 mL of Binding buffer (Affiland SA). The soluble 
IgA/IgM in binding buffer was run over an equilibrated Mouse IgA Resin bed by 
gravity flow, and washed with 100 mL of PBS until flow through contained no protein 
as determined by spectrophotometry UV280nm. Bound IgA was eluted using Elution 
Buffer (Affiland SA) and protein containing fractions determined by 
spectrophotometry. Protein containing fractions were pooled and concentrated using 
a 30 kDa molecular weight cut-off centrifuge filter (Millipore), resuspended in PBS 
and concentrated again. The protein concentration was determined by 
spectrophotometry UV280nm and diluted to a final concentration of 2 mg/mL in 
PBS. Purity of purified IgA was determined by non-reducing/non-denaturing and 
reducing/denaturing SDS-PAGE, western immunoblotting and antigen-specific 
ELISA and was determined to be >90 % IgA. Aliquoted IgA was stored at -80oC until 
required.  
Cell Lines  
C2Bbe1, HEC-1A, McCoy B, MDCK I, MDCK II and Vero E6 cells used in this study 
were obtained and grown as described in materials and methods 3.5.3.   
Chlamydia Strain 
C. muridarum (Weiss) was used throughout this study and was prepared as 
previously described in materials and methods 3.3. 
RT-PCR of Human pIgR 
To quantify the amount of human pIgR, FcRn and GAPDH mRNA transcription in 
cell lines, BEAS-2b, C2Bbe1, ECC-1 and HEC-1A cells were grown in culture, lysed 
and mRNA extracted with Trizol (Invitrogen) as per the manufacturer’s instructions. 
Exon-spanning primers were designed from BLAST human mRNA sequences. 
Primers for the amplification of human pIgR (200 bp, forward: 5’-
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TGGCGGTCTTCCCAGCCATC -3’; reverse: 5’-GCTGGAGACGTAGCCCTCCGT-
3’), human FcRn (83 bp, forward: 5’-CAGGGTGGAGCTGGAATCTC-3’, reverse: 5’-
CGCTGCCGTGAGTAGCAA-3’), and human GAPDH (69 bp, forward: 5’-
CCACCCATG GCAAATTCC-3’, reverse: 5’-TGGGATTTCCATTGATGACAA-3’). 
The RNA fractions were processed into cDNA and quantitative PCR performed 
using a rotorgene thermocycler (Qiagen, Doncaster, VIC, Australia) with the 
conditions; 35 cycles of denaturing at 95oC for 20 seconds, annealing at 60oC for 20 
seconds, and amplification at 72oC for 20 seconds.  
Transfection of Murine pIgR 
C2Bbe1 cells were transfected with a vector encoding murine pIgR using 
Lipofectamine 2000 (Invitrogen) and Plus Reagent (Invitrogen) as per the 
manufacturer’s instructions. Briefly, Lipofectamine complexed with pcDNA3.1 
encoding murine pIgR (mpIgR) generously donated by Finn-Erik Johansen 
(University of Oslo, Oslo, Norway), was transfected into equilibrated C2Bbe1 cells. 
Positive cells were selected for following 2 days of incorporation by incubating in 
DMEM + C2Bbe1 supplemented with 550 µg/mL of G418 (Invitrogen).  
The ability of transfected C2Bbe1 clones to bind murine IgA was determined by 
immunocytochemistry (Figure 5.4 A). Cells were grown on cover slips overnight, 
fixed in 100% methanol for five minutes, and washed with PBS. Cells were 
incubated with 1% (v/v) serum from a naive pIgR knockout mouse in PBST for one 
hour at room temperature. Cells were washed three times with PBST and incubated 
with goat anti-mouse IgA conjugated with horseradish peroxidase [1:1000] for one 
hour at room temperature. Cells were washed five times with PBST and IgA bound 
cells visualized by incubating the cells with DAB (Thermo Fisher Scientific) in 
hydrogen peroxide buffer for 10 minutes. DAB precipitation was stopped with three 
washes of distilled H2O, and cells counterstained with Mayer’s hematoxylin (Sigma 
Aldrich). Cells were dehydrated through an increasing ethanol gradient and mounted 
on slides using Depex (Sigma Aldrich). Images were taken with an Olympus BX41 
light microscope. 
The ability of IgA-binding C2Bbe1-mpIgR clones to transcytose murine IgA was 
evaluated in transwells. C2Bbe1 wild type (WT), or C2Bbe1 mpIgR cells were 
seeded at 105 cells into 24 well transwell inserts with 0.4 µm pores (BD Falcon), and 
incubated until polarized as described in material and methods (3.5.4). Once 
polarized as determined by measurement of transepithelial electrical resistance 
(TEER) (>300 ohms.cm2), 50 µg of purified mouse IgA diluted in media was loaded 
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into the basolateral chamber and allowed to transcytose at 37oC 5% CO2 with apical 
chamber supernatants collected at various time points. Apically transcytosed murine 
IgA was quantified by sandwich ELISA as per materials and methods 3.4.2. The 
amount of IgA transcytosed was determined from the standard curve of controls.  
In Vitro Intracellular IgA Neutralization of Chlamydia 
To determine the protection offered by intracellular IgA during in vitro C. muridarum 
infection, C2Bbe1 ± mpIgR were seeded onto transwell inserts as per materials and 
methods 3.5.4. and allowed to polarize for five days at 37oC 5% CO2. 50 µg of 
antigen-specific mouse IgA was loaded into the basolateral chamber, and cells were 
infected from the apical chamber with 105 IFUs of C. muridarum (titrated from sub 
confluent C2Bbe1 cells) and incubated at 4oC for 1 hour to allow EB attachment to 
the apical surface and IgA attachment to basolaterally expressed pIgR. Plates were 
then incubated at 37oC in 5% CO2 for 22 hours to allow growth of inclusions for 
quantification. Media was then replaced with fresh DMEM+ and C2Bbe1 and cells 
incubated for a further two hours at 37oC 5% CO2 to allow unbound antibody to be 
cleared. Cells were washed three times with ice-cold PBS, and fixed with 4% (v/v) 
paraformaldehyde (PFA) in PBS on ice for 20 minutes. The transwell membrane 
was excised from the insert, and cells were permeabilized with 0.1% (v/v) Triton 
X100 in PBS for 15 minutes. Inserts were blocked in 10% (v/v) goat serum in PBST 
for one hour at room temperature. Inserts were probed with sheep anti-C. 
muridarum MOMP (1:250) (produced in house) and rabbit anti-mouse LAMP1 (2 
µg/mL) (Sapphire Bioscience), rabbit anti-sequestosome 1 (SQSTM1/p62) (2 
µg/mL) (Sapphire Bioscience), or rabbit anti-PARP (2 µg/mL) (Sapphire Bioscience) 
in blocking buffer overnight at 4oC. Inserts were washed three times with PBST, and 
incubated with secondary antibodies, donkey anti-sheep IgG-conjugated to Alexa 
Fluor 488 (1 µg/mL) (Invitrogen), and goat anti-rabbit IgG-conjugated to Alexa Fluor 
528 (1 µg/mL) (Invitrogen), or goat anti-mouse IgA TRITC (1:250) (Southern 
Biotechnology) for one hour in the dark at room temperature. Cells were washed five 
times with PBST, and incubated with DAPI for 20 minutes at room temperature in 
the dark. Membranes were washed twice with PBS, mounted onto slides with 
Prolong Gold (Invitrogen) and #1.5 coverslips and allowed to dry overnight. 
Distribution of proteins was identified with a Leica SP5 confocal microscope using 
with diode, argon, diode-pumped solid-state and HeNe lasers. To quantify the IFUs, 
overlays of 10 different compressed Z-stacks were imaged per insert, and IFUs 
enumerated. Data are representative of triplicate inserts per condition. 
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Animal Work 
Mice 
Male C57BL/6 WT mice, 6-8 weeks of age, were obtained from the Animal 
Resource Centre (ARC) (ARC, Perth, WA, Australia), and male C57BL/6 pIgR -/- 
were bred and provided by Odilia Wijburg (University of Melbourne, Melbourne, VIC, 
Australia). Mice were housed in an accredited laboratory animal care facility under 
specific pathogen-free conditions. Only mice from the same litter where caged 
together to minimize fighting. Mice received food and water ad libitum. All 
procedures were approved by the Queensland University of Technology Animal 
Research Ethics Committee (approval number 0800000824).  
Respiratory Infection and Monitoring 
Respiratory infection was conducted as described in materials and methods 3.6.6. 
Briefly, mice were anesthetized intraperitoneally (IP) with ketamine (100 mg/kg) 
(Parnell Laboratory) and xylazine (10 mg/kg) (Bayer), and challenged intranasally 
(IN) with 103 IFUs of Chlamydia muridarum (Weiss), in a 10 µL volume, 5 µL into 
each nare. Mice were weighed daily to monitor the progression of lung infection 
indirectly through cachexia.  
Immunization Procedure 
Mice were housed for 1 week prior to the initial immunization and immunized on 
days 0, 14 and 25 via the intranasal route. Mice were anesthetized with ketamine 
(100 mg/kg) and xylazine (10 mg/kg), placed on their backs, and received IN 
immunizations, in a total volume of 5 µL, 2.5 µL per nare. On days 0 and 14, 20 µg 
of antigen and 0.5 µg of cholera toxin was immunized IN, and on day 25 mice 
received a boost of 50 µg of antigen, 1 µg of cholera toxin and 10 µg of CpG ODN 
(5’-TCC ATG ACG TTC CTG ACG TT-3’)(Sigma) in a total volume of 2.5 µL per 
nare. On day 30, blood was taken via saphenous vein puncture and serum analyzed 
by antigen-specific ELISA to determine systemic antigen-specific antibody 
production. 
Depletion of CD4+ Cells 
The rat anti-mouse CD4 monoclonal hybridoma (GK1.5) was cultured and purified 
as described in materials and methods (3.5.5). Mice were depleted of CD4+ cells by 
IP injection of 200 µg of purified GK1.5 two days prior to penile challenge, and 
received continuous depletion with IP injection of 100 µg of GK1.5 every 7 days until 
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euthanasia (days -2, 4, 11, 18 of genital infection). Splenocytes, caudal and lumbar 
lymph nodes were taken, mechanically disrupted by passing through a 70 µm nylon 
filter as per materials and methods 3.6.15, and kept at 4oC until processing for flow 
cytometry. 
Intrapenile Infection and Monitoring  
Male mice were infected as per materials and methods (3.6.5). 
Animal Sacrifice and Sample Collection 
Mice were euthanized with sodium pentobarbitone, cardiac blood collected (3.6.13), 
together with the penis, bladder, prostate and testes of mice for cell culture 
(3.6.14.3) and quantification of C. muridarum IFUs (3.3.1). Tissues and sera were 
stored at -80oC until required. 
Flow Cytometry 
Splenocytes, caudal and lumbar lymph nodes were collected at sacrifice, 
enumerated with a hemocytometer and fixed with 4% PFA for 15 minutes on ice. 
Between 106-107 fixed cells were aliquoted into each test tube. Fixed cells were 
centrifuged at 300 g for 5 minutes and blocked with 10% (v/v) HI-FCS in PBS and 2 
µg/mL of 2.4G2 for 1 hour on ice. Cells were pelleted by centrifugation at 300 g for 5 
minutes and incubated with 0.06 µg of anti-mouse CD3 (145-2C11)-conjugated with 
APC (Jomar Bioscience, Kensington, SA, Australia), and 0.06 µg of anti-mouse CD4 
(GK1.5)-conjugated to PE (Jomar Bioscience) and incubated on ice in the dark for 
30 minutes. Cells were washed once with PBS and pelleted at 300 g for 5 minutes. 
Cells were resuspended in 200 µL of PBS. Lymphocytes were gated by forward and 
side scatter, and CD3+ and CD4+ expression determined on a FC500 flow 
cytometer (Beckman Coulter). Data was analyzed with FlowJo flow cytometeric 
software (TreeStar).    
ELISA 
Antigen-specific ELISA was performed as previously described in materials and 
methods (3.4.1). 
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5.4  RESULTS 
5.4.1  Establishment of an In Vitro Model to Determine the Protection 
Provided by IgA and pIgR during C. muridarum Infection 
As cell polarization is required for efficient transcytosis of IgA in epithelial cells, the 
ability of polarized cells to become infected with C. muridarum was determined. 
Madine Darby Canine Kidney endothelial cells (MDCK I and II), human endometrial 
cells (ECC-1), human endometrial cells (HEC1A), human colorectal epithelial cells 
(C2Bbe1), immortalized human bronchial epithelial cells (BEAS-2b), and African 
green monkey kidney epithelial cells (Vero E6) were grown on transwell inserts and 
allowed to polarize. C2Bbe1, ECC-1, HEC-1A and MDCK I cell lines passed the 
arbitrary threshold of strong polarization of 200 Ωcm2 [44] by day 3 and maintained 
polarization until day 5. BEAS-2b, MDCK II and Vero E6 cells were unable to 
surpass 100 Ωcm2 after 5 days and are therefore considered weakly polarizing cell 
lines (Figure 5.1).  
Following 5 days of culture on transwell inserts, polarized cells were infected with 5 
x 104 IFUs of C. muridarum (Weiss) (titrated on McCoy B cells) for 24 hours. The 
ability of polarized cells to become infected was determined by fluorescent 
microscopy. Polarized BEAS-2b, C2Bbe1 and HEC-1A retained infectivity greater 
than 50% of sub-confluent McCoy cells demonstrating that the infectivity of C. 
muridarum was not greatly affected by polarization in these cells. Conversely, 
polarized ECC-1, MDCK I, MDCK II and Vero E6 permissiveness to C. muridarum 
infection was less than 50% of sub-confluent McCoy-B cells (Figure 5.2).  
C2Bbe1 and HEC1A achieve strong TEERs values and are permissive to C. 
muridarum infection following polarization. As both C2Bbe1 and HEC-1A are human 
in origin, they required transfection with a vector coding murine polymeric 
immunoglobulin receptor. Furthermore, human pIgR can bind and transcytose 
murine IgA [279]. Thus, the relative expression of human pIgR mRNA was 
determined by qRT-PCR (Figure 5.3), revealing that C2Bbe1 and HEC-1A cells 
transcribed endogenous human pIgR mRNA. To minimize potential transport of 
mouse IgA by human pIgR, C2Bbe1 cells were used for subsequent experiments as 
they transcribed 850 times less pIgR mRNA than HEC-1A cells. 
Transfection of Human Cell Lines with pcDNA-Murine pIgR (mpIgR) 
C2Bbe1 cells were transfected with pcDNA mpIgR and positive transfectants 
selected for with 550 µg/mL of G418. The ability of transfectants to bind (Figure 5.4 
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A) and transcytose murine IgA (Figure 5.4 B) revealed that C2Bbe1 pcDNA mpIgR 
transfectants bound murine IgA with the highest staining intensity but were unable to 
bind human IgA from sera, presumably as it mostly in monomeric form. C2Bbe1 
mpIgR transfectants also transcytosed murine IgA significantly more than wild type 
controls (p < 0.05). It was apparent that there was some low level of endogenous 
human pIgR  transport of small amounts of murine IgA (Figure 5.3) [279].   
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Figure 5.1 
TEERs of Cell Lines Grown on Transwell Inserts  
The TEERs of BEAS-2b, C2Bbe1, ECC-1, HEC-1A, MDCK I, MDCK II and Vero E6 
cells were monitored with an EVOM electrode daily following seeding onto transwell 
inserts (n=3). The dotted line indicates an arbitrary indication of strong (> 200 Ωcm2) 
and weakly (< 150 Ωcm2) polarizing cells. Error bars represent S.E.M. 
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Figure 5.2  
Polarization of C2Bbe1 Cells Does Not Reduce Infectivity of C. muridarum 
After 5 days of growth on transwell inserts, BEAS-2B, C2Bbe1, ECC-1, HEC-1A, 
MDCK-I, MDCK-II and Vero E6 cells were apically infected for 24 hours with 5 x 104 
IFUs of C. muridarum (determined from McCoy-B sub-confluent monolayers). IFUs 
per insert were determined by fluorescent microscopy (n = 3). Error bars 
representative of mean ± S.E.M. 
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Figure 5.3  
Transcription of Human pIgR mRNA in Human Cell Lines 
Relative mRNA transcription of human pIgR (hpIgR) to GAPDH. Human pIgR and 
GAPDH transcription was determined by qRT-PCR. (A) hpIgR mRNA expression in 
cells relative to housekeeping gene GAPDH. (B) Agarose gel electrophoresis of 
qRT-PCR amplicons. ND = not detected. 
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Figure 5.4  
Binding and Transcytosis of Murine IgA by C2Bbe1 Cells Transfected with 
Murine pIgR 
(A) Serum from pIgR -/- mice and human serum was applied to mock and pcDNA 
mpIgR-transfected C2Bbe1, and IgA binding determined by ICC. (B) Transcytosis of 
murine IgA in pcDNA mpIgR transfectants and mock C2Bbe1 cells. Polarized 
C2Bbe1 cells grown on transwells had purified murine IgA aliquoted in the 
basolateral chamber, and samples of the apical chambers were taken at 1, 3, 6 and 
24 hours. Transcytosed IgA was determined by sandwich ELISA (n = 3). Error bars 
representative of S.E.M. Statistics determined by Student’s t test. 
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5.4.2  Neutralization of Extracellular Chlamydial EBs is Mediated by 
pIgR Delivery of anti-MOMP IgA 
 To determine the protective role of anti-MOMP IgA in chlamydial infection, wild type 
C2Bbe1 or C2Bbe1 cells expressing murine pIgR were grown for five days on 
transwell inserts until polarized (> 250 Ωcm2). Murine total IgA purified from the sera 
of pIgR -/- mice intranasally immunized with recombinant C. muridarum MOMP or 
ovalbumin (OVA) was then loaded into the basolateral chamber and allowed to 
transcytose to the apical chamber for 24 hours. Transcytosed antibody in the apical 
supernatant was carefully removed and incubated with 105 IFUs of C. muridarum 
(MOI 1) for one hour at room temperature to allow transcytosed antibody to bind 
chlamydial EBs. Following binding, the chlamydial and antibody mixture was 
returned to the insert and allowed to infect for 24 hours.  
The ability of anti-MOMP IgA to neutralize chlamydial infection was determined from 
the percent reduction of IFUs relative to OVA-IgA groups in both cell types. C2Bbe1 
cells expressing murine pIgR demonstrated a significant reduction (p < 0.01) of 
inclusion formation mediated by anti-MOMP IgA (15%), with the neutralization 
abrogated in cells lacking murine pIgR (Figure 5.5). This suggests that only 
polarized cells transfected with murine pIgR were able to efficiently transcytose IgA 
to the apical chamber where anti-MOMP IgA was able to bind chlamydial EBs and 
inhibit chlamydial attachment.   
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Figure 5.5  
In vitro Neutralization of C. muridarum EBs by MOMP-SIgA is Mediated by 
pIgR  
Polarized C2Bbe1 cells +/- mpIgR were grown on transwell inserts until polarized, 
50 µg/mL of total murine IgA purified from MOMP or OVA immunized mouse serum 
was loaded into the basolateral chamber and allowed to transcytose for 24 hours. 
The apical supernatant was then collected and incubated with 105 IFUs of C. 
muridarum EBs for 1 hour at room temperature, before returning to the cell 
monolayers and infecting for 24 hours. IFUs were enumerated by fluorescence 
microscopy. Percent neutralization of MOMP IgA was calculated by the reduction of 
IFUs relative to the OVA IgA inserts (n = 3). Error bars represent S.E.M and 
statistics determined by Student’s t test (p < 0.05). 
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5.4.3  The pIgR Mediates Delivery of Antigen-Specific IgA to 
Internalized Chlamydial Antigens 
To determine if IgA could bind and neutralize internalized chlamydiae in vitro, 
C2Bbe1 cells were grown on transwell inserts until polarized. Murine polyclonal IgA 
(50 µg/mL) purified from the sera of pIgR -/- mice intranasally immunized with OVA, 
recombinant C. muridarum IncA, CPAF or C. muridarum intracellular lysate 
(IncMem) were added to the basolateral chamber and C. muridarum EBs (MOI 1) 
added to the apical chamber. Inserts were incubated at 4oC for 1 hour to allow 
antibody to bind pIgR, and EBs to attachment. Cells were then incubated at 37oC in 
5% CO2 for 24 hours. The ability of anti-IncA/IncMem/CPAF IgA to neutralize 
chlamydial growth was determined by enumeration of inclusions following incubation 
relative to OVA controls (Figure 5.6 A). C2Bbe1 mpIgR transfectants incubated with 
IncA, IncMem and CPAF IgA demonstrated a small, but insignificant reduction in 
inclusion formation. The minimal neutralizing ability of anti-IncA/IncMem/CPAF IgA 
observed in the mpIgR transfectants was absent in the wild type cells.  
Despite the inability of anti-IncA/IncMem/CPAF IgA to reduce chlamydial inclusion 
formation, the internalization and co-localization of anti-IncA IgA with the inclusion 
was demonstrated by confocal microscopy (Figure 5.6 B). Mouse IgA was observed 
to co-localize with the chlamydial inclusion, remaining attached for the duration of 
infection. To determine if bound IgA was able to activate lysosomal, sequestosomal 
or apoptotic pathways, cells were probed with LAMP1, SQSTM1/p62 or PARP 
polyclonal antibodies. Up regulation of LAMP1 or PARP was not seen in any 
conditions (not shown). However; the SQSTM1/p62 protein was observed inside the 
inclusions of IncA-IgA treated cells, and to a lesser extent in OVA controls (Figure 
5.6 C). Together, these data suggest that IgA, in the process of transcytosis, is able 
to associate with chlamydial inclusion, but that IncA and IncMem-specific IgA are 
unable to prevent chlamydial development in polarized monolayers of epithelial cells 
at the concentrations tested which are higher than those observed in vivo in the 
reproductive tracts of mice [280], and represent an intermediate IgA concentration in 
human reproductive tract mucosal secretions (Table 2.1).  
 
92 
 
 
Figure 5.6  
Intracellular IgA has a Limited Role in Reducing Chlamydial Growth in 
Polarized Epithelial Cells 
Cells grown on transwell inserts were loaded basolaterally with purified mouse IgA, 
and infected apically with C. muridarum. (A) The reduction of IFUs (neutralization) 
by IgA against chlamydial antigens IncA, CPAF and inclusion membrane lysates 
(IncMem) relative to OVA IgA controls in murine pIgR-transfected and wild type 
C2Bbe1 cells (n = 3). (B) Intracellular anti-IncA IgA (red) co-localizes with the 
chlamydial inclusion (green). (C) IncA-IgA binding up-regulates SQSTM1/p62. Error 
bars representative of mean ± S.E.M. No statistical difference from OVA-IgA treated 
controls was observed with Student’s t test. Scale bars = 10 µm. 
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5.4.4  Experimental Schedule to Determine the In Vivo Role of IgA and 
pIgR During Chlamydial Infection 
To determine the role of IgA and pIgR in vivo, wild type and pIgR deficient mice 
were used. Passive immunization of biotinylated IgA intraperitoneally 
(Supplementary Figure 5.1 A), or intravenously (Supplementary Figure 5.1 B) did 
not transport of sufficient amounts of IgA to the urogenital tract and thus the passive 
immunization model was not used. To determine the protection provided by IgA and 
pIgR in vivo, male mice were immunized with antigen, allowed to develop an 
immune response over 33 days. As CD4+ T cells provide protection in the male 
reproductive tract [281], but are also associated with the breakdown of immune 
privilege [3], we sought to determine if immunity in the absence of CD4+ T cells was 
possible. To address this, immunized mice were subsequently depleted mice of 
CD4+ cells with anti-mouse CD4 antibody prior to urogenital chlamydial challenge.  
To initially determine if CD4+ cells played an important role in chlamydial infection of 
the male mouse reproductive tract, wild type and pIgR -/- mice were immunized 
intranasally with OVA and cholera toxin, and challenged with a urogenital tract 
chlamydial infection on day 35. To elucidate the role of CD4+ cells in chlamydial 
infection, OVA-immunized mice were mock depleted (naïve) or depleted of CD4+ 
cells with monoclonal antibody prior to, and continuously throughout the infection 
(Figure 5.7 A-B). To determine whether IgA against extracellular and intracellular 
chlamydial antigens had a protective role in vivo, wild type and pIgR -/- mice were 
immunized three times intranasally with cholera toxin as an adjuvant and MOMP, 
IncA, IncMem, or OVA (control) as antigens. Mice were then depleted of CD4+ cells, 
and then challenged for 21 days with a genital tract C. muridarum infection (Figure 
5.7 B).  As previous studies have demonstrated intranasally infection can produce 
partial protection in the reproductive tract [282], we sought to determine if there was 
any non-CD4+, non SIgA-specific immunity developed. To address this, mice were 
given a respiratory infection on day 0 with 103 IFUs of C. muridarum and monitored 
until cachexia resolved (Figure 5.7 C). 
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Figure 5.7 
Experimental Schedule to Determine the in vivo Role of IgA and pIgR during 
Chlamydial Infection 
Male WT and pIgR -/- mice received intranasal (IN) immunizations or respiratory 
prime infection, with or without CD4+ T cell depletion, and prior to urogenital 
chlamydial challenge. (A) The normal infection control group were IN immunized 
with OVA, mock depleted with PBS, and challenged with a genital tract infection of 
C. muridarum. (B) Mice that previously received IN immunizations of MOMP, IncA, 
IncMem, or OVA mice were continuously depleted of CD4+ T cells and challenged 
with a genital tract C. muridarum infection. (C) Mice were primed with a respiratory 
C. muridarum infection to develop protective immunity prior to CD4+ depletion, and 
genital tract challenge for 21 days.  
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5.4.4.1  The pIgR is Not Necessary for Resolution of Acute Respiratory 
Chlamydial Infection 
As an indirect measurement of chlamydial burden in mice primed with a respiratory 
infection, the body weight loss was measured daily following challenge (Figure 5.8 
A) [232-233, 283]. Both wild type and pIgR -/- mice demonstrated similar cachexia 
over nine days, with the peak of weight loss in both groups observed by day seven, 
which quickly resolved by day eight. To determine if there was any difference in the 
intensity and duration of cachexia, the area under the curve for the duration of the 
infection was calculated and there was no significant difference between the strains 
(Figure 5.8 B). This suggests that pIgR, and hence SIgA are not required to resolve 
primary chlamydial infections of the respiratory tract and agrees with studies in the 
murine FRT [6]. 
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Figure 5.8  
The pIgR is Not Required for Resolution of a Primary C. muridarum 
Respiratory Infection  
(A) Wild type (WT) pIgR -/- mice infected IN with 103 IFUs of C. muridarum showed 
similar weight loss (cachexia) and returned to normal weight by day 8 of infection. 
(B) Area under the curve analysis demonstrated a non-significant increase in 
cachexia of WT mice compared to pIgR -/- mice. Error bars representative of mean 
± S.E.M. (n = 5). Statistics calculated with Student’s t test. 
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5.4.4.2  Depletion of Systemic and Reproductive Tract-Draining Lymph 
Node CD4+ T cells in Male Mice 
Long term depletion of CD4+ cells with intraperitoneal administration of monoclonal 
anti-mouse CD4+ rat IgG2b (Clone GK1.5) successfully depleted both systemic and 
draining lymph node CD4+ cell populations (Figure 5.9).  Of the gated splenocyte 
lymphocyte populations (based on side and forward scatter), WT mice had a mean 
of 32 % CD3+ (T cell marker), and pIgR -/- mice had a higher mean of 43% CD3+ 
cells in the spleen in response to infection. This elevated T cell population in pIgR-
deficient mice has been reported previously [284], and may be an immune 
compensation for a lack of SIgA. The elevated CD3+ population in pIgR -/- mice was 
also observed in the caudal and lumbar lymph nodes which drain the male 
reproductive tract. In these lymph nodes, CD3+ T cells made up approximately 
37.2% and 71.0% of all lymphocytes in wild type and pIgR -/- mice respectively. 
Cells that stained both CD3+ and CD4+ were identified as the resident CD4+ T cells 
in the spleen and draining lymph nodes. Of the lymphocytes with this phenotype, 
there were 21% and 62% more CD3+CD4+ T cells in the spleen and reproductive 
tract draining lymph nodes in mice deficient in pIgR.  
Following 23 days of CD4+ depletion with 21 days of urogenital tract C. muridarum 
challenge, all GK1.5-treated mice had significantly fewer (p < 0.0001) CD4+ T cells 
in the spleen (99.5 ± 0.3 %), and draining lymph nodes (97.5 ± 2.0 %). This 
indicated that both WT and pIgR -/- mice had negligible counts of CD3+CD4+ T cells 
systemically (spleen) and locally (caudal and lumbar lymph nodes), and that the role 
protective immunity in the absence of CD4+ cells could be determined. 
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Figure 5.9  
Continuous IP Administration of GK1.5 Depletes CD3+CD4+ T cells in the 
Spleen and Lymph Nodes in Wild Type and pIgR -/- Mice 
(A) Flow cytometry representative of PBS mock and GK1.5 treated mice. Complete 
data for CD3/CD4-stained splenocytes (B) and reproductive tract draining lymph 
nodes lymphocytes (C) showing all mice treated with GK1.5 anti-CD4 antibody have 
significant reductions in CD4+ T cells. Statistics calculated with Student’s t test 
against mock treated mice of the same background (**** = p < 0.0001). Error bars 
represent mean ± S.E.M. (n = 5). 
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5.4.4.3  Immunogen and Adjuvant-Specific Antibody Responses  
 
Serum Humoral Responses Prior To CD4+ Depletion 
To determine the antibody responses prior to CD4+ cell depletion and genital tract 
challenge, saphenous vein blood was collected on day 30 and systemic IgA and IgG 
responses determined by antigen-specific ELISA. All immunized mice tested 
demonstrated systemic antigen-specific IgA (Figure 5.9 A) and IgG (Figure 5.9 B) 
production by day 30 of immunization.  Mice immunized intranasally with cholera 
toxin and OVA demonstrated the highest systemic antigen-specific IgA responses 
(WT = 18,950 ± 18,167; pIgR -/- = 81,412 ± 44,164), followed by MOMP (WT = 
5,374 ± 2,598; pIgR -/- = 30,427 ± 17,173). Mice challenged intranasally with C. 
muridarum had systemic IgA specific for extracellular domains of UV-inactivated C. 
muridarum EBs (WT = 4,598 ± 854; pIgR -/- = 47,838 ± 18,167). Mice deficient in 
pIgR demonstrated antigen-specific IgA endpoint titers approximately 10 fold greater 
than wild type mice as a consequence of the inability of pIgR deficient mice to 
transport dIgA from the serum into the bile [257]. Antigen-specific IgG responses in 
MOMP (WT = 824,905 ± 280,781; pIgR -/- = 729,881 ± 76,020), and OVA (WT = 
733,039 ± 67,554; pIgR -/- = 685,979 ± 189,284)-immunized mice were 
approximately equal between antigens and strains of mice. Intranasally infected 
mice had similar IgG endpoint titers to the extracellular domains of UV-inactivated 
EBs between mouse strains (WT = 111,789 ± 56,622; pIgR -/- = 115,897 ± 52756), 
but were approximately 10 fold greater in the cholera toxin-immunized groups. Pre-
challenge IgA and IgG endpoint titers for IncA and IncMem immunized groups were 
not determined as the proteins were difficult to purify and were required for other 
experiments. Together, these data suggest that all mice tested had both antigen-
specific systemic IgA and IgG prior to CD4+ depletion and genital tract chlamydial 
challenge.  
Serum Antigen-Specific IgA Responses at Sacrifice 
To determine the antigen-specific antibodies present at sacrifice, serum was 
collected by cardiac puncture and antigen-specific ELISA performed for all mice. 
Similarly to pre-infection, all groups had both IgA and IgG antibodies against the 
immunogen (Figure 5.10 A, C) and adjuvant (Figure 5.10 B, D) with no IgA or IgG 
against cholera toxin detectable in the intranasally infected group. As previously 
demonstrated, antigen-specific IgA was > 10 fold greater in pIgR -/- mice than in WT 
mice as a consequence of these mice not being able to clear dIgA from the serum. 
100 
 
MOMP, IncA, IncMem and OVA immunization produced similar anti-immunogen IgA 
serum responses (Figure 5.10 A), and approximately 10 fold greater IgA endpoint 
titers against the adjuvant cholera toxin in these mice (Figure 5.10 B). Intranasally 
immunized groups did not have observable differences in immunogen-specific IgA 
production compared to the identical mice endpoint titers pre-CD4 depletion and 
pre-genital challenge (Supplementary Figure 5.2). There was no significant 
difference observed in OVA control groups with or without CD4 depletion indicating 
that CD4+ cells do not play an import role in continued expansion of IgA production, 
in the absence of antigen. Interestingly, mice primed with a respiratory infection 
continued to produce 10 fold more EB-specific IgA than pre-challenge levels, which 
occurred in both strains of mice, in the absence of CD4+ T cells, and was not 
dependent on exposure to the tested antigens as mice immunized with an 
immunodominant antigen (MOMP) had a decrease in IgA production following 
infection. This suggests that other antigens (likely chlamydial LPS) may have 
induced T-cell independent B cell activation.  
Serum Antigen-Specific IgG Responses at Sacrifice 
Antigen-specific serum IgG was detected in MOMP, IncA, IncMem, OVA and 
respiratorily infected WT and pIgR -/- mice (Figure 5.10 C). Unlike IgA responses, 
anti-immunogen IgG endpoint titers were not significantly different between WT and 
pIgR -/- mice for any antigens, and demonstrated different antigenicity between 
immunogens. Compared to test bleeds prior to infection and CD4 depletion, OVA 
and respiratorily infected groups but not MOMP-immunized groups had increased 
IgG endpoint titers indicating IgG production continued in the absence of CD4+ T 
cells (Supplementary Figure 5.2 C-D). Uniquely, anti-MOMP serum IgG levels show 
a reduction post-infection, albeit non-significant, compared to test bleeds 
(Supplementary Figure 5.2 A-B). Anti-adjuvant IgG endpoint titers were again 
approximately 10 fold greater than the immunogen in immunized groups indicating 
the strong immunogenicity of the adjuvant over the immunogens, despite CT only 
making up 2.5% of the total protein in the immunizations (Figure 5.10 D).  
Serum from respiratorily primed, urogenitally challenged groups was probed for IgA 
and IgG production against recombinant MOMP, UV-inactivated C. muridarum EBs 
and E. coli LPS by ELISAs (Supplementary Figure 5.3 A-B). Respiratorily infected, 
and CD4 depleted WT and pIgR -/- mice both demonstrated increases in anti-
MOMP and anti-EB serum IgA, but not E. coli LPS (EPT <100 data not shown). 
Antigen-specific serum IgG continued to increase as observed with other antigens.  
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This indicates that previous infection can increase IgA production in a CD4+ T cell 
independent manner. Taken together, these data demonstrate high levels of serum 
anti-immunogen IgA and IgG are present in all mice groups at sacrifice, and that the 
in vivo protection offered by could be determined. 
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Figure 5.10  
Systemic Antigen-Specific Antibody Responses Prior to CD4+ Depletion and 
Chlamydial Infection  
Systemic antigen-specific IgA (A) and IgG (B) were determined from saphenous 
vein sera by limiting dilution EPT on direct ELISA specific for the immunogen. 
Serum responses in mice that received intranasal (respiratory) infections were 
titrated on UV-C. muridarum EBs. Error bars represent mean ± S.E.M. (n = 5).  
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Figure 5.11  
Systemic Antigen-Specific IgA and IgG Titers at Sacrifice  
Immunized antigen (MOMP, IncA, IncMem, UV-EB or OVA)-specific IgA (A) and IgG 
(C), and anti-cholera toxin (adjuvant) IgA (B) and IgG (D) serum EPT of WT and 
pIgR -/- mice at sacrifice (n = 5). EPT were determined by limiting dilution on direct 
ELISA with cognate antigen. Antigen-specific antibodies in mice previously infected 
with a respiratory infection were determined using UV-inactivated EBs. Error bars 
represent mean ± S.E.M.  
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5.4.4.4  The pIgR and SIgA Mediates Tissue-Specific and Antigen-
Specific Protection in the MRT in the Absence of CD4+ T cells  
To determine the level of protection offered by IgA antibodies in chlamydial infection 
of the murine MRT, tissues were collected at sacrifice, homogenized in SPG and 
cultured on McCoy cell monolayers. The number of C. muridarum IFUs was 
determined by fluorescence microscopy to demonstrate the recoverable quantity of 
viable and infectious C. muridarum EBs (Supplementary Figure 5.4). The percent 
reduction of chlamydial burden was determined relative to CD4+ depleted and OVA-
immunized control mice of the same phenotype (Figure 5.12). There was no 
significant (p > 0.05) differences in the tissue weights of any groups (not shown). 
Macroscopic inflammation was not observed in any of the CD4+ T cell depleted 
mice, however small amounts of epididymal inflammation were observed in the 
OVA-immunized and non-depleted mice suggesting CD4+ T cells played a role in 
inflammation (not shown). 
Chlamydial Burden in the Testes 
The testes and rete testes are vulnerable to chlamydial infection and orchitis [90], 
and express low amounts of pIgR (Figure 4.5 and 4.6). Thus, we sought to 
determine if immunization with the selected antigens reduced the intensity of an 
ascending chlamydial infection upstream of pIgR expression, in a CD4+ T cell 
independent and pIgR-dependent manner.  
In WT CD4+ depleted mice there was a significant reduction in the burden of MOMP 
(41 %), IncA (73 %), IncMem (36 %) or IN Cmu (49 %) immunized mice compared 
to OVA CD4+ depleted controls (Figure 5.12 A). The protection afforded by MOMP 
immunization of WT mice was abrogated in pIgR deficient mice (p < 0.05).  
Interestingly, in the absence of pIgR, MOMP immunized mice had a non-significant 
enhancement in chlamydial burden compared to OVA immunized controls (p = 
0.08). This suggests that the protection observed in CD4+ depleted MOMP 
immunized WT mice was entirely dependent on pIgR expression and transcytosis of 
anti-MOMP SIgA, and in the absence of these molecules chlamydial burden is 
enhanced.  
In contrast, the protection afforded by IncA, IncMem or IN Cmu was not significantly 
different (p > 0.05) between WT and pIgR deficient mice suggesting that the 
protection afforded in the testes was not reliant on SIgA and is unsurprising as only 
trace levels of pIgR are detectable in these tissues (Figure 4.5 and 4.6). In addition, 
there were no significant differences between OVA immunized mice of either 
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phenotype and regardless of CD4+ depletion, suggesting that CD4+ T cell 
responses had played a limited role in the testes after 21 days of MRT infection.  
Chlamydial Burden in the Bladder 
The murine bladder constitutively expresses pIgR under normal conditions and in 
response to chlamydial infection (Figure 4.5 and 4.6). Thus, we could determine if 
pIgR and antigen-specific SIgA mediated protection in this tissue in the absence of 
CD4+ T cells.  
Similarly to the testes, only WT mice immunized with MOMP had a significant 
reduction (p < 0.05) of chlamydial burden in the bladder (37%) compared to OVA 
controls, with the protection again abrogated in pIgR -/- groups (-26 %) (Figure 5.12 
B). In the absence of MOMP-SIgA and pIgR, an enhancement of infection was 
observed, although this was not significantly different from OVA pIgR deficient mice 
(p = 0.56). 
In other CD4+ T cell depleted mice, both WT and pIgR-deficient mice had significant 
reductions (50 % and 41 % respectively) of the chlamydial burden in the bladder, 
when compared to OVA control mice (p < 0.05). Similarly to the testes, the 
protection mediated by IncA immunization was not significantly different between 
WT and pIgR deficient CD4+ depleted mice. Again, there was no significant 
differences between mock and CD4+ depleted OVA immunized mice, regardless of 
phenotype.  
Chlamydial Burden in the Penis 
The murine penile urethra has been shown to express pIgR at the lumenal interface 
(Figure 4.5 and 4.6), is the initial site of infection, facilitates transmission of 
pathogens to sexual partners, and is readily colonized by C. muridarum (Figure 4.1) 
[116-117].  
Similarly to the testes and bladder, WT mice immunized with MOMP had a 
significant reduction (66 %) of chlamydial burden in the penis, when compared to 
OVA controls (p < 0.01)(Figure 5.12 C). Again, the protection afforded by MOMP 
immunization and CD4-depletion was abrogated in mice deficient in pIgR and 
MOMP-SIgA (p < 0.05).  
IncA immunized and CD4+ T cell depleted WT mice had a significant (p < 0.05) 
reduction (52%) in chlamydial burden when compared to OVA controls. This was 
abrogated in pIgR deficient mice (only 9% reduction), but not statistically significant 
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(p = 0.12). This suggests that some protection was afforded by SIgA against IncA in 
the penile urethra. When compared to OVA controls, IncMem and IN Cmu 
immunized WT mice both had non-significant reductions in penile burden (37 % and 
39 % respectively). Again, there was no significant protection afforded by CD4+ 
after 21 days of infection, evidenced by a minimal difference between mice 
immunized with OVA, with or without CD4+ T cell depletion.   
Chlamydial Burden in the Male Reproductive Tract 
To determine to protective effect of immunization on pathogenic load in multiple 
tissues, and in the absence of CD4+ T cells, the reduction in burden was 
determined from the sum of tissue burden of the testes, prostate, bladder and penis 
(Figure 5.13).  
As seen in the individual tissues, there was significant (p < 0.01) reduction of the 
MRT chlamydial burden in WT mice immunized with MOMP (44 %), when compared 
to OVA controls. This protective effect was again significantly (p < 0.01) abrogated 
in MOMP immunized mice deficient in pIgR and MOMP-SIgA. Enhancement of 
burden in pIgR deficient mice immunized with MOMP was also observed, however, 
this was not statistically different for OVA pIgR deficient controls. 
Both WT and pIgR deficient mice immunized with IncA had a significant (p < 0.01) 
reduction in MRT chlamydial burden (57 % and 35 % respectively) compared to 
OVA controls. Interestingly, mice deficient in pIgR had significantly (p < 0.05) less 
reduction in burden compared to WT controls. This suggests that unlike MOMP, the 
protection afforded from IncA immunization is assisted by pIgR and IncA-SIgA, but 
another mechanism is also providing protection. As all of these tissues express 
FcRn (Figure 4.1 and Figure 4.2), it appears likely that IncA-IgG may have afforded 
the majority of the protection. 
IncMem and IN Cmu immunized WT and pIgR deficient mice all had reductions in 
chlamydial burden compared to OVA controls. However, this was only significantly 
different in pIgR deficient mice immunized with IncMem (p < 0.001). There was also 
no significant difference between WT and pIgR deficient mice suggesting that SIgA 
against IncMem or previous infection played a minimal protective role. Similarly to 
other tissues, mice immunized with OVA but mock depleted showed no significant 
differences in the reduction of MRT chlamydial burden compared to mice 
continuously depleted of CD4+ T cells. This suggests that 21 days of infection was 
insufficient to develop a protective CD4+ T cell response in the MRT. 
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Figure 5.12  
Antigen-Specific IgA and pIgR-dependent Reduction of Chlamydial Burden in 
the Testes, Bladder and Penis of Immunized Mice  
The reduction of chlamydial burden in the testes (A), bladder (B), and penis (C) of 
immunized mice infected for 21 days was determined by direct culture of tissue 
homogenate on McCoy cell monolayers, and quantified by fluorescence microscopy. 
An asterisk above the graph indicates the group was significantly different from the 
OVA immunized CD4+ depleted group of the same mouse phenotype. Error bars 
represent mean ± S.E.M. (n = 5). Statistics determined by Student’s t test (* = p < 
0.05; ** = p < 0.01). 
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Figure 5.13  
Antigen-Specific IgA and pIgR Reduces Chlamydial Burden in the Murine MRT  
The pooled chlamydial burden in the testes, bladder, and penis of immunized mice 
infected for 21 days was determined by direct culture of tissue homogenate on 
McCoy cell monolayers, and quantified by fluorescence microscopy. To determine 
the significance per group, the sum of the total tissue chlamydial burden for each 
mouse was calculated. An asterisk above the graph indicates the group was 
significantly different from the OVA immunized CD4+ depleted group of the same 
mouse phenotype. Error bars represent mean ± S.E.M. (n = 5). Statistics 
determined by Student’s t test (* = p < 0.05; ** = p < 0.01; *** = p < 0.001). 
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5.5  DISCUSSION 
The pIgR is a crucial immunoglobulin transport receptor responsible for binding IgA 
and delivering it to the mucosal lumen. The exact protective role of these two 
glycoproteins in chlamydial infection of the genital tract remains unclear. Whilst IgA 
is not required for resolution of primary chlamydial infection of female mice [6], SIgA 
specific for MOMP reduces chlamydial shedding in the murine FRT [269] and MRT 
[117, 193]. Similarly in humans, there is a statistically significant inverse relationship 
with the concentration of SIgA and the burden of C. trachomatis recoverable from 
the endocervix [195].  
Humoral immunity against chlamydial EB outer membrane proteins (particularly 
MOMP) have been widely investigated [117, 193, 228-229, 269, 278, 285]. On an 
experimental level, the protection afforded by antibodies is commonly inferred  from 
in vitro neutralizations of chlamydiae in monolayer cultures [285], with only a handful 
of studies investigating chlamydial infection of polarized epithelia [44, 286-287]. In 
contrast to unpolarized cells, polarized cells express and redistribute functional 
receptors [11, 176-177, 218, 288], secrete cytokines [287, 289], and establish 
epithelial barriers [44, 46] more consistent with in vivo conditions. Furthermore, as 
demonstrated again here, polarizing some epithelial cells greatly or completely 
inhibits chlamydial infection [44]. Thus, to investigate the protection offered by 
transcytosed antibody in vitro, human epithelial cells transfected with mouse pIgR 
were grown as polarized monolayers on transwell inserts. The cells were then 
allowed to transport IgA, from the basolateral compartment (representing the lamina 
propria) to the apical compartment (lumen), mimicking in vivo conditions. C. 
muridarum were then incubated with the transcytosed antibody, and the cells 
infected apically to more closely reflect in vivo infection conditions.  
Unsurprisingly, apical delivery of anti-MOMP IgA (SIgA) was significantly more 
protective than anti-OVA IgA, and this delivery was entirely dependent on pIgR. This 
demonstrates that pIgR-transported anti-MOMP IgA provides protection in a 
secretory component-dependent manner. The rate of transyctosis in this model was 
calculated in mpIgR transfectants to be approximately 1 µg/cm2/day (equivalent to 
0.35 µg/well or 1.75 µg/mL of polyclonal total IgA transcytosed into the apical 
compartment). Despite this low rate of transfer, MOMP-IgA afforded 24.4 % 
neutralization, and was significantly dependent of transcytosis by pIgR. Additionally, 
the concentration is lower than total polymeric IgA levels observed in rodent vaginal 
washes (5.29  ± 5.81 µg/mL) [280], and much lower than human vaginal fluid (21 - 
118 µg/mL), uterine cervical fluid (3 - 330 µg/mL) and ejaculate (11 - 23 µg/mL) 
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(Table 2.1). The amount of antigen-specific IgA that can interact with immune-
accessible domains of EBs is also likely to be only a small percentage of the total 
IgA transported. This suggests that the amount of IgA required to bind and 
neutralize EBs is much lower. 
Recently, studies investigating intracellular replicating HIV have demonstrated an 
ability of IgA in the process of transcytosis to bind and extrude viral antigen into the 
apical lumen [11, 176-177]. As replicating chlamydiae are internalized within an 
inclusion, purified total IgA specific for inclusion membrane proteins or a secreted 
protease were added to the basolateral chamber of polarized cells. Whilst mpIgR-
transfectants showed some protection from anti-IncA and anti-IncMem IgA, the 
results were not significantly greater than anti-OVA controls. Similarly, IgA against 
the secreted protease CPAF provided little protection and is consistent with studies 
investigating the role of humoral responses against this antigen [278]. Together, this 
suggests that antigen-specific IgA provided small amounts neutralization, and was 
dependent of mpIgR expression. Whether higher concentrations of IgA can improve 
neutralization remain unknown and could be investigated with monoclonal IgA to 
these antigens. 
To determine how IncA-IgA afforded protection against intracellular antigen, 
transfected cells were infected and immunofluorescently stained to detect mouse 
IgA and markers of lysosomes (LAMP1), sequestosomes (SQSTM1/p62), and 
apoptosis (PARP). Confocal microscopy revealed that whilst IgA co-localized with 
the chlamydial inclusion, it did not activate the lysosomal pathway, or the apoptotic 
pathway. Interestingly, weak staining of SQSTM1 was observed within the inclusion 
of IncA-IgA treated cells. While the intracellular in vitro neutralization afforded by 
pIgR-transported IgA may provide protection against other chlamydial antigens, 
targeting inclusion membrane and secreted proteases with IgA appears to have 
limited efficacy at the concentrations used. 
As the MRT is a poor inductive site for immune responses [101, 250], but is known 
to secrete antibody [101, 117, 214, 290], we vaccinated male mice intranasally with 
chlamydial antigens to induce a local immune response via the common mucosal 
route. While not investigated here, the use of cholera toxin as an adjuvant via the 
intranasal route has previously been shown to elicit local antigen-specific antibody 
production in both female [291-292] and male [117, 193] mouse reproductive tracts 
via the common mucosal route. To determine the protective role of pIgR and SIgA, 
WT and pIgR-deficient mice were used in this study.  
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To study the role of SIgA in the absence of CD4+ T cells we depleted these cells by 
continuous administration of GK1.5 throughout the course of the infection. 
Furthermore, priming mice with a live respiratory chlamydial infection prior to genital 
tract challenge has previously been shown to be protective [282, 293]. Thus we 
sought out to determine if any antibodies produced in response to a primary 
infection could provide protection from secondary challenge in the absence of CD4+ 
T cells. Mice with or without the pIgR and SIgA had an equivocal resolution of 
respiratory chlamydial infection as determined by cachexia, supporting other studies 
which also show minimal protection afforded by IgA in primary infections [6]. 
Interestingly, pIgR expression previously been shown to assist IFNγ and TNFα 
production during mycobacterial infections of the respiratory tract [294], suggesting 
that pIgR is also involved in modulation of pro-inflammatory responses. However, 
we observed indirect evidence that this process was not impaired in chlamydial 
respiratory infections. 
Prior to CD4+ depletion and challenge, all mice screened exhibited antigen-specific 
antibody responses. Immunized mice were then depleted of CD4+ cells, and 
challenged urogenitally with C. muridarum for 3 weeks, and continued to produce 
antigen-specific IgA and IgG. The chlamydial burden in tissues was used to 
determine the protective role of pIgR/SIgA, previous infection, and 
MOMP/IncA/IncMem antigens in the absence of CD4+ T cells. Whilst MOMP-
immunized WT and pIgR-deficient mice had similar systemic anti-MOMP IgG titers 
pre-challenge/CD4+ depletion and at sacrifice, only WT mice had significantly less 
chlamydial burden in the testes, bladder and penis. In fact, in the absence of pIgR, 
MOMP-immunized mice had the same burden as mice immunized with the control 
antigen OVA, regardless of CD4+ depletion. These data suggest that anti-MOMP 
SIgA affords a significant amount of protection, even in tissues that do not express 
detectable pIgR (Chapter 4). This may be due to a reduction of chlamydial burden 
downstream of the testes (bladder, prostate, penis) leading to a lower total burden in 
the MRT, or that SIgA has diffused into the upper reproductive tract. Regardless, 
non-SIgA (such as IgG) against MOMP seems to play a minimal role in protection 
within the MRT. To definitively confirm to role of IgA in chlamydial infections, these 
experiments should be repeated with µMT mice, which lack immunoglobulin, and 
would isolate the role of antibody-mediated protection. 
We also demonstrate that immunizing with an intracellular chlamydial protein (IncA) 
also provided some in vitro neutralization, which also was associated with a 
significant reduction in burden in vivo. Furthermore, a significant reduction in 
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protection was seen in the absence of CD4+ T cells and pIgR. Interestingly, of all 
the immunized groups, WT mice immunized with IncA and depleted of CD4+ cells 
had the lowest chlamydial burden in the MRT. This suggests that IncA-IgA as well 
as a non-CD4+ antigen-specific response (presumably IgG) reduced burden in 
these mice. 
Recently, previous respiratory chlamydial infection with live EBs (but not UV-
inactivated EBs) has been shown to reduce infectious shedding and pathology 
following FRT challenge [282]. We did not observe this protection in the MRT in the 
absence of CD4+ T cells. When primed with a respiratory infection prior to genital 
tract challenge, mice had only marginally less chlamydiae than OVA controls at 
sacrifice, suggesting that non-CD4+ T cell responses generated by a primary 
respiratory infection provided little protection from genital challenge. While WT and 
pIgR-deficient mice immunized with OVA and depleted of CD4+ had the same 
burden, intranasally infected pIgR-deficient mice had a minor but non-significant 
increase in vaginal chlamydial burden suggesting that infection-induced IgA played 
a small role in protection. This is in agreement with data from primary and 
secondary infections of IgA-deficient female mice and suggests acquired immunity 
from natural infection is not reliant on IgA [6]. However, immunizing with specific 
antigens (MOMP and IncA) did provide a significant IgA-dependent reduction in 
burden suggesting subunit vaccines targeting IgA responses may be more effective 
than attenuated live infections.  
It is widely accepted that MHC-II, IFNγ, and CD4+ Th1 immune responses are 
important in the resolution of primary chlamydial infection in female mice [82], with 
some evidence also suggesting that CD4+ T cells are important in males [281]. 
However, IFNγ and TNFα secreting CD4+ T cells are associated with the 
development of orchitis, autoimmunity and sterility [2-3]. Here we demonstrate that 
non-CD4+ responses can also provide significant protection after 3 weeks of 
chlamydial infection, and that SIgA and pIgR are more critical than IgG when using 
MOMP as a vaccine antigen. Furthermore, the intracellular inclusion membrane 
protein IncA, but not secreted protein CPAF are potential efficacious vaccine 
antigens when attempting to elicit an IgA-focused response. We also demonstrate 
that non-CD4+ T cell responses (presumably IgG) to intracellular chlamydial antigen 
IncA can further reduce infectious burden in mice. 
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5.6  SUPPLEMENTARY DATA 
 
 
  
 
Supplementary Figure 5.1 
In vivo Transcytosis of Biotinylated IgA into the Murine MRT  
To determine the transport of IgA to the murine male reproductive tract, mice were 
passively immunized intraperitoneally or intravenously with 200 µg of biotinylated 
murine IgA. After different time periods, first pass urine and prostatic fluid was 
collected by electro-ejaculation. The quantitative amount of IgA transported from the 
peritoneum or the circulatory system was determined by sandwich ELISA. Error bars 
representative of mean ± S.E.M. (n = 3).  
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Supplementary Figure 5.2  
Antigen-Specific IgA and IgG Titers Respond Differently to Antigens Following 
CD4 Depletion and MRT Chlamydial Challenge 
Previous exposure to live chlamydial challenge boosts antigen-specific IgA and IgG 
responses in a CD4+ T cell-independent manner. Antigen specific systemic IgA (A-
B) and IgG (C-D) responses prior to genital tract challenge and CD4 depletion leads 
to decreasing IgA responses in MOMP and OVA immunized mice, but not mice with 
a previous respiratory challenge. Conversely, IgG titers to EBs and OVA but not 
MOMP continue to increase, even in the absence of CD4+ T cells. Error bars 
represent mean ± S.E.M. Statistics calculated with Student’s t test (p < 0.05 = *, 
<0.01 = **, <0.001 = ***, <0.0001 = ****). 
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Supplementary Figure 5.3 
Respiratory Priming and CD4 Depletion Does Not Prevent Increases in 
Antibody Production Against Extracellular Membrane Proteins 
EPT of intranasally infected WT and pIgR -/- mice were determined by direct ELISA 
against recombinant MOMP or UV-inactivated EBs. Error bars represent mean ± 
S.E.M. Statistics calculated with Student’s t test (p < 0.05 = *, <0.01 = **, <0.001 = 
***, <0.0001 = ****). 
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Supplementary Figure 5.4 
The Chlamydial Burden in the Testes, Bladder and Penis of Immunized Mice  
The chlamydial burden in the testes (A), bladder (B), and penis (C) of immunized 
mice infected for 21 days was determined by direct culture of tissue homogenate on 
McCoy cell monolayers, and quantified by fluorescence microscopy. Error bars 
represent mean ± S.E.M. (n = 5). Statistics determined by Student’s t test relative to 
CD4-depleted OVA controls (*) or non-depleted OVA controls (#) of the same strain 
(WT or pIgR -/-). Number of symbols represents significance (* = p < 0.05; ** = p < 
0.01)  
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Chapter 6 
 
FcRn-Mediates the Delivery of IgG to 
Intracellular Antigens in Chlamydia-
Infected Epithelial Cells 
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6.1  ABSTRACT 
Here we demonstrate in vitro and in vivo that IgG can be also specifically target 
antigens expressed only during the intracellular phase of the chlamydial 
developmental cycle. IgG targeting intracellular chlamydial antigens IncA and CPAF 
was found to significantly reduce inclusion formation in C. muridarum infected 
epithelial cells, in an FcRn-dependent manner. IgG specific to IncA and IncMem was 
also found to co-localize with the chlamydial inclusion, inducing aberrant inclusion 
morphology, and recruit a marker of the ubiquitin/proteasome, but not lysosomes. 
CPAF IgG and IgG from immune mice was found to bind IgG within the host 
cytoplasm, suggesting that internalized IgG can also bind cytoplasmic protein. When 
male WT mice and male mice lacking functional FcRn and MHC-I (B2m knockout) 
were intranasally immunized, depleted of CD4+ T cells, and uro-genitally infected 
with C. muridarum, the reduction in infectious burden of the testes afforded from 
IncA immunization compared to OVA immunization was abrogated in B2m deficient 
mice. This suggests that the reduction in chlamydial burden was independent of 
CD4+ T cells, and dependent on antigen-specific IgG and functional FcRn and/or 
MHC-I/CD8+ responses. Additionally, IgG produced in response to a previously 
resolved chlamydial infection was unable to reduce infectious burden compared to 
OVA controls, demonstrating the limited role of acquired humoral immunity 
generated from primary infections. Together, these data demonstrate that in addition 
to extracellular antigens, vaccines utilizing IgG can also bind intracellular secreted 
and inclusion membrane antigens in an FcRn-dependent manner. Intracellular IgG 
also induced morphological change in the inclusion, recruited sequestosomes and 
led to a reduction of infectious burden in the upper reproductive tract.  
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6.2  INTRODUCTION 
Until recently, the role of antibody was widely accepted to be limited to extracellular 
antigens. Intracellular IgA has previously been shown to bind both internalized HIV 
[11, 177] and influenza virus [274], but the potential for IgG to also mediate 
intracellular neutralization was unknown until recently [4]. Whilst other 
immunoglobulin receptors assist cells in phagocytosing IgG-opsonized antigens for 
intracellular degradation [51, 295], the FcRn has been shown to internalize unbound 
IgG and neutralize internalized virus within the cytoplasm of epithelial cells [4]. As C. 
trachomatis is an obligate intracellular bacterium, we sought to determine if this 
FcRn-mediated delivery of IgG could also apply to chlamydial infections.  
The FcRn is a MHC class I-like glycoprotein, which similarly to MHC-I requires 
dimerization with B2m to be functional [237]. The FcRn is a mammalian receptor 
that binds, internalizes and slows the catabolism of IgG and albumin [203]. Unlike 
other FcγRs which bind near the hinge region of IgG, and are dependent on 
glycosylation of IgG [221], FcRn binds IgG at the CH2-CH3 domain regardless of 
the state of IgG glycosylation [203, 222]. FcRn affinity for IgG has a strict pH-
dependence with binding occurring at an acidic pH (< 6.5) and release at neutral pH 
(7.4) [296]. FcRn is expressed by a wide variety of cells including epithelia, 
endothelia, professional APCs, PMNs, hepatocytes, podocytes and 
syncytiotrophoblasts [203, 226]. FcRn is also found throughout the body in the 
gastrointestinal, respiratory, and urogenital tracts [203, 209, 213]. As both male and 
female reproductive tracts express FcRn [213-214], and have acidic lumens in the 
epididymes [253], prostate [216], vagina and cervix [217], the potential for FcRn to 
deliver IgG against sexually transmitted diseases is of great scientific interest.    
C. trachomatis is an obligate intracellular bacterium that infects the mucosal 
epithelia of the respiratory, gastrointestinal and urogenital tracts. Reproductive tract 
C. trachomatis infections affect an estimated 90 million people annually, are often 
asymptomatic, and can induce scarring, occlusion, pelvic inflammatory disease, 
ectopic pregnancy and infertility [24]. Whilst C. trachomatis is sensitive to macrolide 
antibiotics, notifications continue to rise and in the USA have quadrupled in the last 
two decades [25],  costing an estimated US$ 2 billion per annum [29]. In addition to 
the clinical problem of chlamydial evolution of antibiotic resistance, there is also 
evidence that antibiotic intervention can allow epidemics to return with more 
intensity due to abrogation of any potential to acquire immunity [9, 273]. 
Mathematical modeling has also predicted that even if a vaccine that was only 
partially effective was developed, C. trachomatis infections could be significantly 
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reduced within a few decades [297]. Hence, the development of a chlamydial 
vaccine has been the focus of a large amount of research.  
Whilst CD4+ T cells, MHC-II and IFNγ are necessary to resolve chlamydial 
infections in both sexes [90, 273], these processes are actively suppressed in the 
upper MRT to minimize autoimmunity following adolescence [10]. However, 
prolonged chlamydial infection of the upper MRT can compromise immune 
suppression of antigen presentation and may lead to the development of 
autoimmunity and sterility [111]. Additionally, IFNγ is produced in response to 
chlamydial infections and is necessary for resolution [1], but Th1 CD4+ T cells 
secreting IFNγ and TNFα are known to induce autoimmune orchitis [3]. This 
suggests that a male chlamydial vaccine utilizing this immune response may 
potentially exacerbate morbidity associated with C. muridarum infections. However, 
the upper MRT does transcytose a significant amount of IgG in and out of the 
epididymal and testicular lumen [214]. Thus, whilst establishing immunity at this site 
is difficult due to immune suppression, and prolonged infection may lead to infertility, 
previously generated IgG from immunization via the common mucosal route could 
be used to target chlamydial antigens.  
Chlamydia spp. have a biphasic development cycle consisting of an extracellular 
and metabolically-inert EB phase, and an intracellular replicative RB phase. Unique 
from other intracellular bacteria, chlamydiae grow within a parasitophorous vacuole, 
termed an inclusion, and secrete proteins which hijack and inhibit normal host 
processes including apoptosis [298-299] MHC-I [300], and MHC-II presentation 
[301]. Chlamydiae can also avoid fusion with the host endocytic system by binding 
and preventing the recruitment of lysosomes [302]. As chlamydiae are auxotrophic, 
the inhibition of host defenses occurs in unison with the acquisition of sphingomyelin 
and cholesterol trafficking through the exocytic pathway [44]. Thus, chlamydiae are 
non-fusogenic with late endosomes and early lysosomes, and secrete proteases 
which degrade immune processes, whilst parasitizing host metabolites.  
As recent studies observed that IgG and FcRn-mediated intracellular neutralization 
of influenza virus by lysosomal degradation [4], we sought to determine if FcRn and 
antigen-specific IgG could overcome chlamydial inhibition of lysosomal fusion and 
whether uptake of IgG would affect normal chlamydial growth or change the host 
cell response to infection. 
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6.3  MATERIALS AND METHODS 
General Stocks and Solutions 
Supplemented DMEM for mECap18 Cells (DMEM+ mECap18) 
DMEM+ media was prepared with an additional 50 nM of 5α-androstan-17β-ol-3-
one (dihydrotestosterone) (Sigma Aldrich) included. To minimize contaminating 
bovine IgG binding mouse FcRn [220], HI-FCS was stripped of IgG prior to addition 
to media by running over equilibrated Protein G resin [303]. MeCap18 and shRNA 
transfectants were grown in DMEM+ mECap18 media +/- 0.1 µg/mL puromycin 
(Invitrogen). DMEM+ mECap18 media was stored at 4oC. 
Hank’s Buffered Salt Solution (HBSS) + pH 6.0 
HBSS containing additional 1.26 mM CaCl2 and 0.5 mM MgCl2 (Invitrogen) was 
supplemented with an additional 50 mM 2-(N-morpholino) ethanesulfonic acid 
(MES) (Sigma Aldrich), and pH adjusted to 6.0 with 5M NaOH. The solution was 
sterilized with 0.2 µm filters. HBSS+ pH 6.0 was stored at 4oC. 
HBSS+ pH 7.4 
HBSS containing additional 1.26 mM CaCl2 and 0.5 mM MgCl2 (Invitrogen) was 
supplemented with 25 mM (2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), and the pH adjusted to 7.4 with 5M NaOH. The solution was sterilized 
with 0.2 µm filters. HBSS+ pH 7.4 was stored at 4oC. 
RIPA Lysis Buffer 
RIPA lysis buffer was prepared fresh with 50 mM Tris, 150 mM NaCl, 0.1% (w/v) 
SDS, 0.5% (w/v) sodium deoxycholate (Sigma Aldrich), 1% (w/v) NP-40 (Sigma 
Aldrich), 1 mM PMSF (Sigma Aldrich) and 1x protease inhibitors (Sigma Aldrich).  
Production and Purification of Antigens 
Recombinant C. muridarum MOMP, IncA and CPAF, as well as inclusion membrane 
lysates were prepared as described previously (3.2). 
Purification of Murine IgG from Sera 
Male BALB/c mice (5-6 weeks) were immunized intranasally on days 0, 7, 14 and 25 
with 100 µg of antigen and 5 µg of cholera toxin, in a total volume of 5 µL, 2.5 µL per 
nare as described in materials and methods (3.6.3). On day 35, mice were 
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euthanized with sodium pentobarbitone and cardiac blood taken (3.6.13). Blood was 
allowed to clot at 4oC, centrifuged at 18,000 g for 15 minutes, and sera collected 
and pooled between groups. Sera were diluted 1:10 in PBS pH 7.4 and clarified by 
centrifugation at 4,000 g for 10 minutes. The supernatant was collected, 0.2 µm 
filter-sterilized and passed over an equilibrated Protein G resin affinity column 
(Genscript) as per the manufacturer’s instructions. Briefly, resin was washed with 
PBS until flow through contained no protein as determined by spectrophotometry 
with absorbance at 280 nm. IgG was eluted in fractions of 850 µL of 0.1 M glycine 
pH 2 into 150 µL of neutralization buffer (1 M Tris pH 8.0). Protein-containing 
fractions were identified by spectrophotometry (Abs at 280 nm), pooled, and 
dialyzed in PBS. Total IgG was concentrated with 30 kDa molecular weight cutoff 
centrifuge filters (Millipore), resuspended to final concentrations of 2 mg/mL in PBS, 
and stored at -80oC. Antigen specificity IgG was detected by antigen-specific ELISA, 
and reactivity confirmed by ICC of C. muridarum-infected McCoy B cells. 
Chlamydia Strain 
Chlamydia muridarum (Weiss) (VR-123) was purified as previously described (3.3). 
C. trachomatis serovar D and L2, and C. pneumoniae AR39 were generous gifts 
from Wilhelmina Huston (QUT, Brisbane, Australia) and were semi-purified as 
previously described (3.3). 
Silencing of FcRn Expression 
SV40 T antigen-immortalized murine caput epididymal epithelia (mECap18) cells 
were a generous gift from Petra Sipila (University of Turku, Turku, Finland) [231], 
and were maintained in DMEM+ mECap18 media. The mECap18 cell line was 
found to constituatively express FcRn. FcRn small hairpin (sh)RNA were transfected 
into mECap18 cells as per the manufacturer’s instructions. Briefly, a shRNA vector 
pGIPZ shRNA 2 (Open Biosystems # V2LMM_43474) encoding a hairpin repeat of 
5’- CCTCTCACTGTGGACCTAGAT -3’ homologous with the alpha domain of 
mouse FcRn mRNA (869-889 bp) (Genbank NM_010189.3) was transfected using 
Arrest-In transfection reagent (Millennium Bioscience). Stable transfectants were 
selected for in DMEM + DHT media supplemented with 0.1 µg/mL of puromycin 
(Invitrogen) for several days at 37oC 5% CO2. Positive clones were resistant to 
puromycin and expressed green fluorescence protein visible under the FITC 
channel of a fluorescent microscope. To determine expression of FcRn, 
transfectants were grown to confluence in T75 culture flasks. Protein expression in 
wild type mECap18 and FcRn shRNA transfectants was determined by western blot 
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of whole cell lysate. Briefly, cells were lysed with a RIPA lysis buffer, and total 
protein calculated from a standard curve using BCA (Thermo Fisher Scientific) 
calculation as per manufacturer’s instructions. 25 µg of protein was loaded into the 
wells of 10% SDS-PAGE gels and separated at 120 V for 70 minutes. Protein was 
transferred onto nitrocellulose membrane, and blocked with 5% (w/v) skim milk 
powder in PBST for two hours at 4oC. Blots were probed with polyclonal rabbit anti-
mouse FcRn-cytoplasmic domain, IgG (5 µg/mL) or sheep anti-GAPDH Ig (1:1000) 
(Sapphire Bioscience) in blocking solution overnight at 4oC. Blots were washed five 
times with PBST, and incubated with goat anti-rabbit IgG-HRP (1:1000) or goat anti-
sheep IgG-HRP (1:1000) in blocking buffer for one hour at room temperature. Blots 
were washed five times with PBST and detected with enhanced chemiluminescence 
(ECL) (Thermo Scientific) and visualized using a Biorad Universal Hood II detector.   
Characterization of Tight Junction Formation in mECap18 Cells 
To determine the ability of mECap18 cells to polarize, 105 cells were seeded into 24-
well transwell inserts with 0.4 µm pores (BD Falcon). Inserts were incubated with 
200 µL of media in the apical chamber (transwell insert), and 700 µL of media in the 
basolateral chamber (24 well plate) at 37oC and 5% CO2 changing media every 
second day. TEER measurements were taken daily with an EVOM electrode 
(Millipore). TEERs of cultured cells were calculated using the equation: TEER (ohms 
cm2) = (resistance of sample – resistance of blank insert) x surface area of the insert 
(cm2). Rate of non-specific transfer of small soluble molecules Lucifer Yellow 
dilithium salt (LY) (approx 1 kDa) (Sigma Aldrich) and FITC-conjugated dextran 
(FD4) (4 kDA) (Sigma Aldrich) across the cell monolayer was calculated by loading 
100 µM of LY or 100 µM of FD4 in HBSS+ 7.4 with 1% (v/v) dimethyl sulfoxide 
(DMSO) into the apical chamber and collecting the basolateral chamber after two 
hours of incubation at 37oC 5% CO2 at 50 rpm. Concentration of transported 
molecules was quantified from standard curves using a fluorescent plate reader 
(POLARstar) with emission and excitation filters (Ex 440 ± 10 nm, Em 510 ± 10 nm). 
The rate of transfer was calculated with the equation: dQ/dT (mM/sec) = [apparent 
permeability (cm/s) = ((ratio of original concentration x volume of donor chamber 
(cm3)) / (time (sec) x surface area of insert (cm2))] / (1 / surface area of insert (cm2) x 
initial concentration of donor chamber (mM)). Zona occludens 1 (ZO-1) tight junction 
protein expression was demonstrated by immunocytochemistry. Briefly, confluent 
mECap18 cells grown in transwells for five days were fixed with methanol, blocked 
with 10% (v/v) heat-inactivated goat serum in PBST for 1 hour, probed with rabbit 
anti-mouse ZO-1 IgG (5 µg/mL in blocking buffer) (Invitrogen) in blocking buffer 
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overnight at 4oC, and detected with goat anti-rabbit IgG-conjugated with Alexa Fluor 
488 (1 µg/mL in blocking buffer) (Invitrogen) at room temperature. DNA was labeled 
by incubation with DAPI (Invitrogen) for 20 minutes at room temperature. Inserts 
were excised and mounted onto glass slides with Prolong Gold (Invitrogen), and 
visualized via confocal microscopy. FcRn-mediated transport of IgG was 
demonstrated by culturing mECap18 wild type or FcRn shRNA cells in transwells for 
five days, serum starving cells in HBSS+ pH 7.4 for one hour, pH polarizing cells 
with HBSS+ pH 6.0 in the apical chamber and HBSS+ 7.4 in the basolateral 
chamber for 40 minutes at 37oC and then loading 50 µg of purified murine IgG or 
chicken IgY into the apical chamber and incubating the culture at 37oC 5% CO2 for 2 
hours. Transported antibody was quantified by collecting the recipient chamber and 
calculating from standard curves by sandwich ELISA (3.4.2). 
In Vitro Intracellular IgG Neutralization and Viability of Chlamydia 
To determine the neutralization potential of antigen-specific IgG during the 
intracellular phase of chlamydial infection, mECap18 wild type and FcRn shRNA 
cells were seeded onto transwell inserts and allowed to polarize for five days at 
37oC 5% CO2, changing media every second day. The mECap18 variants were 
serum-starved in HBSS+ pH 7.4 for one hour at 37oC, and pH polarized with HBSS+ 
pH 6.0 in the apical chamber and HBSS+ pH 7.4 in the basolateral chamber for 40 
minutes at 37oC 5% CO2. Cells were infected with 105 IFUs in HBSS+ pH 6.0 in the 
apical chamber for one hour at 4oC to allow attachment of EBs to the apical surface. 
Cells were then incubated for one hour at 37oC 5% CO2 to allow chlamydial 
internalization. The media was removed and cells washed three times apically with 
warm HBSS+ pH 6.0 and basolaterally with HBSS+ pH 7.4. Media replaced with 
HBSS+ pH 6.0 in the apical chamber, and HBSS+ pH 7.4 including 50 µg/mL of 
purified mouse IgG loaded into the basolateral chamber. Cells were incubated at 
37oC 5% CO2 for 6 hours, and then DMEM + mECap18 media was added to bring 
the final concentration of 10% (v/v) HI-FCS. After 24 hours of infection, fresh media 
was added and cells were incubated for an additional hour to allow unbound 
antibody to be cleared. Cells were then fixed and stained and chlamydial IFUs 
enumerated by microscopy as described previously (3.3.1). In vitro neutralization 
was determined from the formula: neutralization (%) = 100 – ((IFUs per well/average 
IFUs of OVA controls) x 100). Enhancement of infection was determined using the 
inverse of neutralization.   
Immunocytochemistry 
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Cells were prepared as above but fixed with 4% (v/v) PFA in PBS, and 
permeabilized with 0.1 % (v/v) Triton X100 in PBS, at 4oC for 10 minutes. Cells were 
blocked with 10% (v/v) goat serum in PBST (blocking buffer) for 2 hours at RT. Cells 
were then probed with primary antibodies overnight at 4oC. C. muridarum MOMP 
(sheep anti-MOMP) was prepared in house and used at a dilution of 1:250 in 
blocking buffer. Rabbit anti-LAMP1 (Sapphire Bioscience), rabbit anti-SQSTM1 
(Sapphire Bioscience), rabbit anti-PARP 214/215 cleavage (Invitrogen), and 
monoclonal anti-C. trachomatis EBs –FITC conjugate (1:10)(Vital Diagnostics, Bella 
Vista, NSW, Australia) were used as per the manufacturer’s instructions. Rabbit 
anti-mouse FcRn cytoplasmic tail and rabbit anti-human FcRn cytoplasmic tail 
antibody was generously donated by Richard Blumberg (Brigham and Women’s 
Hospital, Boston, USA) and used at 2.5 µg/mL.  Following washes, primary 
antibodies were detected with goat anti-rabbit IgG Alexa Fluor 633 or Alexa Fluor 
488 (Invitrogen), goat-anti mouse IgG Alexa Fluor 528 (Invitrogen), and donkey anti-
sheep IgG Alexa Fluor 488 (Invitrogen) in appropriate combinations at 1 µg/mL in 
blocking buffer for 1 hour at RT. Cells were washed further with PBST and 
incubated in DAPI (Invitrogen) for 20 minutes before mounted with Prolong Gold 
(Invitrogen), and visualizing with a Leica SP5 confocal microscope.  
Mice 
Male C57BL/6 wild type and C57BL/6 B2m -/- (C1D) mice, 6-8 weeks of age were 
housed as described in materials and methods (3.6.1). All procedures were 
approved by the QUT Animal Research Ethics Committee (approval number 
0800000824).  
Intranasal Infection and Monitoring 
Intranasal infection was conducted as previously described (3.6.6).  
Immunization Procedure 
Intranasal immunization was conducted as previously described (3.6.3). 
Depletion of CD4+ Cells 
CD4+ depletion was conducted as previously described (5.3). 
Intrapenile Infection and Monitoring  
Intrapenile infection was conducted as described in materials and methods (3.6.5). 
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Animal Sacrifice and Sample Collection 
Animals were sacrificed and specimens collected as described in materials and 
methods (3.6.14 and 3.6.15). Briefly, cardiac blood, spleens, and the testes from 
mice were collected to determine serum antibody titer, CD4 expression and 
chlamydial burden.  
Flow Cytometry 
Splenocytes were stained and quantified by flow cytometry as previously described 
(3.6.15 and 5.3).   
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6.4  RESULTS 
6.4.1  Fc Receptor Expression in mECap18 Cells 
As the caput epididymis has been shown to express high levels of FcRn in rats [214] 
and mice (Chapter 4), the relative expression of FcRn in mECap18 WT and stable 
pGIPZ transfectants containing small hairpin complement of the FcRn mRNA alpha 
domain (869 – 889 bp) was determined. Following stable transfection targeting 
FcRn and a non-silencing control, there was an 80% reduction in FcRn protein 
expression, as determined by densitometry of Western immunoblots (Figure 6.1 A).  
To demonstrate that down-regulation of FcRn decreased the transcytosis of IgG, 
cells were grown on transwells, serum-starved, pH polarized, and mouse IgG or 
chicken IgY added to the apical chamber for 2 hours at 37oC 5% CO2. The amount 
of mouse IgG or avian IgY transcytosed to the basolateral chamber was determined 
by sandwich ELISA (Figure 6.1 B). WT mECap18 cells transcytosed significantly 
more (p < 0.05) mouse IgG to the basolateral chamber than shRNA knockdown 
cells. IgY was not detectable in the basolateral chamber of either cell type. These 
data indicate silencing of FcRn expression (70 - 80 %) using a shRNA lentiviral 
vector translated to a 72% reduction of receptor-mediated transcytosis.  
Tight junction formation was also determined indirectly by TEER (Figure 6.2 A) and 
showed both cells types had weak electrical resistance. When apically loaded with 
small fluorescent molecules LY (1 kDA), or FD4 (4 kDA), non-specific transport was 
lowest at day 5 (Figure 6.2 B) coinciding with a plateau in TEERs. When cells were 
stained for ZO-1 expression at the peak of TEER, there was observable ZO-1 
staining at cell junction borders (Figure 6.2 C). This tight junction formation was less 
intense relative to other polarizing cell lines (MDCK I, and C2Bbe1 not shown) at the 
epithelial barrier, but is characteristic of ZO-1 staining in normal epididymal epithelia 
[304]. 
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Figure 6.1  
Silencing of FcRn in mECap18 Cells  
(A) Western blots of mECap18 cell WT and shRNA2 (FcRn knockdown), and non-
silencing vector (mock) were lysed in a RIPA lysis buffered and immunoblotted for 
FcRn and GAPDH expression. (B) Apical to basolateral transcytosis of murine IgG 
or chicken IgY over 2 hours was determined in FcRn shRNA and control mECap18 
cells grown on Transwells for 5 days. Quanititative Ig transport into the basolateral 
chamber was determined by sandwich ELISA. None detectable (ND). Error bars 
indicative of mean ± S.E.M. (n = 3). Statistics calculated using Student’s t test (p < 
0.05 = *). 
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Figure 6.2  
Tight Junction Formation of mECap18 Cells  
(A) mECap18 variants were seeded onto transwell inserts and were weakly 
polarizing as determined by TEER. (B) The passive transport of LY and FD4 from 
the apical to basolateral chambers was determined by fluorescence 
spectrophotometry. (C) Tight junction protein ZO-1 was detected between mECap18 
cells on day 5 by immunocytochemistry. Error bars indicative of mean ± S.E.M. (n = 
3). White arrows identify ZO-1 expression in mECap18 cells. Scale bars = 10 µm. 
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6.4.2  In Vitro Neutralization of Internalized Chlamydia is Mediated by 
FcRn Delivery of Antigen-Specific IgG 
To determine if intracellular IgG could neutralize chlamydial infection in vitro, 
mECap18 cells or shRNA FcRn cells were polarized and infected with C. muridarum 
(MOI 1) from the apical chamber for 2 hours at 37oC to allow internalization and the 
establishment of an inclusion. Media was then replaced with fresh media at pH 6.0 
containing total IgG (50 µg/mL) from mice immunized intranasally with CT and 
recombinant C. muridarum IncA, CPAF or native IncMem, or CT alone. Cells were 
then incubated for a further 22 hours at 37oC and 5% CO2. Cells were then fixed 
and stained for chlamydial inclusions, and enumerated by microscopy. 
A reduction in inclusion numbers was (Figure 6.3) observed in mECap18 cells 
treated with IncA-IgG, IncMem-IgG and CPAF, but not in FcRn shRNA cells. There 
was a significant difference between mECap18 cells treated with IncA-IgG and Neg-
IgG (p < 0.01), and between IncA-IgG in control and FcRn shRNA groups (p < 0.05). 
IncMem-IgG treated wild type mECap18 cells also approached 30% neutralization 
but was not significantly different from negative controls. CPAF-IgG treated WT 
mECap18 cell had the least neutralization of the chlamydial antigens tested, but was 
significantly greater than negative control IgG (p < 0.05). 
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Figure 6.3  
In Vitro Neutralization by Intracellular Antigen-Specific IgG is Mediated by 
FcRn  
Wild type and FcRn-silenced mECap18 cells were grown on transwell inserts for 5 
days, infected with C. muridarum, and incubated for 24 hours at 37oC with or without 
IgG purified from IncA, IncMem, CPAF or cholera toxin (Neg) immunized mice. Cells 
were fixed, stained, and inclusion forming units determined by microscopy. 
Neutralization was determined from Neg IgG and No IgG controls. Error bars 
represent mean ± S.E.M. (n = 3). Statistics calculated with Student’s t test (p < 0.05 
= *, p < 0.01 = **). 
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6.4.3  FcRn Internalizes IgG which Co-Localizes with Chlamydial 
Antigens 
To determine whether intracellular IgG could bind intracellular chlamydial antigens, 
mECap18 cells were grown on coverslips, equilibrated in HBSS pH 7, then 
incubated in HBSS pH 6 for 1 hour prior to infection with C. muridarum (MOI 1) for 2 
hours at 37oC. Following attachment and internalization, unbound EBs were 
removed by washing with HBSS pH 6 and then replaced with DMEM+ mECap18 
media adjusted to pH 6.0 and containing 50 µg/mL of purified polyclonal total IgG 
from immunized mice. Purified IgG was pooled from mice immunized with CT alone 
(neg IgG), IgG purified from female mice that had resolved a previous infection (day 
30 post infection immune IgG), IgG purified from mice immunized with IncMem/IncA 
or recombinant secreted protease CPAF.  After 23 hours of infection the media was 
replaced with fresh media and incubated for a further hour to allow unbound IgG to 
clear the cell. Cells were fixed with 4% PFA and stained for mouse FcRn, mouse 
IgG, and DNA and viewed by immunofluorescence confocal microscopy (Figure 
6.4). 
Uninfected cells grown in the absence of IgG showed a uniform distribution of FcRn 
throughout the cytoplasm with no detectable staining by anti-mouse IgG antibodies. 
Once infected, FcRn appears to co-localize to the chlamydial inclusion in an IgG-
independent manner suggesting FcRn is sequestered at the inclusion interface 
regardless of IgG transport. The non-specific accumulation of FcRn at the inclusion 
membrane was also observed in all other infected cells, regardless of what IgG was 
added suggesting either host or pathogen mediates this process. When control IgG 
(neg) was added, no IgG colocalized with the inclusion. Similarly, when immune IgG 
was added, co-localization of FcRn and IgG was observed mostly in the cytoplasm, 
and not colocalized to the inclusion membrane. When anti-IncMem or IncA IgG was 
added to the cells, both FcRn and IgG co-localized at the inclusion membrane.  
Internalized CPAF-IgG did not co-localize with the chlamydial inclusion, but was 
observed in the cytoplasm similar to immune IgG treated cells, suggesting that FcRn 
mediated transport of IgG where it bound secreted cytoplasmic CPAF. 
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Figure 6.4  
Antigen-Specific IgG and FcRn Co-Localizes with the Chlamydial Antigens  
To determine if IgG could be internalized and bind chlamydial antigen, mECap18 
cells were infected with C. muridarum for 2 hours, washed, and pH 6.0 media 
containing various purified IgG added and incubated for 24 hours. Cells were fixed 
and stained for DNA (DAPI), mouse FcRn (green) or mouse IgG (red). White arrows 
identify chlamydial DNA visible under DAPI, yellow arrows demonstrate co-
localization of IgG and FcRn. Scale bars = 10 µm. 
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6.4.4  Chlamydia Sequesters FcRn at the Inclusion Membrane 
As FcRn was observed colocalizing with the chlamydial inclusion independent of 
IgG, we sought to determine when this occurred, and whether this was mediated by 
the host cell or the pathogen. The mECap18 cells were infected with C. muridarum 
and the infection stopped throughout various times of development (Figure 6.5). Co-
localization of C. muridarum and FcRn occurred between 6 and 8 hrs post infection, 
consistent with the intermediate stage of the C. muridarum developmental cycle 
[65]. Interestingly, when incubated in the presence of various eukaryotic inhibitors, 
this process was not prevented (Figure 6.6). Co-localization of FcRn and C. 
muridarum continued despite inhibition of host protein biosynthesis (cycloheximide), 
microtubule depolymerization (nocodazole), autophagy (3-MA), phosphoinositide 3 
kinases (wortmannin), and proteasomes (MG132). This suggests that the co-
localization occurs independently of the host cell response to infection and is not 
trafficked along microtubule networks. 
To determine if FcRn co-localization to the inclusion membrane was an artifact of C. 
muridarum infection of mECap18 cells or representative of chlamydial infections in 
general, mammalian cell lines expressing endogenous FcRn were infected for 48 
hours with C. pneumoniae AR39, and C. trachomatis serovar D or L2 (Figure 6.7). 
Cells were then fixed and stained for DNA, anti-C. trachomatis EB proteins, and 
human or mouse FcRn. Confocal imaging of infected cells revealed anti-Ctr EBs 
antibodies did not cross react with C. pneumoniae antigens but did bind C. 
trachomatis serovar D and L2. Human reproductive tract (Figure 6.7 A) and 
respiratory tract (Figure 6.7 B) cells, of carcinoma and immortalized origin 
respectively, both express WT human FcRn (hFcRn) which upon infection with 
Chlamydia spp. co-localizes, or is sequestered at the inclusion membrane. Similarly, 
mouse FcRn expressed in McCoy-B cells (Figure 6.7 C) also co-localized with all 
Chlamydia spp. suggesting the variations in homology between mouse and human 
FcRn do not affect binding to chlamydiae. Taken together, these data reveal the C. 
muridarum (Figure 6.4), C. pneumoniae, and C. trachomatis D and L2 all sequester 
human or mouse FcRn at the inclusion membrane.  
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Figure 6.5  
FcRn is Sequestered by C. muridarum during the Mid Stage of Growth  
MECap18 cells were infected with C. muridarum (Weiss) and the infection stopped 
at 2, 4, 6, 8, 12 and 24 hours. Cells were stained for DNA (DAPI), chlamydial MOMP 
(green) and FcRn (red) and viewed by fluorescent confocal microscopy. White 
arrows identify non-co-localized FcRn/Chlamydia, yellow arrows identify co-
localization of FcRn/Chlamydia. Scale 5 µm. 
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Figure 6.6  
Eukaryotic Inhibitors Do Not Prevent Accumulation of FcRn at the Inclusion 
To determine if eukaryotic inhibitors could prevent the accumulation of FcRn at the 
inclusion, mECap18 cells were grown on coverslips and infected with C. muridarum  
in the presence of DMSO (control), cycloheximide, nocodazole, 3-MA, wortmannin 
or MG132. Cells were fixed after 24 hours of infection and stained with DAPI (Blue), 
anti-MOMP (Green), and anti-FcRn (Red). Images taken were taken with a confocal 
microscope. Scale 5 µm. 
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Figure 6.7  
Chlamydia spp. Sequester Human and Murine FcRn  
To determine if different Chlamydia spp. were also able to sequester FcRn, multiple 
cell lines were infected for 48 hours with either C. pneumoniae AR39 (Cpn AR39), 
C. trachomatis serovar D (Ctr D), or C. trachomatis L2 (Ctr L2). Human endometrial 
epithelia HEC1A (A), human bronchial epithelium BEAS-2B (B), or murine fibroblast 
McCoy B cells (C) were infected and stained for human or mouse FcRn expression. 
White arrows identify chlamydial inclusions, observable under DAPI. Images were 
taken with a confocal microscope. Scale = 5 µm. 
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6.4.5  IncA and IncMem IgG Interferes with Chlamydial Development 
To identify the effect that bound anti-IncA and anti-IncMem IgG had on chlamydial 
growth, cells were grown and infected as previously described (6.4.4) but were 
incubated in HBSS pH 6.0 media at the start of infection to minimize FcRn binding of 
bovine albumin and IgG when inclusion proteins were being expressed. Following 
infection for 2-3 hours, cells were washed and incubated in DMEM+ (pH 6.0) 
containing IncA IgG (Figure 6.8 A), IncMem IgG (Figure 6.8 B) or control mouse IgG 
(Figure 6.8 C) for 24 hours. Cells were then and stained for DNA (DAPI) and 
chlamydia (MOMP), and viewed by confocal microscopy.  
Cells treated with anti-IncA or anti-IncMem IgG had smaller inclusions (4.2 ± 0.5 µm 
and 4.5 ± 0.7 µm respectively) than control IgG (7.0 ± 0.7 µm) (Figure 6.6 D). As 
individual EBs or RBs are each surrounded in their own outer membrane containing 
MOMP, it was possible to identify individual units of Chlamydia growing within the 
inclusion. Observing individual EBs/RBs within the inclusion (Figure 6.8 E), negative 
control IgG treated cells had bacterial units (EBs and RBs) of uniform diameter (0.6 
± 0.2 µm), whilst IncA/IncMem IgG treated cells had EBs/RBs that were larger and 
aberrantly shaped, with varying sized DNA staining observed within bacterial unit 
(IncA = 1.5 ± 0.3 µm; IncMem 1.7 ± 0.5 µm). There appeared to be much fewer 
bacterial units (ranging between 10 - 50 individual units) compared to negative 
controls (>200 individual units). The smaller  aberrant shaped inclusions, and 
swollen individual bodies in IncA and IncMem IgG treated cells suggests that the 
growing Chlamydia was blocked or starved of nutrients in early development, or that 
the presence of anti-IncA or IncMem IgG affected the fusion of the inclusion 
membranes. This aberrant development of chlamydial inclusions with no effect on 
viability was observed previously in C. trachomatis infected cells micro-injected with 
anti IncA (but not IncG or IncF) antibodies [64].  
To determine if the aberrant inclusion formation translated into a reduction in viability 
of the progeny, cells were infected for 24 hours and incubated with respective 
antibody, lysed by sonication and infected onto new monolayers (Figure 6.9). The 
reduction in viability was associated with both antigen-specific IgG and FcRn 
expression. This reduction in viability was inversely associated with an increase in 
neutralization (Figure 6.3), suggesting that IncA and IncMem IgG reduced viability 
as a consequence of fewer inclusions but not that the remaining inclusions were 
significantly effected. Here we demonstrate an evolved mechanism of FcRn-
mediated delivery of IgG to the inclusion membrane, which interferes with homotypic 
fusion and/or chlamydial growth but does not influence viability in monoculture.  
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Figure 6.8  
Intracellular IncA and IncMem-IgG Changes Inclusion Morphology.  
Cells grown on coverslips were serum starved in pH 6 HBSS and then infected with 
C. muridarum EBs for 1 hour. Media was removed and replaced with HBSS pH 6 
containing anti-IncA total IgG (A) anti-IncMem ( B) or control IgG (C) for 12 hours. 
Media with 10% FCS was then added until stopping the infection at 24 hours. Cells 
were stained for confocal microscopy with DAPI showing DNA (blue) and chlamydial 
MOMP (green). The variation in inclusion (D) and individual bacterial units (EB/RBs) 
(E) diameter was calculated from images (n = 10). Scale bar = 2.5 µm. Error bars 
represent mean ± SD. Statistics calculated with Student’s t test (p < 0.05 = *, p < 
0.01 = **). 
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Figure 6.9 
FcRn Mediates Delivery of IgG and Influences Viability of Chlamydial Progeny 
WT and FcRn knockdown mECap18 cells were seeded on to transwell inserts until 
polarized. Cells were apically infected with C. muridarum, and polyclonal IgG 
against IncA, IncMem, CPAF or cholera toxin (control) added for 24 hours. Cells 
were lysed and infectious progeny quantified by inoculation onto fresh monolayers 
for 24 hours. Inclusions were enumerated by fluorescent microscopy. Viability was 
determined by calculating the reduction in progeny, relative to controls. Statistics 
determined by Student’s t test (n = 3). Errors bars represent mean ± S.E.M. 
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6.4.6  Intracellular IgG Recruits Sequestosomes, but not Lysosomes in 
Chlamydia-Infected Epithelia  
To determine what intracellular processes were occurring during IgG/FcRn binding, 
cells were grown as described previously with negative control IgG, IncA IgG or 
IncMem IgG, (6.4.3). Following fixation, infected cells were stained for markers of 
early lysosomes (LAMP1), sequestosomes (p62), or apoptosis (PARP). Cells 
treated with IncA or IncMem IgG demonstrated minimal up-regulation of lysosomal 
marker LAMP1 (Figure 6.10, Supplementary Figure 6.1), although some LAMP1 
was observed in the cytoplasm of the infected cells. Cleavage of a classical 
apoptotic marker (PARP) was not observed under any conditions (not shown). 
Interestingly, addition of IncA or IncMem IgG, but not control IgG induced up-
regulation of ubiquitin-proteasome marker SQSTM1/p62 in C. muridarum infected 
cells. SQSTM1/p62 co-localized with the inclusion membrane in IncA and IncMem 
IgG treated cells. This indicated that antigen-specific IgG mediated recruitment of 
sequestosomes, but not lysosomes to the inclusion membrane.  
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Figure 6.10  
Internalized IncA-IgG by Chlamydia-Infected Epithelia Induces Sequestosomal 
Aggregation at the Inclusion Membrane Independent of Lysosomes  
MECap18 cells were infected with C. muridarum, and incubated with control or anti-
IncA IgG for 24 hours. Non-infected cells (A, D) and infected cells (B, C, E, F) were 
stained for lysosomal marker LAMP1 (A-C) or sequestosome 1 (SQSTM1/p62) (D-
F). White asterisk (*) indicates chlamydial inclusion. White arrow demonstrates 
SQSTM1 accumulation at the inclusion. Scale bars = 7.5 µm.  
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6.4.7  Immune Responses of Wild Type and B2m Deficient Male Mice  
To determine if in vitro results correlated in vivo, male adolescent C57BL/6 WT and 
B2m-deficent mice (with a high rate of IgG catabolism and deficient in functional 
FcRn, MHC-I and CD8+ T cells [238, 305]) were immunized, depleted of CD4+ cells 
and urogenitally infected with C. muridarum as previously described (5.4.4). To 
determine if B2m was critical in resolution of chlamydial infection and whether 
protective antibodies were produced, WT and B2m deficient mice were intranasally 
infected with 103 IFUs of C. muridarum. WT mice primed with a respiratory 
chlamydial infection resolved lung infection by day 15 (determined indirectly from 
cachexia), but this was significantly delayed (p = 0.01) in mice deficient in B2m 
(Figure 6.11).  
Following 21 days of C. muridarum urogenital challenge, no mice exhibited 
macroscopic inflammation due to infection, which is likely a consequence of CD4+ 
depletion. Mock-depleted OVA-immunized control mice had small amounts of 
macroscopic inflammation in the epididymes (not shown). To determine the quantity 
of CD4+ and CD8+ T cells in the immunized mice, splenocytes were collected and 
stained for CD3+, CD4+ and CD8+ by flow cytometry. WT mice depleted of CD4+ 
cells with GK1.5 demonstrated a significant (p < 0.0001) depletion (93.1 ± 3.3 %) of 
CD4+ T cells in the spleen (Figure 6.12 A). Mice deficient in B2m had higher 
numbers of CD4+ T cells than WT mice demonstrating a compensation for loss of 
CD8+ efficacy [306]. Additionally, depletion of splenic CD4+ T cells in B2m deficient 
mice was less effective (63.8 ± 10.6 %) than WT mice.  
Mice were also screened for CD8+ T cell numbers in the spleen by flow cytometry 
(Figure 6.12 B). WT mice had splenic CD8+ T cells regardless of CD4+ depletion 
(35.8 ± 7.4 % of CD3+ T cells), whilst all B2m-deficient mice had low total numbers 
of CD8+ T cells (2.3 ± 0.7 % of CD3+ T cells). The low number of CD8+ T cells in 
B2m-deficient mice is unsurprising as they also lack functional MHC-I, a co-receptor 
necessary to expand CD8+ T cells [307]. Similar to immunizations of WT and pIgR 
deficient mice (Chapter 5), systemic IgA (Figure 6.13 A) and IgG (Figure 6.13 B) 
were produced. Unsurprisingly, all B2m-deficient mice had a 1 log lower endpoint 
titer of antigen-specific IgG compared to WT mice (p < 0.05). This is a consequence 
of an increased catabolism of IgG in the absence of functional FcRn [235, 238]. 
Hence, it is possible to define the role of antigen-specific IgG, and the role of FcRn 
in absence of CD4+ T cells urogenital chlamydial infections of male mice. 
 
148 
 
 
 
 
 
Figure 6.11  
B2m plays a Protective but Non-Essential Role in Resolution of Respiratory C. 
muridarum Infection  
(A) Wild type and B2m -/- mice received a respiratory C. muridarum infection (103 
IFUs) and cachexia (weight loss) was measured over time. (B) The negative area 
under the curve was calculated from total weight loss to determine severity and 
duration of infection. Statistics calculated with Student’s t test (n = 5). Error bars = 
mean ± S.E.M. 
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Figure 6.12 
CD4+ and CD8+ Splenic T Cells Following CD4 Depletion 
Splenocytes were collected and pooled between groups. Cells were stained for 
CD3+ (APC), CD4+ (PE) and CD8+ (PE-Cy7) surface marker expression, and 
quantified by flow cytometry. (A) CD3+CD4+ splenocytes following GK1.5 treatment 
and infection. (B) CD3+CD8+ splenocytes following GK1.5 treatment and infection.  
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Figure 6.13  
Systemic Antigen-Specific IgA and IgG Responses in WT and B2m -/- Male 
Mice at Sacrifice 
Antigen-specific IgA (A) and IgG (B) end point titers were determined by direct 
ELISA against appropriate immunogen. Error bars = mean ± S.E.M. Statistics 
determined by Student’s t test (p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***, p < 
0.0001 = ****). 
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6.4.8  Functional FcRn and MHC-I are Necessary to Reduce the 
Chlamydial Burden in the Testes of IncA, but not MOMP, Immunized Mice 
The upper MRT has previously been shown to express large amounts of FcRn 
(Chapter 4). We sought to determine if immunization and CD4+ T cell depletion of 
WT and B2m deficient mice could reduce chlamydial burden in the testes following 
challenge infection (Figure 6.14).  
WT mice immunized with MOMP or IncA showed significant decreases in chlamydial 
burden in the testes compared to OVA-immunized controls, 26.6 ± 13.0 % and 38.0 
± 14.9 % respectively. Interestingly, this was dependent on B2m expression in IncA-
immunized mice, but not MOMP-immunized mice. This suggests that IncA-mediated 
protection was afforded by IgG, B2m, FcRn, MHC-I or CD8+ T cells but not CD4+ T 
cells. Alternatively, MOMP protection was afforded in the absence of CD4+ and 
CD8+ T cells, IgG, FcRn, B2m and MHC-I suggesting that protection was 
dependent on other immune mechanisms and is consistent with previous findings 
demonstrating pIgR transport of SIgA is required (Chapter 5). Mice that were 
previously infected, or immunized with IncMem demonstrated no significant 
reductions in testicular chlamydial burden, but B2m-deficent mice did show a 
reduction similar to MOMP-immunized mice suggesting a non-IgG/MHC-
I/FcRn/CD8+ mediated protection.  
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Figure 6.14  
Reduction of Testicular Chlamydial Burden is Dependent on B2m Expression 
for IncA Immunized mice, but not MOMP Immunized Mice. 
Following 21 days of MRT challenge, the testes from WT and B2m -/- mice (n = 5) 
were collected and chlamydial burden determined by cell culture and microscopy. 
The percent reduction in chlamydial burden relative to OVA-immunized and CD4-
Depleted control mice. Asterisk above the graph indicates this group was 
significantly different from the OVA immunized CD4+ depleted mice of the same 
phenotype. Error bars = mean ± S.E.M. Statistics calculated with Student’s t test (p 
< 0.05 = *, p < 0.01 = **, p < 0.001 = ***, p < 0.0001 = ****).  
  
153 
 
6.5  DISCUSSION 
Recently, the intracellular actions of antibodies have gained scientific attention. 
Immunoglobulin receptors have been shown to mediate phagocytosis of opsonized 
antigens, viruses and bacteria [51, 226-227]; as well as rendezvous with internalized 
viral antigens [4, 11, 177, 295]. Additionally, both FcRn and IgG have been 
demonstrated to bind intracellular viral antigen [4], and mediate MHC-I presentation 
in dendritic cells [227]. Thus, as C. trachomatis is an obligate intracellular bacterium, 
we sought to define if internalized IgG could also target intracellular chlamydial 
antigens for destruction.  
As purification and production of humanized antigen-specific monoclonal IgG is 
tedious to test multi-epitope antigens, we sought to establish a murine model of 
FcRn-mediated delivery of polyclonal IgG. The immortalized murine caput 
epididymal epithelial (mECap18) cells expressed endogenous FcRn, consistent with 
murine (Chapter 4) and rat epididymes [214]. Both WT and FcRn-silenced 
mECap18 cells established weakly polarizing monolayers as determined by TEER, 
but expressed ZO-1, had low apparent permeability of small inert molecules (<4 
kDa), completely inhibited larger molecules like IgY, and had no detectable FcγRI, 
FcγRIIb or FcγRIII. Additionally, silencing of FcRn also resulted in a significant 
reduction of IgG transcytosis, suggesting that this cell line can polarize and transport 
IgG in an FcRn-dependent manner. 
When polarized mECap18 cells were infected with C. muridarum and incubated with 
total IgG purified from mice immunized with different antigens, there was a 
significant reduction in inclusion formation in IncA and CPAF IgG treated cells 
compared to negative controls. The neutralization was highest in IncA IgG treated 
cells, and was dependent on expression of FcRn. This is unsurprising as FcRn 
mediates delivery of IgG intracellularly [4]. However, in serum, antibody is typically 
only 1-2 % (maximally  10%) of total IgG [308], suggesting that the actual antigen-
specific IgG added to cultures was significantly less than 50 µg/mL (0.5 – 1 µg/mL).  
Interestingly, incubation with IncA or IncMem IgG resulted in aberrant chlamydial 
inclusion. This morphology has been observed by Hackstadt and colleagues after 
microinjecting IgG specific for IncA into infected cells, which prevented homotypic 
fusion of the inclusion membrane and demonstrated that IncA has domains that 
interact with the host cytoplasm [63-64]. We build on these findings, describing a 
receptor-mediated mechanism for IgG delivery into infected cells. Despite the low 
neutralizing ability, we sought to determine what intracellular processes were 
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occurring that caused the reduction in the number and change in morphology of 
chlamydial inclusions.  
When mECap18 cells were fixed and stained, FcRn was found abundantly in the 
host cytoplasm. After C. muridarum infection, FcRn accumulated at the inclusion 
membrane of human and murine cell lines. This was also observed in both host cell 
types infected also with C. trachomatis (D and L2) and C. pneumoniae, and in the 
presence of eukaryotic inhibitors of protein biosynthesis, microtubule polymerization 
and autophagy. When infected with C. muridarum (Weiss), which has a shorter life 
cycle than C. trachomatis, accumulation of FcRn and C. muridarum was observed 
between 6 and 8 hours post infection. This suggests that the inclusion accumulates 
host FcRn at an intermediate (mid-late) stage of the development cycle. Whether 
this phenomenon is of major significance to the growth of chlamydiae remains 
unknown, but Chlamydia spp. are grown routinely in HeLa cells [36, 69, 309], which 
lack detectable FcRn [213]. This may be another mechanism that chlamydiae have 
evolved to reduce host responses to infection [1]. The chlamydial inclusion contains 
a variety of cytoplasmic-facing inclusion membrane proteins which bind and 
sequester host membrane trafficking and fusion regulators including SNAREs and 
Rab GTPases [302, 310]. The binding of Rab 4 by CT 229 [311], and Rab 11 by 
IncG [310] facilitates chlamydial hijacking of host cellular protein trafficking and 
secretory pathways. Interestingly, FcRn is also trafficked from endosomes to the 
plasma membrane via Rab 4 and Rab11 GTPases [312]. This suggests that the 
recruitment of FcRn to the inclusion of a variety of chlamydial species observed in 
this study is a consequence of Rab 4 and/or Rab 11 binding by inclusion membrane 
proteins. Thus, whilst not necessary for chlamydial growth, the sequestration of 
FcRn must be considered in IgG-inducing vaccines which target mid-late 
intracellular chlamydial proteins (>6 hr), as more and more FcRn will be 
immobilized, minimizing the bioavailability of FcRn to endocytose IgG. 
To determine if FcRn could traffic antigen-specific IgG within an infected cell, we 
infected and treated cells for 23 hours, but changed media 1 hour prior to fixation to 
allow unbound IgG to be removed from the cells. When stained for FcRn and mouse 
IgG, only small amounts of IgG were observable in uninfected and C. muridarum-
infected cells, with or without control IgG. Conversely, cells incubated with IncA IgG, 
IncMem IgG, immune IgG and CPAF IgG demonstrated accumulation of both FcRn 
and IgG in distinct cellular regions. IncA and IncMem IgG co-localized with FcRn at 
the inclusion membrane, whilst immune and CPAF IgG co-localized with FcRn 
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distant from the inclusion. This suggests that IgG could target both cytoplasmic, and 
inclusion membrane chlamydial proteins.  
Chlamydia actively inhibits fusion of the host endocytic pathway at the inclusion 
membrane with a variety of SNARE-like proteins to prevent phagosomal and 
lysosomal degradation [302]. We hypothesized that IgG binding to the inclusion 
membrane could disrupt this host/pathogen equilibrium and permit binding and 
activation of lysosomes as observed in other IgG-mediated intracellular viral 
neutralization studies [4, 51]. However, incubation with IncA IgG did not recruit 
LAMP1, an early lysosome marker, suggesting that this pathway remained inhibited. 
Unique from LAMP1, both IncA and IncMem IgG treated cells demonstrated co-
localization of sequestosome/p62 to the inclusion membrane. Interestingly, previous 
studies have shown that C. trachomatis infection up-regulate p62 (SQSTM1) 
expression in infected macrophages, but not fibroblasts, and does not co-localize 
with the inclusion membrane [80]. Here we demonstrate that FcRn can mediate 
transport of antigen-specific IgG (anti-IncA/IncMem) and induce recruitment of p62 
to the inclusion membrane of infected epithelial cells. This non-lysosomal, non-
apoptotic but sequestosomal binding at the site of antigen-IgG binding suggests that 
this intracellular process is not using a traditional autophagy-mediated pathway of 
degradation, but may accumulate ubiquitin and traffic IgG-bound antigen to the 
proteasome [313] for degradation and/or MHC-I loading.   
As FcRn, IgG and MHC-I may have been implicated during in vitro chlamydial 
infection; we sought to determine if this also translated to protection in vivo. 
Because adoptive transfer of polyclonal biotinylated mouse IgG resulted in poor 
titers of IgG delivery to the reproductive tracts of male and female mice (not shown), 
we immunized mice with extracellular (MOMP), intracellular (IncA, IncMem) 
chlamydial antigens or control antigen (ovalbumin) as well as giving mice a previous 
infection. To examine the role of FcRn and MHC-I, B2m deficient mice were used as 
they lack functional FcRn and MHC-I, and have a high rate of IgG catabolism [226, 
235, 238]. Additionally, whilst B2m and MHC-I are beneficial in resolution of primary 
chlamydial infections, they are not necessary [314]. Following immunization, mice 
were continuously depleted with GK1.5 to minimize any protection afforded by CD4+ 
T cells during urogenital C. muridarum infection. CD4+ T cell depletion was highest 
in WT mice, but lower in B2m deficient mice and may be due to the inability to 
transport depleting antibody out of the intraperitoneal cavity, or that these mice have 
a higher resident population of CD4+ T cells. Regardless, the chlamydial burden in 
the testes of mice was determined to assess the reduction in infection.  
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WT mice previously immunized with MOMP or IncA demonstrated reduced burdens 
compared to non-specific OVA controls (with or without CD4+ T cell depletion) 
suggesting that protection was afforded in the absence of CD4+ cells. Mice 
immunized with MOMP also retained protection in the absence of B2m, and 
functional FcRn, MHC-I, CD4+ and CD8+. This strongly suggests that the protection 
afforded from MOMP immunization was not dependent on these processes and is 
likely IgA mediated (Chapter 5). Conversely, IncA-mediated protection was 
observed in WT mice only, and was abrogated in B2m deficient mice despite these 
mice having higher residual numbers of CD4+ T cells. This strongly suggests that 
the protection observed in these mice was dependent on IncA-specific IgG, together 
with FcRn, and/or MHC-I and is surprising as MHC-I, CD8+ T cells and IgG specific 
to intracellular antigens are not considered to play a crucial role in genital tract 
chlamydial infections [1]. IncMem immunized mice showed no protection and may 
be a reflection of the polyclonal preparation of the antigen not inducing enough 
antigen-specific antibody to reproduce the results observed in vitro.  
Taken together, these data demonstrate that FcRn can bind and traffic IgG to 
intracellular antigens and is in agreement with recent viral studies [4]. However, all 
intracellular IgG investigated were unable to completely inhibit chlamydial growth, 
which may be due to the maturation of bacterium, or the late transcription of IncA (8-
12 hr) and CPAF (>12 hr) in C. trachomatis infections [65, 315]. However, FcRn was 
shown to deliver of IncA and IncMem IgG to the inclusion membrane which induced 
the development of aberrant inclusions and co-localized sequestosome 1 to the 
inclusion in vitro. When investigated in vivo, protection afforded by IncA IgG was 
dependent on functional FcRn and/or MHC-I. If these processes work in unison to 
target diseased cells for destruction it may explain why recent passive transfer of 
anti-NY-ESO (a common intracellular cancer antigen) monoclonal IgG assisted in 
the elimination of carcinoma in a CD8+ T cell-dependent manner [316]. Together, 
these data identify that IgG against intracellular chlamydial antigens can be targeted 
in vaccines. Furthermore, whether these results are replicated in other disease 
models remains unknown, but vaccination or passive immunizations with IgG that 
specifically target intracellular antigens expressed in cancer, as well as intracellular 
bacterial and viral antigens may improve the prognosis associated with these 
diseases.     
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6.6  SUPPLEMENTARY DATA 
 
 
 
 
 
Supplementary Figure 6.1 
Internalized anti-IncMem IgG Accumulates SQSTM1 but not LAMP1 at the 
Inclusion  
Polarized mECap18 cells were infected with C. muridarum apically, and treated with 
IncMem IgG for 24 hours. Inserts were fixed, and stained identify (A) sequestosome 
1 (SQSTM1), (B) lysosomes (LAMP1), chlamydial inclusions (MOMP) and DNA 
(DAPI). Images were taken with a confocal microscope. Scale bar = 5 µm.  
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Chapter 7 
 
FcRn-Mediated Uptake of IgG-
Opsonized Chlamydia Enhances 
Epithelial Infection and Induces 
Pathology 
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7.1 ABSTRACT 
Antibody dependent enhancement (ADE) of infection is a widely accepted 
mechanism of pathogenic virus entry into host cells. Whilst Fc receptors normally 
traffic opsonized virus or bacterium to lysosomes, some pathogens are able to 
escape fusion with late endosomes or early lysosomes, avoiding degradation and in 
this case provides the pathogen with an additional route of entry. Here we 
demonstrate that C. muridarum EBs opsonized in polyclonal IgG from MOMP-
immunized mice enhance in vitro infection of epithelial cells in an FcRn-dependent 
manner. When inoculated into the vaginal vault of female mice, EBs opsonized with 
MOMP IgG slowed the ascension of infection into the upper reproductive tract,  but 
protracted the duration of infection by 60 %, significantly increased hydrosalpinx, 
and skewed the normal immune response compared to non-opsonized controls in 
WT mice. Conversely, mice deficient in B2m, functional FcRn and MHC-I showed no 
significant differences between groups. Here we demonstrate FcRn and IgG specific 
for MOMP can enhance chlamydial infection in vitro, and induce aberrant pathology 
in vivo. This shows further potential deleterious side effects of immunization or 
previous exposure to MOMP antigen, and should be considered in future vaccine 
trials.   
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7.2 INTRODUCTION 
Antibody mediated enhancement (ADE) of infection is a well recognized immune 
paradigm where viruses and intracellular bacteria opsonized with immunoglobulin 
hijack normal host receptor functions to enter target cells [317]. Whilst opsonization 
of antigens often assists in phagocytosis and processing of extracellular pathogens, 
ADE increases the infectivity of viruses including Dengue virus [318-319], Ross 
River virus [320], measles virus [321], rabies virus [322], Ebola virus [323], influenza 
A virus [324], HSV [325], cytomegalovirus [326], and HIV [327]. ADE has also been 
reported during epithelial internalization of bacteria such as methicillin-resistant 
Staphylococcus aureus [328], Brucella abortus [55], and C. trachomatis [54]. All of 
these pathogens are able to exploit antigen-specific IgG bound to their surface 
proteins to enter host cells via Fc receptors or complement receptors. 
The FcRn is a MHC-I like IgG transporter which is non-covalently associated with 
B2m. Unlike FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) effectors which bind 
IgG at the Fc hinge region, FcRn binds IgG between domains CH2-CH3 [296]. FcRn 
is expressed on a wide variety of cell lineages including professional antigen 
presenting cells, syncytiotrophoblasts, endothelial and epithelial cells [203]. It is 
constitutively expressed by mucosal epithelia of the male and female reproductive 
tracts and assists in bidirectional IgG transport in and out of the lumen [213-214]. As 
well as transportation, FcRn endocytoses and sequesters IgG and albumin 
cytoplasmically slowing catabolism and increasing their half-life [203, 205]. FcRn 
binds IgG and albumin in an acidic pH-dependent manner (pH 4.5 - 6.5) and 
releases at neutral pH [239]. Importantly, both the male and female reproductive 
tracts have acidic lumens. The vagina (pH 4.5), cervix (pH 6.5) [217], epididymes 
(pH 6.5) [215, 253], and prostate (pH 6.1-6.5) [216] all express FcRn [213-214]. 
FcRn is also able to bind and transport IgG complexed with antigen delivering the 
immune complexes to antigen presenting cells in the underlying epithelia [225], and 
has been implicated in enhancement of fetal infection with cytomegalovirus 
opsonized with maternal IgG [206]. 
C. trachomatis infection of the genital tract affects an estimated 90 million people 
annually and can lead to scarring, PID and infertility [24]. Whilst infection can be 
asymptomatic, chronic exposure to infection is associated with the damaging 
sequelae. C. trachomatis infection of the lower female reproductive tract generally 
results in colonization of the endocervix, which can ascend to cause PID in an 
estimated 30% of patients with 10-20 % of PID patients progressing to tubal 
infertility [83]. Pathological changes similar to humans are observed in several 
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mammals including non-human primates, guinea pigs and rodents with mice being 
the most commonly used animal model [242, 329]. Vaginal infection of mice with the 
mouse biovar of C. trachomatis, C. muridarum, leads to an ascending infection and 
severe upper reproductive tract sequelae (tubal occlusion, hydrosalpinx and 
infertility) which closely mimics the immunopathology observed in humans [330].  
Chlamydial MOMP is a multipass transmembrane protein expressed on both the 
extracellular elementary body (EB) and intracellular reticulate body (RB) phases of 
the chlamydial life cycle. MOMP constitutes 60% of the total outer membrane 
protein and is highly cross-linked in disulfide-bonded matrices with other cysteine-
rich outer membrane proteins affording the EB structural integrity in the absence of 
detectable peptidoglycan [31, 33]. MOMP also functions as an adhesin assisting in 
host cell attachment [331], is a general diffusion porin [332-334], and is 
immunogenic during infection [335-336]. Due to MOMPs constitutive expression and 
immune accessible regions, it has been extensively studied and has been included 
in hundreds of vaccine trials in unique preparations with highly variable results. 
Whilst MOMP-specific CD4+ T cells [281], and secretory IgA [117, 269] play a 
protective role, monoclonal MOMP-IgG opsonized EBs can enhance infection of 
epithelia by FcγRIII in vitro [54, 56, 337], and polyclonal antibodies to MOMP in the 
vaginal lavages have been implicated in accelerated pathology in vivo [228]. As 
ADE mediates internalization of a variety of host pathogens including C. 
trachomatis, and FcRn is implicated in internalization and processing of other 
bacterium unable to avoid phagolysosomal degradation [226], we sought to define if 
FcRn and MOMP-IgG:EB immune complexes would facilitate entry of C. muridarum 
in host cells.  
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7.3 MATERIALS AND METHODS 
Animal Experimentation, Antibodies and Chlamydia 
Female WT C57BL/6 mice (>6 weeks) were purchased from the Animal Resource 
Centre (Western Australia, Australia. Female C57BL/6 B2m -/- mice were bred at 
the HMRC. All mice were housed and fed ad libitum at the HMRC. Recombinant C. 
muridarum MOMP was a generous gift from Harlan Caldwell (Rockey Mountain 
Labs, Hamilton, MT, USA) and was prepared as previously described (3.2.1). To 
produce antigen-specific antibodies, mice were intranasally immunized with 100 µg 
of recombinant C. muridarum MOMP and 2.5 µg cholera toxin on days 0, 7, 14 and 
25 (3.6.3). Cardiac blood was taken under anesthesia, and mice were euthanized. 
Total mouse IgG was purified from serum by diluting in 10 times its volume of PBS 
and passing over equilibrated Protein G resin (Genscript) as per the manufacturer’s 
instructions. Purified IgG was diluted to 2 mg/mL in PBS and stored at -80oC until 
required. All animal procedures were performed with approval from the QUT ethics 
committee. C. muridarum (Weiss) was grown and purified as previously described 
(3.3). 
In Vitro Neutralization  
Murine caput epididymal epithelial cells (mECap18) expressing wild type mouse 
FcRn were a generous gift from Petra Sipila (University of Turku, Turku, Finland) 
and were maintained in DMEM+ mECap18 media (Chapter 6). Stable shRNA FcRn 
transfectants were produced as described previously (Chapter 6). Cells were grown 
on transwells as previously described (Chapter 6). 24 well 0.4 µm transwell inserts 
(BD Diagnostics) were seeded with 105 wild type (WT) or shRNA FcRn knockdown 
(FcRn shRNA) mECap18 cells and incubated at 37oC and 5% CO2 for 5 days until 
polarized as determined by TEER, and the inability to passively transport IgY 
between transwell chambers (Chapter 6). Cells were serum starved with HBSS + 20 
mM HEPES pH 7.4 for 1 hour at 37oC. Selected inserts were treated with 150 nM 
wortmannin (Sigma Aldrich) at this time. Following serum starvation, inserts were 
polarized with HBSS + 25 mM MES pH 6.5 in the apical chamber, and HBSS pH 7.4 
in the basolateral chamber for 1 hour at 37oC. At this time, varying concentrations of 
purified mouse IgG were incubated with 5 x 104 IFUs (MOI ~ 0.25) at 37oC for 1 
hour in HBSS pH 6.5. Treated EBs were then added to pH polarized mECap18 cells 
and allowed to infect and internalize for 2 hours at 37oC. Media was then replaced 
with DMEM and 5% (v/v) HI-FCS and cells incubated for a further 24 hours at 37oC. 
Cells were fixed with methanol, inserts excised, and inclusions enumerated by 
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immunocytochemistry. Enhancement was determined with the equation; 
enhancement (%) = - neutralization (%) = - [% IFUs per well (MOMP IgG) – IFUs per 
well (control IgG)] / IFUs per well (no IgG)] x 100.  
In Vivo Challenge 
For in vivo challenge, mice were synchronized with a sub-cutaneous immunization 
of 2.5 mg Depo Provera® and housed for 7 days prior to infections. The saturation 
point of opsonization for anti-MOMP total IgG was determined to be 40 µg/mL for 5 
x 103 UV-killed EBs by direct ELISA (3.4.1). Direct ELISA with recombinant MOMP 
revealed all classes of IgG were produced (IgG1, IgG2b, IgG2a/c, IgG3), but direct 
ELISA with UV-EBs demonstrated that bound antibodies were only of the IgG1, and 
IgG2b isotype at 40 µg/mL (Supplementary Figure 7.1). Prior to infection, aliquots of 
5 x 103 IFUs were incubated with 40 µg/mL of anti-MOMP or control IgG for 1 hour 
on ice. EBs were then pelleted at 12 000 g for 15 minutes at 4oC, unbound antibody 
and media discarded, and EBs resuspended in 10 µL of SPG for each dose. Mice 
were then vaginally infected with antibody-treated EBs. Cervicovaginal swabs were 
collected every 3 days until day 35 (3.6.7). Mice were euthanized by overdose of 
sodium pentobarbitone, hydrosalpinx measured (3.6.16) and reproductive tract 
tissues taken for histology and H&E staining (3.6.14.2). Immunohistochemistry (IHC) 
to detect FcRn expression was performed as previously described (Chapter 4). To 
determine upper reproductive tract burden during the peak of infection, mice were 
infected as above, euthanized on day 6, and uterine horns and oviducts taken for 
quantification by cell culture as previously described (3.6.14.3 and 3.3.1). 
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7.4 RESULTS 
7.4.1  Anti-MOMP IgG Opsonized EBs Enhance in vitro C. muridarum 
infection in Polarized Epithelial Cells  
Murine epididymal epithelial cells expressing endogenous FcRn, or shRNA-treated 
cells were grown on transwells until confluent. Cells were then serum starved, pH 
polarized, and/or treated with the wortmannin to interrupt transcytosis [338].   EBs 
were then incubated with or without varying concentrations of control or anti-MOMP 
total IgG for 1 hour at 37oC. EBs were then loaded into the apical compartment and 
allowed to infect for 24 hours, fixed, and inclusions enumerated by microscopy. 
Despite 5 x 104 IFUs being infected into the apical compartment, infection of 
controls averaged 2.2 x 104 IFUs per insert suggesting infectious EBs decreased 
during the 1 hour incubation and/or were impaired by polarization. As the original 
inoculum was titrated on semi-confluent monolayers the reduction is likely a 
phenotype of confluent polarization and has been observed in other cell lines 
infected with Chlamydia spp. [44].  
Increasing concentrations of anti-MOMP total IgG incubated with EBs increased the 
infectivity of the inoculum (Figure 7.1 A) when pre-incubated with 1 µg/mL (29,091 ± 
416 IFUs) and 100 µg/mL (33,727 ± 2,840 IFUs) of polyclonal IgG from MOMP, but 
not with 100 µg/mL of control IgG. This enhancement was not observed in FcRn 
shRNA knockdown cells or mECap18 cells pretreated with the phosphoinositide 3-
kinase and FcRn endocytosis inhibitor wortmannin [36, 338]. To determine the 
enhancement of infection relative to controls, the increase of IFUs relative to no IgG 
and control IgG were calculated (Figure 7.1 B). MOMP IgG significantly enhanced 
the infectivity at 1 and 100 µg/mL in WT mECap18 cells only. Knockdown of FcRn 
expression or inhibition of receptor-mediated endocytosis with wortmannin 
abrogated the enhancing effect of MOMP IgG.  
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Figure 7.1  
MOMP-IgG Enhances in vitro Chlamydial Infection in an FcRn-Dependent 
Manner 
Anti-MOMP IgG mediated enhances internalization and infection of C. muridarum 
into polarized murine epithelial cells in an FcRn-dependent manner. (A) Total IFU 
counts for treated cells. (B) Enhancement of infection was determined as negative 
neutralization, calculated from control IgG-treated EBs. Error bars = mean ± S.E.M. 
Statistics determined by Student’s t test (n = 3) (p < 0.01 = **, p < 0.001 = ***). 
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7.4.2  Anti-MOMP IgG Opsonized EBs Reduce the Peak but Protracts 
the Duration of Chlamydial Infection in the Murine FRT 
To identify the in vivo role of IgG and C. muridarum enhancement, anti-MOMP IgG-
opsonized and control IgG-incubated EBs were introduced into the vaginal vault of 
Depo-Provera® synchronized female WT and B2m -/- mice. As a consequence of 
not having B2m, these mice also lack functional FcRn and MHC-I [235, 237-238].  
Cervicovaginal swabs were taken every 3 days to determine shedding over time 
(Figure 7.2 A). Following 3 days of infection, WT mice vaginally challenged with 
MOMP-IgG EBs had a non-significant increase in IFUs compared to WT mice 
infected with control IgG:EBs. Interestingly, mice deficient in B2m had the inverse of 
the WT mice with MOMP-IgG treated EBs having a non-significant reduction in IFUs 
compared to control-IgG treated EBs. As the variation at day 3 was high between 
the groups, the trend of the infection over time was also determined. When the 
infection kinetics were observed over the duration of the experiment, WT mice 
infected with MOMP IgG opsonized EBs had a reduced peak of infection compared 
to control IgG treated EBs (day 6), but continued shedding chlamydiae for a further 
9 days, equivalent to a 60% increase in duration of infection. Interestingly, mice 
deficient in B2m had a decreased vaginal chlamydial burden and had reduced 
duration of infection compared to WT mice that had received the same treatment. 
Similarly to WT mice, MOMP-IgG treated EBs reduced the peak of vaginal 
chlamydial burden compared to controls, but unlike the WT mice the infection was 
not protracted. 
Area under the curve (AUC) analysis was performed on the shedding data to 
combine the peak and duration of infection into an intensity and/or antigenic load 
value (Figure 7.2 B). AUC analysis of WT mice demonstrated that despite the 
control IgG treated mice having a larger peak of infection and shorter duration, the 
intensity/antigenic load was equivocal to MOMP-IgG treated mice. B2m -/- mice also 
had a similar burden, with MOMP-treated EBs having a smaller but non-significant 
reduction in AUC.  
To determine if chlamydial burden affected the ascension of chlamydial infection into 
the upper reproductive tract, the experiment was repeated and chlamydial burden in 
the uterine horns (Figure 7.2 C), and oviducts (Figure 7.2 D) during the peak of 
infection (day 6) quantified by cell culture of tissue homogenates. There were no 
significantly different groups in either tissue, however, it is noticeable that burden in 
the upper reproductive tract was lower in WT mice infected with MOMP-IgG 
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opsonized EBs, and mice deficient in B2m having more chlamydial burden. 
Together, these data suggest that opsonization of EBs in MOMP-IgG reduces the 
burden in both the lower and upper reproductive tracts during the peak of infection, 
but attenuates the duration of infection in a B2m-dependent manner.      
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Figure 7.2  
Infection with MOMP-IgG Opsonized EBs Minimizes FRT Peak of Chlamydial 
Burden but Protracts the Duration of Infection in a B2m-Dependent Manner  
(A) Cervicovaginal swabs of wild type and B2m -/- female mice (n = 5) over time 
following infection with IgG-treated C. muridarum EBs. (B) Area under the curve 
analysis of intensity and duration of infection. (C) Day 6 chlamydial burden in the 
uterine horns. (D) Day 6 chlamydial burden in the oviducts. Error bars = mean ± 
S.E.M. Statistics determined by Student’s t test. 
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7.4.3  MOMP-IgG Opsonization of EBs Induces Chronic Inflammatory 
Pathology in the Upper FRT 
To determine pathological outcomes resulting from the differences in chlamydial 
burden, hydrosalpinx of the oviduct was measured on day 35 at the peak of upper 
reproductive tract pathology [126]. All WT mice (n = 5) infected with MOMP-IgG:EBs 
had at least 1 hydrosalpinx (Figure 7.3 A), despite the having a reduced peak of 
infection. Conversely, WT mice infected with control IgG treated EBs had a 
significant (p < 0.05) reduction in oviduct diameter with only 1 mouse (20%) having 
hydrosalpinx. Between all groups there was an equal number of left and right 
hydrosalpinx. Female B2m -/- mice treated with control IgG EBs had more 
hydrosalpinx than WT control IgG EBs mice, although this was not significant (p = 
0.08). Both treatments induced hydrosalpinx in B2m -/- mice, as well as inducing 
severe dilation of the uterine horns (not show). Similar uterine horn dilation has 
recently been reported in female mice infected with C.muridarum or C. trachomatis 
L2 [339-340]. This suggests that B2m deficient female mice have a predisposition to 
upper reproductive tract pathology, and differentiating treatment regimes between 
mice of this phenotype would be difficult. 
Histopathological sections and H+E staining of the vagina, cervix and ovaries 
showed no signs of chronic pathology in any mice (no shown). However, the uterine 
horns of WT mice that had been infected with MOMP-IgG opsonized EBs but not 
control IgG, had a large amount of lymphocyte infiltration in the endometrium and 
lumen (Figure 7.3 B). Mice deficient in B2m all had chronic inflammation in the 
uterine horns once again demonstrating the difficulty in differentiating between the 
treatments. 
Immunohistochemistry (IHC) of uterine horns to detect FcRn expression 
demonstrated high levels of FcRn in the uterine endometrium of uninfected WT 
mice, and infected with MOMP IgG-EBs, but not in control IgG EBs (Figure 7.3 C). 
Only trace amounts of FcRn was detectable in uninfected B2m deficient mice, which 
disappeared following infection. 
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Figure 7.3  
MOMP IgG Opsonized EBs Induce Pathology in the Upper FRT of WT Mice 
(A) Following 35 days of infection, oviduct dilation was measured as the diameter of 
hydrosalpinx above normal controls (2 mm) (n = 10), with % representing the 
number of mice with at least one hydrosalpinx. (B) H & E staining of uterine horn 
sections with black arrows identify chronic inflammation (lymphocyte infiltrate) of the 
uterine endometrium and blue arrow demonstrating lumenal infiltrate. (C) DAB IHC 
of FcRn protein in uterine horns following C. muridarum infection. Statistics 
determined by Student’s t test (p < 0.05 = *, p > 0.05 = ns). Scale bars 50 µm. 
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7.5 DISCUSSION 
Routinely, in vitro neutralization experiments are performed on cell monolayers 
under neutral pH conditions [285]. Whilst this is relatively inexpensive, it does not 
accurately reflect the polarization of epithelium, nor does it reflect the acidic lumen 
observed in the male and female reproductive tracts [253]. Here we demonstrate 
that FcRn mediates the in vitro enhancement of chlamydial infection of polarized 
epithelia by internalizing immune complexes of EBs and anti-MOMP IgG in a dose 
dependent manner and in the absence detectable CD64, CD32 and CD16.  When 
FcRn expression was silenced with shRNA, or endocytic transport blocked with 
wortmannin, the total infectivity dropped to that seen in non-specific IgG controls 
suggesting that enhancement was mediated by FcRn uptake.  
In this study, the in vivo peak and duration of infection was altered simply by 
opsonizing EBs with total IgG purified from MOMP immunized mice. At the peak of 
infection, there was a lower amount of chlamydial burden in cervicovagina, uterine 
horns and oviducts of WT mice, but not B2m-deficient mice, infected with MOMP-
IgG opsonized EBs when compared to controls. This suggests that the effect of 
MOMP-IgG had reduced the initial infectious burden. However, chlamydial burden in 
the FRT was decreased at the peak of infection in WT mice infected with MOMP IgG 
opsonized EBs, the duration of infection as determined from swabs continued for a 
further 9 days, a 60% increase compared to control WT mice. In opposition, both 
MOMP and control IgG treated B2m -/- mice had no detectable IFUs by day 15.  
Despite the variations in shedding, antigen exposure and intensity of infection as 
determined by AUC analysis was equivocal within each mouse phenotype. Whether 
IgG receptors expressed on epithelial cells or other cell types were responsible for 
the small changes in burden and large pathological outcomes remains unknown. 
Interestingly, infection with MOMP IgG opsonized EBs significantly enhanced 
hydrosalpinx formation in WT mice when compared to non-specific IgG controls. 
This suggests that MOMP IgG reduced the initial burden in the lower and upper 
reproductive tracts, presumably via epithelial uptake, but induced immunopathology.  
Whilst small increases in the infectivity of epithelia may be of little significance in 
vivo, the difference in pathological outcomes is of more concern in terms of the 
morbidity associated with C. trachomatis epidemics.  
Recently, Zhong and colleagues mapped the antigenome associated with 
hydrosalpinx formation following C. muridarum infection of the murine FRT [339]. 
Whilst they observed 17 immunodominant antigens (MOMP was recognized by 85% 
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of infected mice) in the antisera of C. muridarum infected females, MOMP (TC0052) 
was not reported as being different between mice with or without hydrosalpinx. We 
add to their data by reporting that IgG to MOMP also induces hydrosalpinx formation 
in mice. As MOMP is an immunodominant antigen recognized in immune sera of 
both human and murine infections with C. trachomatis [341] it’s potential to induce 
detrimental immune responses is of clinical significance. Historically, C. trachomatis 
strains were categorized into serovars based on their seroreactivity to EBs [342], 
which is now known to be due to the variable regions of MOMP [343-345]. 
Additionally, IgG titers to MOMP are used in several commercial serological 
screening ELISAs to differentiate acute from subfertile patients [346-347]. Since 
MOMP was isolated and subsequently cloned into bacterial expression vectors in 
the 1980s [33, 343], it has been included in more than 800 studies. When used in 
vaccines, immune responses to MOMP can often reduce bacterial burden and 
transmission, but have variable protection from pathology [228, 348]. The 
hypervariable surface-exposed regions of the gene encoding MOMP, ompA, 
undergoes accelerated mutations compared with the rest of the genome [349] 
identifying the protein is under immunological pressure to mutate [350-351], and that 
these mutations are sufficient to avoid serological neutralization in monolayer cell 
culture [352]. Thus, production of sub or non-neutralizing antibodies that bind 
domains of one serovar may increase the susceptibility to another serovar.  
Opsonization of C. muridarum EBs with sub/non-neutralizing mouse IgG 
(predominantly IgG1 and IgG2b), induced significantly more pathology in WT mice. 
As ratios of IgG1 and IgG2a/c can be used to infer the T helper bias of the donor 
mice, we can deduce that intranasal immunization with CT and MOMP whilst 
inducing a weak Th2 bias, only allowed EBs to be coated in IgG1 and IgG2b (IgG1 = 
Th2 bias). Interestingly, IgG-immune complexes have been shown to target FcγRs 
on DCs and macrophages, inducing a polarization towards a Th2 response and 
even reversing a pre-disposition for a Th1 response [353-354]. 
This may induce early Th2 responses upon binding of FcγR. This would explain why 
only MOMP-IgG1+2b opsonized EBs infected into WT mice continued producing 
FcRn, whilst controls IgG EBs down regulated FcRn expression as seen in normal 
infections of the FRT and MRT (Chapter 4 and Chapter 7). While normal chlamydial 
infections induce a Th1-dependent pro-inflammatory response [1],  APC binding of 
IgG opsonized EBs may have Th2-skewed the initial immune response. Indeed, Th2 
T cell responses have previously been shown to exacerbate and prolong chlamydial 
infection in female mice [150]. The protraction of infection in this case was 
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dependent on the cytokines secreted by the Th2 cells (principally IL-4), which whilst 
not directly affecting infected-epithelial cells in vitro, may have negatively impacted 
on the innate immune response in vivo [150]. 
Based on in vitro experiments, it has been proposed that murine IgG1 and IgG2b 
preferentially interact with low affinity FcγRIIb and FcγRIII, whilst IgG2a preferentially 
binds the high affinity FcγRI [355]. Conversely, FcRn binds all IgG isotypes with the 
highest affinity for IgG2a [220]. Interestingly, Hazenbos and colleagues have 
demonstrated that murine IgG1 immune complexes binding to FcγRIII enhance 
phagocytosis by macrophages, facilitate trapping of antigen by follicular DCs, and 
induce antibody-dependent cellular cytotoxicity in neutrophils [356]. Whether or not 
coating of EBs with sub/non-neutralizing IgG facilitated entry into 
macrophages/DCs/PMNs remains unknown, but warrants further investigation. 
An immunological paradigm exists in the chlamydiae literature with a large amount 
of studies correlating bacterial burden with immunity, often not presenting 
pathological data which is arguably the requirement for a vaccine [357]. The 
morbidity of urogenital chlamydial infections is strongly dependent on the host 
response to infection, rather than the pathogen itself. Mathematical modeling has 
suggested that even if only a partially effective vaccine was developed, the 
decreases in transmission could significantly reduce epidemics of C. trachomatis in 
two decades [297]. However, transmission of infection may continue to cause 
immunopathology in sexual partners as evidenced by lower chlamydial inoculums 
often not preventing (and sometimes enhancing) upper reproductive tract pathology 
in mice [126, 358]. Thus, short of sterilizing immunity, a vaccine targeting only 
reductions in burden, and not beneficially modulating the host response to infection 
is likely to fail. In support of this argument, intramuscular and intranasal 
immunization with UV-inactivated EBs can reduce shedding but does not prevent 
pathology [282]. Conversely, immunization of mice with TARP or prior infection with 
attenuated (plasmidless) chlamydiae fails to reduce shedding, but minimizes 
pathology [359-360]. It is still poorly known why some patients only experience self-
limiting infections; whilst others go on to develop severe immunopathology and 
further understanding of what drives this dichotomy of prognosis is required.  
As infection with C. muridarum requires synchronization pretreatment with 
progesterone or Depo-Provera® (lasting > 30 days), the types of cells present in 
diestrus must be considered [255]. While antigen presentation is not affected by 
progesterone [361], the epithelial lining is thinner and leukocytes migrate from the 
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stroma into the epithelium and lumen [96]. During the secretory phase and under the 
influence of progesterone, the total numbers of macrophages, DCs and PMNs are 
elevated in the upper reproductive tract [96], and all these cells express FcRn [226-
227, 239].  Interestingly, Vidarsson and colleagues demonstrated that PMNs and 
monocytes can internalize IgG-opsonized Streptococcus pneumoniae via FcRn, and 
target them for phagolysosomal degradation [226]. Additionally, monocyte derived 
CD8-CD11b+ DCs can internalize IgG-opsonized peptide for cross presentation on 
MHC-I or target them for lysosomal degradation in an FcRn dependent-manner 
[227, 362]. Human PMNs have also been shown to release reactive forms of oxygen 
in the presence of C. trachomatis, in a serum-depended manner, although this did 
not appear to be antigen specific [363]. Together, these studies suggest under the 
influence of progesterone (i.e. contraceptives), APCs and PMN numbers are 
increased, and opsonized EBs are targeted to FcγRs and FcRn. The cells then 
either phagocytose the EB where is avoids lysosomal degradation and could 
disseminate to other tissues, or just initiates positive feedback for Th2 cytokine 
production.    
During a normal infection of epithelial cells, Chlamydia spp. escapes the endocytic 
pathway via SNARE-mimicry, which allows them to avoid lysosomal degradation 
independent of the route of entry [54]. The immunopathology observed in this study 
may be due to an early Th2 polarizing of the immune system away from protective 
immunity in WT mice. While opsonization of EBs in MOMP-IgG minimized the peak 
of shedding in WT mice, the duration of infection and immunopathology observed 
was enhanced. In B2m deficient mice, there were no outstanding differences except 
for a lower peak of infection.  
As MOMP is an immunogenic outer membrane protein identified during infection, 
the potential to transfer opsonized EBs to the sexual partner and induce damaging 
pathology must be considered. Progesterone contraceptives are widely used, and 
could provide a similar cellular environment to that of Depo-Provera® treated mice 
used in this study. While not investigated here, it would be interesting to determine 
whether EB opsonization in IgG is driving a Th2 polarization to the detriment of the 
host, and whether this may be clinically significant with regards to transmission of C. 
trachomatis and immunopathology. With hundreds of chlamydial vaccines utilizing 
MOMP as an antigen, and the potential to induce deleterious pathology from 
infected sexual partners or chronic infections, a more comprehensive understanding 
and of immune outcomes is required. 
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7.6  SUPPLEMENTARY DATA 
 
 
 
Supplementary Figure 7.1 
Purified MOMP IgG Isotypes Binding to MOMP and EBs 
Purified mouse IgG from pooled sera (n=10 mice) was serially diluted on ELISA 
plates coated with immunogen MOMP-MBP, or UV-inactivated EBs. Secondary 
antibodies targeting IgG isotypes (IgG1, IgG2a(c), IgG2b, IgG3) were used to detect 
types of IgG capable of binding antigen. Results representative of both BALB/c 
(IgG2a) and C57BL/6 (IgG2c) immunizations. 
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8.1  GENERAL DISCUSSION 
The protective role of immunoglobulins during primary chlamydial infections has 
varying degrees of efficacy dependent on the model of infection examined. In 
human FRT C. trachomatis infections, IgA but not IgG, appears to inversely 
correlate with chlamydial burden in the cervix [195]. In trachoma patients, antibody 
fractioned from eye secretions of C. trachomatis-infected humans was able to 
neutralize C. trachomatis and prevent infection of owl monkeys [364], and this 
protective effect was not provided from intravenous passive immunization of 
immune sera suggesting local production of antibody is required [272]. However, in 
the most common model of chlamydial genital infection, female mice, the infection is 
self-limiting in C. muridarum and C. trachomatis genital infections [242]. This 
adaptive immunity is highly dependent on CD4+ Th1 cell immunity [251, 365-367], 
but more specifically; αβ T cells, IFNγ, and MHC-II restricted presentation [148, 
366]. Mice are also able to rapidly clear a secondary C. muridarum challenge 
suggesting that the antigen-specific immunity is responsible for clearance, rather 
than elevated inflammatory responses as a consequence of non-specific innate 
immunity. Controversially, the rapid immune response to secondary C. muridarum 
infection is not dependent on CD4+ or CD8+ T cell responses [153] suggesting that 
once CD4+ Th1 cells have been expanded in response to primary infection, a yet 
unidentified subset of cells or responses downstream of CD4+ activation can confer 
protective immunity.  
In mice a primary chlamydial infection resolves independently of antibody but 
clearance is accelerated during secondary infection with antibodies [5], in an IgA-
independent manner [6]. This suggests that other classes of antibody, such as IgG, 
play an important role in the rapid resolution of secondary infections. This is 
evidenced by increased chlamydial burden and decreased cell-mediated responses 
in mice deficient in IgG receptors FcγRI, FcγRIIb and FcγRIII which facilitate 
macrophage-induced antibody-dependent cellular cytotoxicity [197, 270]. Passive 
systemic immunization of polyclonal anti-MOMP immunoglobulins from immune 
heterozygous athymic (nu/+) mice to homozygous (nu/nu) athymic mice also delays 
the onset of death associated with respiratory C. muridarum infection. Additionally, 
passive immunization with immune IgA and IgG fractions to naïve heterozygous 
mice (nu/+) enhances protection [147]. This synergistic effect of humoral and cell-
mediated immunity is also observed in reinfection of guinea pigs [271]. Together, 
this suggests that both humoral and cell-mediated responses are critical in 
immunity.  
180 
 
As mice are a commonly used model of pathogenic infections and more specifically, 
chlamydial infections, the relative distribution of immunoglobulin transporter proteins 
FcRn and pIgR was determined (Chapter 4). While expression of FcRn and pIgR in 
the murine female reproductive tracts is known [181, 213], as is FcRn and pIgR 
expression in the male rat reproductive tracts [214, 368], expression of both pIgR 
and FcRn in the murine MRT are unknown. Furthermore, the influence of chlamydial 
infection on the expression of these receptors remained unknown. Here we 
demonstrate that both FcRn and pIgR are constitutively yet differentially expressed 
in the male and female reproductive tract tissues, and we confirmed that their 
expression and distribution was consistent with other animal models [181, 213-214]. 
Interestingly, in both sexes the expression profile of both receptors is similarly 
polarized in response to chlamydial infection (Figure 8.1).  
Consistent with quantification of FcRn mRNA in the rat MRT [214], both FcRn 
mRNA and protein were highly expressed in tissues of the mouse upper MRT, in 
particular the epididymes, but also in the bladder and prostate. Interestingly, 
urogenital infection with C. muridarum for 21 days down-regulated expression of 
FcRn mRNA and protein as determined by both qRT-PCR and IHC. Initially, this 
suggests that chlamydial infection also down-regulates IgG transcytosis. FcRn 
down-regulation may be a consequence of IFNγ up-regulation in response to 
chlamydial infection of the reproductive tracts [251], which is known to down-
regulate FcRn transcription in immune cells via JAK/STAT1 signaling [252]. 
Strikingly, down-regulation of FcRn in response to chlamydial infection of the MRT 
and FRT did not decrease, but instead increased the concentration of IgG in 
prostatic fluid, urine, vaginal or uterine horn lavages. This increase in lumenal IgG 
has also been observed in the urethras of human males infected with C. trachomatis 
[101]. However, the down-regulation of FcRn leading to an increased secretion or 
pooling of IgG in the lumen is not in agreement with studies using female mice 
deficient in FcRn that had significantly lower concentrations of IgG in vaginal 
washes compared to WT mice [213]. This may be explained by an increased 
catabolism of IgG in these mice as a consequence of FcRn not being able to 
salvage IgG [235, 238]. However, intraperitoneal delivery of rabbit IgG revealed that 
less IgG was transported into the vagina of FcRn deficient mice [213]. To account 
for variability in murine IgG binding to other receptors, we biotinylated murine IgG 
and passively administered it intraperitoneally and systemically into WT and B2m 
deficient mice. Vaginal and uterine lavages of intraperitoneally immunized mice 
revealed that both stains transported IgG maximally within 6 hours, with WT mice 
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exceeding that of the B2m-deficient mice by 5 fold. Interestingly, systemic passive 
transfer with mouse IgG demonstrated that WT mice had only slightly more IgG in 
the vaginal washes than B2m-deficent mice, but there was significantly more IgG in 
the uterine horns. This may be due to the down-regulation of FcRn preventing 
uptake of IgG, or increased mucosal leakiness associated with chlamydial pathology 
but requires further investigation. 
In contrast to females, Knee and colleagues demonstrated in male rats that despite 
FcRn being dominantly expressed in the caput epididymes, IgG flow rate was 15 
fold higher into the lumen of the rete testes than in the entire epididymes and that 
94% of IgG transported into the rete testes was immediately reabsorbed by the 
proximal (caput and corpus) epididymes [214].  Uptake of IgG by FcRn in the 
epididymes seems likely, as in addition to expressing high amounts of FcRn, the 
epididymal lumen is acidic (pH 6.5) allowing binding and uptake by FcRn [253]. This 
is in agreement with our findings that whilst FcRn expression was detected in the 
testes and rete testes, FcRn mRNA expression was 2.5 times greater in the caput 
epididymes. Passive transudation of IgG into the rete testes is unlikely as the rete 
testicular fluid equilibrates with serum concentrations of water and urea within 3 
hours, has slower transport of ions (Na+, K+, Rb+, Cl-, I-), creatine and galactose, 
whilst excluding larger molecules like EDTA, inulin or albumin [256]. Together, this 
suggests that in the male rodent at least, FcRn expression does not correlate with 
exclusive transcytosis of IgG into the lumen, but rather IgG reabsorption, and would 
explain why FcRn down-regulation can lead to pool of IgG in the lumen.  
Expression of pIgR in the murine MRT, unlike FcRn, was predominantly localized to 
tissues and accessory organs of the lower reproductive tract. Only trace mRNA 
expression and no visible pIgR protein was observed in the testes, rete testes, 
epididymes and vas deferens. This is in agreement with studies in the male rat 
[368]. In female mice, pIgR expression was detected in the vagina and uterine horns 
and is in agreement with previous studies [181]. In contrast to FcRn down-regulation 
during chlamydial infection, pIgR expression was up-regulated in all tissues of male 
and female mice. Interestingly, while IFNγ-mediates down-regulation of FcRn 
expression, pIgR expression is up-regulated in response to IFNγ [185, 187, 254] and 
would explain why an increase of pIgR mRNA was observed. Functionally, IgA in 
mucosal secretions increased in response to chlamydial infection of the male and 
female reproductive tracts. Whilst not significantly different, these changes are in 
agreement with increased total IgA secretion into the urethral lumen of males 
infected with C. trachomatis [101].  
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Figure 8.1 
Qualitative Heat Map Demonstrating the Murine MRT and FRT Expression of 
FcRn and pIgR in Response to Chlamydial Infection 
An FcRn and pIgR expression heat map was assembled from qualitative 
interpretation of mRNA and IHC of murine MRT and FRT reproductive tract tissues. 
Tissues were sampled prior to infection (normal), during chlamydial infection 
(+Cmu). 
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Outside of (or aside from) in vitro neutralization studies containing a pool of 
antibody, investigating the protective role of IgA specifically against chlamydial 
infection has been limited to a few studies focusing on monoclonal IgA hybridomas 
[369], as well as female mice deficient in IgA [6]  or male mice deficient in pIgR 
[117]. Implantation of wild type mice with hybridoma ‘backpack tumors’ secreting 
monoclonal anti-MOMP IgA has revealed that IgA conferred only a marginal 
reduction in chlamydial shedding, but reduced immune cell infiltrate and pathology in 
the oviducts [369]. Despite the authors reporting mean IgA concentration ranges of 
between 0.1-0.4 µg/mL in vaginal secretions and 35-92 µg/mL in the serum, the 
amount of IgA complexed with secretory component (and hence transcytosed by 
pIgR) in vaginal secretions was not determined. It is also worth noting that the 
monoclonal IgA used had surface reactivity to EBs on dot blots but did not neutralize 
C. muridarum in vitro, representing a significant problem for any interpretations 
made from in vivo infections [369]. Furthermore, the majority of female mouse 
uterine IgA is produced locally, and systemic immunization, whilst producing high 
serum titers, does not translate into recruitment of IgA-secreting cells or increases in 
uterine lumenal IgA [292]. Polyclonal antibodies to surface receptors would provide 
more substantial evidence to evaluate the normal in vivo responses to poly-epitope 
antigen/s but technical difficulties in inducing and purifying high titer murine IgA have 
made evaluations of efficacy prohibitive.  
Whilst the role of IgA appears to be negligible in primary or secondary infections of 
female mice [6], anti-MOMP IgA in the prostate of male mice is strongly correlated 
with a reduction of chlamydial burden [193]. Another study which attempted to 
define the relationship of pIgR in this protection revealed that male mice deficient in 
pIgR (and hence SIgA) had an increased bacterial burden in the penis and prostate 
compared to WT controls suggesting that SIgA in the MRT plays an important role in 
minimizing the severity of primary chlamydial infections [117]. In this thesis, a simple 
method of extracting polyclonal IgA from mouse serum was developed to evaluate 
the protection offered from pIgR-transcytosed SIgA in vitro. To increase the yield of 
IgA obtained from sera, pIgR deficient mice were used as they pool IgA in their 
circulation [257, 370]. Basolateral loading of polyclonal murine IgA onto polarized 
pIgR-transfected cells mediated apical delivery of IgA. Total IgA from MOMP-
immunized mice conferred 24% in vitro neutralization from apical chlamydial 
challenge, despite only approximately 1 µg/mL (200 ng total) of the polyclonal IgA 
pool being transcytosed to the apical chamber. Sandwich and anti-MOMP ELISA of 
the IgA added to the basolateral chamber revealed that approximately 8% (80 
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ng/mL) of IgA was antigen-specific, and that less than 1% (10 ng/mL) was bound to 
UV-inactivated EBs. This demonstrates that relatively low concentrations of anti-
MOMP IgA are required to neutralize EBs in vitro, and that improving antigen-
specific IgA production in local mucosal tissues may further decrease the chlamydial 
burden.  
To investigate the protection conferred by anti-MOMP IgA in vivo, male WT and 
pIgR deficient mice were immunized and infected as per Cunningham et al. [117], 
but also depleted of CD4+ cells prior to infection. All mice exhibited systemic and 
urine (not shown) antigen-specific IgA and IgG in response to intranasal 
immunization. Although not investigated here, previous studies in our group using 
the same mice strains, antigen, adjuvant and route of immunization demonstrated 
that there was significantly more anti-MOMP IgA in the prostate of wild type 
compared to pIgR-deficient mice [117, 193]. This difference in anti-MOMP IgA with 
endpoint titers of only 150 in wild type mice compared to < 5  in pIgR-deficient mice 
was sufficient to strongly correlate with the 3.5 fold decrease in chlamydial burden in 
the prostate of pIgR deficient mice [117]. Similarly in this thesis, the absence of pIgR 
and hence SIgA in MOMP-immunized/CD4 depleted mice returned chlamydial 
burden to levels observed in non-specific OVA controls. This suggests that anti-
MOMP IgG played a limited role in the reduction of chlamydial burden and the 
reduction was principally due to the presence of pIgR-mediated transport of SIgA.  
As intracellular IgA has been shown to bind and neutralize influenza virus [274], and 
HIV [11, 177], murine IgA against intracellular chlamydial antigens IncA, IncMem 
and CPAF were produced and purified to determine if similar intracellular 
neutralizing potential was possible against chlamydial infection. Human intestinal 
epithelial cells transfected with murine pIgR were polarized on transwell inserts, 
infected with C. muridarum, and purified IgA loaded into the basolateral chamber. All 
antigen-specific IgA elicited small amounts of neutralization (maximum of 10% 
compared to non-specific controls) suggesting that IgA against the intracellular 
domains of these antigens has minimal effects on chlamydial inclusion formation. 
However, intracellular antibody (IgA) was found to co-localize with the inclusion 
(IncA and IncMem), but did not affect inclusion size or viability (not shown) 
suggesting sub/non-neutralizing capability. Whilst neutralization was minimal, there 
was a reduction of inclusions in cells expressing mouse pIgR suggesting that 
different intracellular antigens may improve neutralization.  
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To determine if the small reduction in inclusions observed in vitro was reproduced in 
vivo, wild type and pIgR-deficient male mice were immunized with IncA or IncMem 
and then depleted of CD4+ cells prior to urethral C. muridarum challenge. Wild type 
and pIgR deficient male mice immunized with IncA both demonstrated a significant 
reduction in bacterial burden of the testes compared to OVA immunized groups. 
When tissues were pooled, there was a small but significant increase in the 
chlamydial burden of pIgR-deficient mice suggesting that intracellular IgA/SIgA did 
play a small protective role. In contrast to in vitro results, IncMem-immunized mice 
demonstrated a small but significant decrease in burden in the testes, and non 
significant decreases in burden in the bladder and penis suggesting a limited role for 
anti-IncMem IgA in vivo, or a consequence of the polyclonal homogenate used to 
immunize mice. In agreement with studies using IgA-deficient mice challenged with 
a secondary infection [6], we demonstrated that immunity acquired from primary 
naturally infected and recovered mice was not SIgA-mediated.  
Taken together, in vitro and in vivo data supports the protective role of anti-MOMP 
IgA in reducing chlamydial burden, and that targeting the extracellular (surface-
exposed) domains of chlamydial EB antigens like MOMP in a subunit vaccine could 
potentially afford sterilizing immunity to the host. Targeting intracellular chlamydial 
antigens with IgA may prove less successful as a vaccine strategy as determined by 
the small reductions observed with IgA specific for IncA, IncMem and CPAF 
antigens both in vitro and in vivo. Whilst small amounts of sequestosomal activation 
was observed in vitro, this did not translate to inhibition in vivo and demonstrates 
that protection afforded by intracellular IgA may be limited to neutralizing/blocking of 
important chlamydial antigens, or extrusion of immature EBs prior to inhibition of 
phagolysosomal fusion (less than 6 hours post infection [54, 302]). Whilst pIgR/IgA 
and EBs are trafficked throughout the host cell by microtubule networks and could 
interact with each other [69, 371], achieving long-lived IgA-secreting plasma cells in 
the reproductive tract has proven difficult in mice and humans without invasive 
immunization schedules [250, 263, 372-373]. This represents a contemporary 
limitation of utilizing IgA/pIgR-mediated local immunity in the reproductive tract and 
would require improvements in adjuvant technology for inducing long-lived IgA 
responses. 
In vitro neutralization is often performed to determine the ability of serum or 
secretions to prevent infection. We sought to define the protective ability of IgG, and 
the role FcRn in delivery of antibody against chlamydial antigens expressed during 
the extracellular and intracellular stages of the chlamydial developmental cycle. 
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MECap18 cells grown on transwell inserts were found to transport mouse IgG (but 
not avian IgY) in an FcRn-dependent manner.  
C. muridarum infection of confluent and polarized mECap18 cells, followed by 
loading of antigen-specific IgG demonstrated that anti-IncA, IncMem and CPAF total 
IgG was able to provide a 20 - 30 % reduction in inclusions, in an FcRn-dependent 
manner. Fluorescence microscopy of cells infected with C. muridarum and treated 
with IgG demonstrated that IgG was internalized via the FcRn, and that IncA, 
IncMem, CPAF and immune IgG remained bound within the host cell. Interestingly, 
anti-IncA and IncMem IgG was able to co-localize with the chlamydial inclusion and 
affect inclusion morphology. In contrast, IgG specific for secreted protease CPAF 
and immune sera bound to antigen distant to the chlamydial inclusion and did not 
affect inclusion morphology.  
Recently, in vitro intracellular neutralization of influenza virus by IgG was 
demonstrated in polarized epithelial cells [4]. The cellular mechanisms that reduced 
viral titer were determined to function through trafficking of FcRn-IgG-virus immune 
complexes to lysosomes. As chlamydiae actively inhibit inclusion fusion with host 
cell phagolysosomes [302] we sought to define if reductions in inclusion formation 
were due to lysosomal fusion of antigen-bound IgG. However, our results showed 
that whilst anti-IncA and anti-IncMem IgG were able to bind the inclusion membrane, 
lysosomal marker LAMP1 did not accumulate at the site of binding. However, it was 
observed in the cytoplasm away from the inclusion membrane, particularly in 
IncMem-IgG treated cells and may reflect the polyclonal nature of the IncMem 
homogenate used to immunize mice. Interestingly, IncA and IncMem IgG treated 
cells also had increased sequestosome production/recruitment at the site of 
antibody binding. As the sequestosome is an early marker of ubiquitination, and 
autophagy, we sought to determine the fate of IgG treated cells. No cells were found 
to be undergoing apoptosis in response to IgG binding as determined by the lack of 
PARP cleavage.  
Recently, autophagy-mediated activation of proteasome-dependent and 
independent MHC-I loading of viral peptide has been demonstrated [374-375]. 
Furthermore, murine dendritic cells have also been shown to load IgG bound 
immune complexes and cross-present onto MHC-I instead of MHC-II [227]. As the 
protection afforded by IncA immunization was completely absent in mice lacking 
functional FcRn and MHC-I, further studies should be undertaken to define if the 
ubiquitin/proteasome could be also used to flag infected epithelial cells for 
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destruction by CD8+ T cells. While confirmation tests are underway, FcRn-delivery 
of IgG to intracellular antigen and loading of MHC-I represents a novel mechanism 
of antigen-specific targeting of infected cells for destruction by the immune system. 
This pathway could apply to other intracellular pathogens including viruses, but also 
intracellular cancer proteins. As FcRn is expressed on a variety of cells including 
epithelia, endothelia, dendritic cells, macrophages, neutrophils and 
syncytiotrophoblasts [203], this offers the potential to treat a wide variety of diseases 
with therapeutic passive monoclonal antibody delivery, or vaccination. Indeed, active 
phase III clinical trials utilizing immune responses with vaccines or monoclonal IgG 
targeting a common intracellular cancer antigen NY-ESO, has been shown to kill 
carcinoma in a CD8+ T cell-specific manner [316]. While commonly accepted to play 
a non-essential but supportive role in chlamydial infections, our data suggests that 
CD8+ T cells may have played an important role in unison with antigen-specific IgG 
and FcRn. 
In vivo immunization with IncA and CD4+ T cell-depletion of WT and B2m-deficient 
male mice further demonstrated the protective role of IgG, B2m, and functional 
FcRn and/or MHC-I presentation. This was evidenced by the loss of IncA-mediated 
protection in B2m-deficient mice. Similarly to wild type and pIgR-deficient mice 
previously infected or immunized with IncMem, wild type and B2m-deficient mice did 
not exhibit a reduction in burden compared to OVA-immunized control mice. This 
may be due to the large concentrations of total IgG used in the in vitro study (50 
µg/mL), which may not be reached in the mouse reproductive tract [280], but are 
reflective on human reproductive tract mucosal secretion IgG concentrations (Table 
2.1). Additionally, the crude polyclonal protein preparation in IncMem immunizations 
may have diluted out protective antigens. Interestingly, protection mediated by 
MOMP immunization was not significantly effected in CD4+-depleted B2m-deficient 
mice indicating a limited role for CD4+, CD8+, MHC-I, FcRn and IgG in these mice. 
Together, these data confirm that the IgG response to IncA is sufficient to reduce 
infectious burden in the upper MRT, and that this antigen-specific protection was 
mediated by B2m expression, functional FcRn-mediated transcytosis of IgG and/or 
MHC-I presentation. Furthermore, the protective role of MOMP immunizations was 
confirmed to be non-CD4+/CD8+/FcRn/MHC-I mediated (as in Chapter 5).  
As FcRn was highly expressed in the upper MRT and enhancement of infection was 
observed in the absence of pIgR and SIgA against MOMP, we sought to determine 
if there was an IgG-mediated enhancement of infection as documented in other 
studies [36, 54, 56, 228, 337]. To determine if the increased burden and/or 
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pathology in the absence of IgA was due to uptake of anti-MOMP IgG opsonized 
EBs, mECap18 wild type and FcRn knockdown cells were grown in transwells and 
infected with MOMP-IgG1 and IgG2b opsonized C. muridarum EBs. We observed 
that there was an FcRn and PI3-K-dependent enhancement of infection, in an 
antigen-specific IgG dose-dependent manner. Building on previous studies 
implicating monoclonal anti-MOMP IgG, and mouse FcγRIIb or human FcγRIII [337] 
in enhancement of infection [36, 54], we also demonstrated that FcRn can also 
mediate uptake of opsonized EBs into epithelial cells.  
Previous studies have implicated anti-MOMP immunoglobulin in accelerated 
pathology in vivo [228], so we  sought to define if infection with anti-MOMP IgG 
opsonized EBs would accelerate pathology. We observed only small and non-
significant enhancement of vaginal chlamydial shedding in WT female mice and this 
effect was reversed in mice deficient in B2m and functional FcRn. However, by day 
six, chlamydial shedding of the control treated EBs had surpassed MOMP-IgG-EB 
infected mice. This may be due to the degradation of the initial IgG, and/or C. 
muridarum going through 4-6 rounds of infectious life cycles in this time. Although 
not enhancing the shedding significantly, infection with MOMP-IgG opsonized EBs 
extended the duration of detectable shedding in WT mice by 9 days. This was not 
observed in B2m-deficient mice, suggesting functional FcRn may have attenuated 
the initial immune response. Interestingly WT mice infected with MOMP-IgG 
opsonized EBs had severe oviduct hydrosalpinx (100%) whilst WT mice infected 
with control IgG treated EBs induced significantly less hydrosalpinx (20%, p< 0.05). 
B2m-deficient female mice all exhibited pathology, which may have been due to the 
inability to mount a competent CD8+ T cell response. 
While the chlamydial shedding profile was only slightly altered due to infection with 
opsonized EBs, the pathological outcomes were significantly different, suggesting 
the immune response had responded differently. FcRn is expressed on epithelia 
(Chapter 4 and 5), neutrophils, DCs, macrophages, and monocytes [203, 376], and 
chlamydial infection or inappropriate activation of these immune cells may direct the 
immune response towards damaging pathology. This suggests that the initial 
response to infection may influence the pathological outcomes. Importantly, MOMP 
is commonly used in vaccine trials [242], is immunogenic during human infections 
[341], may predispose the patient with sub/non-neutralizing IgG to accelerated 
pathology when infected with serovar variants, and may pre-coat EBs prior to 
inoculation of the sexual partner during intercourse. Hence, the mechanism of the 
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deleterious responses mediated by MOMP-IgG, FcRn and/or FcγRIIb/FcγRIII needs 
to be further investigated.  
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Figure 8.2 
Antigen-Specific Responses Reduce Chlamydial Burden in the Testes via 
Different Immune Effector Mechanisms 
Male WT (n = 10), pIgR -/- (n = 5), and B2m -/- (n = 5) C57BL/6 mice were 
immunized and urogenitally infected with C. muridarum for 21 days. Mice were 
depleted of CD4+ cells were indicated. The reduction of chlamydial burden in the 
testes was determined as a percentage of OVA-immunized CD4 depleted control 
mice of the same strain. Results pooled from two experiments. Statistics determined 
by Student’s t test. Error bars = S.E.M. 
# Mice were immunized with non-chlamydial antigen (OVA) and infected without 
CD4 depletion (i.e. a naive response to a primary infection) 
Δ Mice were previously challenged and recovered from respiratory C. muridarum 
infection (i.e. Non-CD4 mediated acquired immunity)  
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8.2  CONCLUSIONS 
The distribution, relative expression, functional delivery and effector actions of IgA 
and IgG against a variety of chlamydial antigens expressed intra and extracellularly 
were investigated. A vast spectrum of protection from infection, burden and 
pathology was discovered and is summarized in Table 8.1.  
This thesis also identified intracellular antibody effector functions and may lead to 
more refined vaccine trials for chlamydial infections, but may also assist in 
developing immunizations against other intracellular pathogens. Further 
identification and elucidation of specific pathways, screening of other intracellular 
antigens, and targeting of desired responses will accelerate the development of 
efficacious chlamydial vaccines. 
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Table 8.1  
Contributors to Reduced Chlamydial Burden in the MRT 
*  potential to elicit enhancement of infection/pathology [54, 228] 
^  found to be beneficial in other mouse studies [1, 242, 281, 377-378] 
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8.3  FUTURE DIRECTIONS 
Based on the findings of these experiments, a more comprehensive understanding 
of the role of antibodies in chlamydial infections was elucidated. The protective role 
of secretory IgA and pIgR, IgG and FcRn in the reproductive tracts was also 
explored. As these receptors were differentially expressed throughout the 
reproductive tracts during chlamydial infection, the effectiveness of utilizing their 
delivery of antibody at different stages of disease must be considered. Targeting 
intracellular antigen with antibody was also investigated and demonstrated that the 
chlamydial inclusion and secreted proteases can be targeted with IgA, and more 
effectively with IgG. While IgG may be effective at targeting extracellular antigen, as 
chlamydial infection continues, the effectiveness of FcRn-mediated delivery of IgG 
will wane as FcRn expression is naturally down regulated. Conversely, IgA 
responses both intracellularly and extracellularly could be targeted as pIgR is 
actively up-regulated during infection.  
Most chlamydial studies investigating the neutralizing capability of antibodies have 
focused on the extracellular life cycle of chlamydiae (MOMP, PmpD), but the 
majority of chlamydial proteins are expressed during intracellular growth [65]. As the 
FcRn is expressed on a wide variety of cells types, and mediates delivery of IgG to 
intracellular antigen, a large amount of chlamydial antigens could now be explored 
as potential targets for intracellular IgG (Figure 8.3). Combination subunit vaccines 
targeting host cytoplasm-facing epitopes of inclusion membrane proteins like 
CT813, CT223 and CT229 as well as improving immune responses to IncA may 
provide greater reductions in burden and pathology. Recently, anti-CT229 IgG 
microinjected into infected cells has been shown to inhibit chlamydial growth in vitro 
[311, 379], and FcRn delivery of IgG to this antigen could potentially arrest 
chlamydial growth. We have identified that FcRn mediates delivery of IncA-IgG to 
intracellular antigen, and up regulates SQSTM1 in vitro. Additionally, the in vivo 
protection afforded from IncA immunization was entirely dependent of the presence 
of B2m, functional FcRn and MHC-I. 
Additionally, it would be important to repeat these experiments with human cell lines 
expressing FcRn using human IgG to determine if this phenomenon occurs outside 
of the rodent model, but this seems likely as humans also express FcRn in the 
reproductive tracts [213], and similar mechanisms have been observed in other 
mammalian-derived cells and tissues [4]. Furthermore, these experiments should be 
repeated in mice deficient in FcRn only (i.e. B2m +/+), as well as trialing passive 
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immunization with humanized IgG and mFcRn -/- hFcRn +/+ chimeric mice [225] to 
determine if the same mechanism could occur in humans. 
As anti-MOMP IgG was found to enhance epithelial uptake of opsonized EBs in 
vitro, and induce damaging pathology in vivo, the mechanisms and consequences of 
this process require further understanding. It would be ideal to definitively determine 
if FcRn mediates this process alone using FcRn-deficient mice, as well as determine 
if this mechanism is applicable to humans in mice expressing human FcRn and 
passively immunized with human IgG. It is important to determine what immune 
cells are responsible for this early skewing of the immune response, as well as 
which cytokines they secrete. This may be due to enhanced inflammatory responses 
(neutrophils), attenuated antigen-presentation (dendritic cells and macrophages), or 
that infected cells may act as reservoirs of infection which could migrate from the 
reproductive tract to other organs (reactive arthritis, hepatitis). It would also be 
interesting to determine if this phenomenon is repeatable with C. trachomatis or C. 
muridarum infection of mice, with or without MOMP-immunization, and whether prior 
exposure to different serovars also accelerates the pathology. Finally, it would be 
important to determine whether immunization with MOMP, primary or secondary 
infections of male mice can also induce damaging pathology in the female 
reproductive tract following mating.  
The purpose of this study was to investigate the role of immunoglobulins and their 
transporter receptors in chlamydial infections, aiming to direct and refine furture 
future vaccine development. Importantly for male chlamydial infections, we are able 
to demonstrate that antibodies can provide protection from chlamydial burden in a 
variety of tissues, and that this does not require CD4+ T cells which are associated 
with the development of infertility. Whist long-lasting high SIgA titers may be hard to 
achieve in vulnerable sites such as the testes and epididymes, systemic IgG may be 
a more viable option in a chlamydial vaccine. IgG could be secreted by long-lived 
plasma cells in the bone marrow and released into the circulatory system, where it 
could then traffic into the upper reproductive tract and potentially deliver long-lived 
immunity. Furthermore, the development of systemic immunoglobulin responses is 
easily achieved with FDA-approved adjuvants (such as alum or AS04) and use of an 
appropriate (intracellular) chlamydial antigen could be immunized systemically 
without the need for improving mucosal vaccine delivery systems.  
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Figure 8.3  
Proposed Model for Targeting Chlamydial Antigens with Antibodies 
(1) Targeting extracellular epitopes of chlamydial EBs (MOMP or PmpD) could 
physically block chlamydial attachment to the host cell (IgA and IgG*). (2) Antibodies 
could target EB T3S system machinery (T3SS) (TARP, CdsD, CT584) which are 
important in facilitating host internalization of EBs (IgA and IgG). (3) IgG could be 
used to target and/or block cytoplasmic-facing domains of chlamydial inclusion 
membrane proteins (IncA, CT813, CT223, CT229). (4) Antibodies could target a 
range of important RB-phase T3S system proteins (CPAF) or secreted proteins 
(HtrA, Tsp) to minimize hijacking of host cell machinery (IgA and IgG). 
*  Potential for enhancement of infection/pathology 
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